Analysis of squamous cell carcinoma invasion identifies a role for TRAF6 by Chaudhry, S.I.
1Analysis of squamous cell carcinoma
invasion identifies a role for TRAF6
Shahid Iqbal Chaudhry
BDS MBBS FDSRCS MRCP(UK)
Tumour Cell Biology Laboratory
Cancer Research UK London Research Institute
44 Lincoln’s Inn Fields
London
WC2A 3PX
Thesis submitted for the degree of Doctor of Philosophy
University College London 2010
2Declaration
I, Shahid Iqbal Chaudhry, declare that the contents of this dissertation are my own and 
that this work has not previously been submitted, in part or in full, for a degree or 
diploma to this or any other University or Examining Board.
Work performed in collaboration with other individuals and laboratories or obtained 
from other sources is clearly stated in the appropriate place.
Word count ~ 58, 100
………………………………
    Shahid Iqbal Chaudhry
3Abstract
The principal objectives of the work in this thesis were: (a) to investigate cancer cell 
invasion in squamous cell carcinoma (SCC) by examining the role of ubiquitin-linked 
pathways in the regulation of the actin cytoskeleton and (b) to establish a human tissue 
bank of SCCHN specimens matched to adjacent non-cancerous tissue.
An siRNA screen was performed with the premise that genes that regulate the actin 
cytoskeleton would be involved in the invasion of cancer cells. 289 E3 ubiquitin ligases 
and 137 de-ubiquitinating enzymes (DUBs) were screened yielding 3 gene hits 
(RKHD2, TRAF6 and ZA20d1) capable of regulating both the F-actin cytoskeleton of 
SCC cells as well as their collective invasion in a three-dimensional organotypic 
invasion system. A secondary morphological and functional screen of 20 E3 ligases and 
9 DUBs in carcinoma-associated fibroblasts demonstrated that 5 genes (MKRN2,
RKHD2, TRAF6, ZA20d1 and USP6) influenced the ability of stromal fibroblasts to 
promote SCC invasion. Following transcriptional analysis using qPCR, the E3 ligase 
TRAF6 and its complementary DUB ZA20d1 emerged as candidate genes for detailed 
study.
TRAF6 was shown to influence NF-ĸB signalling in SCC cells by modulating the levels 
of IĸBα. Given the importance of NF-ĸB activation in the pathogenesis of SCC, I 
investigated its significance in our organotypic system. Using TNFα, IL-1α and several 
IKK inhibitors, I demonstrated that SCC invasion was dose-responsive and NF-ĸB 
dependent. Furthermore, infliximab (a monoclonal antibody to TNFα in clinical use) 
inhibited carcinoma invasion at a therapeutic dose. 
Ethical and R&D approval for the establishment of a human tissue bank was obtained 
and SCCHN tumour samples with patient matched control tissue are now being banked. 
Analysis of these specimens and commercial tissue microarrays indicates that TRAF6 is 
overexpressed in a subset of SCC.
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Chapter 1
Introduction
1.1 Squamous cell carcinoma (SCC)
1.1.1 Squamous cell carcinoma of the head and neck (SCCHN)
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common 
cancer worldwide and represents greater than 90% of all head and neck cancers 1. It 
constitutes a heterogeneous group of malignancies each of which have distinct 
pathophysiology, biological behaviour and varying degrees of sensitivity to therapeutic 
intervention 2. 
Every year in the UK more than 5,000 people develop oral cancer of which six out of 
ten patients present with late-stage disease. Patient mortality rates exceed 50% in 5 
years and treatment often results in significant problems with eating, swallowing, 
speech and appearance 1. The burden of mouth cancer is therefore greater than that of 
other cancers with approximately 13,000 people in the UK currently being left disabled 
by the disease.
SCC is an epithelial derived cancer of variable clinical presentation and histological 
appearance (Figure 1.1). Important tumour-related factors associated with patient 
prognosis include the tumour type, size and grade, the depth of carcinoma invasion,
infiltration of neighbouring structures such as nerves and bone, evidence of extra-
capsular spread, and the presence or absence of  metastases 3, 4.
The management of the neck is central to the treatment strategy of SCCHN 5. In the 
absence of neck disease, the pathological and local features of the primary tumour 
described above determine the need for a neck dissection.  A selective neck dissection
directed to the regions at risk for lymphatic spread is generally used in this instance 2. 
Conversely, palpable neck metastases necessitate comprehensive clearance of the 
cervical lymph nodes and related structures - the ‘radical’ neck dissection 4. 
Figure 1.1 Squamous cell carcinoma of the head and neck (SCCHN)
(a) Photograph of an extensive SCC involving the right lateral border of the 
tongue. Image courtesy of Professor Stephen Porter, Honorary Consultant in 
Oral Medicine, UCL Eastman Dental Institute, London. (b) Photomicrograph 
of an H&E section of a SCCHN. Red arrows indicate the invasive front. 
Image magnification 10x. 
b
a
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With an improved understanding of cancer cell biology, an increasing knowledge of the 
factors influencing cancer cell invasion, and enhanced surgical techniques the 
‘functional’ neck dissection has evolved. This in turn has led to improved patient 
survival and outcome 6.
In principle, early-stage SCCHN can be adequately treated with surgery alone. Patients 
with late-stage disease, however, require adjuvant therapy which traditionally has been 
either radiotherapy or chemotherapy; both have been shown to improve patient 5 year 
survival rates 7. More recently cancer scientists have focused their attention on the 
tumour micro-environment. This has led to a greater appreciation of the interactions a 
cancer cell has with its surrounding stroma and an increasing awareness of the influence 
the host’s immune system and inflammatory response has on cancer progression. 
Targeted therapy, immune therapy and gene therapy have thus emerged as additional 
treatment modalities for the management of SCCHN 8, 9.
1.1.2 Cutaneous squamous cell carcinoma (CSCC)
Cutaneous squamous cell carcinoma (CSCC) represents approximately 20% of non-
melanotic skin cancers 10. Exposure to ultraviolet (UV) light is the most common cause 
of this cancer and therefore the majority of lesions arise in the sun-exposed areas of the 
head and neck 11. 
Carcinoma in situ (CIS) is defined histologically by cellular atypia involving the full 
thickness of the epidermis without invasion into the dermis. The most common forms 
are Bowen’s disease and erythroplasia of Queyrat. Left untreated, CIS may progress to 
invasive disease 12.
Primary CSCC typically presents as a raised, firm papule or plaque on the background 
of photodamaged skin (Figure 1.2). Surface changes may include ulceration, scaling and 
crusting. Several variants of CSCC are recognised but in some cases these may be 
difficult to distinguish with routine histology alone. Immunohistochemical staining with 
antibodies to cytokeratins and epithelial membrane antigens is therefore used to 
determine the epithelial origin of the tumour in such circumstances.
Figure 1.2 Cutaneous squamous cell carcinoma (CSSC)
(a) Photograph of a CSCC involving the vermillion border of the lower lip. 
(b) Photomicrograph of an H&E section of a CSSC. Red arrows indicate 
an epithelial nest (keratin or squamous pearl). Image magnification 20x. 
b
a
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Patients diagnosed with CSCC and regional lymphadenopathy should undergo nodal 
biopsy to allow adequate staging. Subsequent complete lymphadenectomy of the 
draining nodal basin in these individuals along with adjuvant radiotherapy improves 5 
year survival rates to as high as 73% 13. In addition, sentinel lymph node biopsy (SLNB) 
has been shown to identify micrometastasis in 21% of patients with high-grade SCC and 
clinically negative nodes 14. These observations taken together imply that early 
detection of nodal metastases is likely to be beneficial to patient outcome. Unfortunately 
prognostic models that accurately predict which tumours give rise to nodal 
micrometastasis and therefore which patients should undergo nodal staging do not exist. 
Identifying cancer cell molecular markers and genetic signatures which correlate with 
metastatic risk would therefore be of significant clinical benefit.
The majority of people with primary CSCC have an excellent prognosis 15. For those 
with metastatic disease, however, the long-term prognosis is poor with 10 year survival 
rates being less than 20% and 10% for regional and distant metastases respectively 11.  
Most metastatic nodes from head and neck CSSC occur in the parotid gland and the 
upper cervical nodes within the first 2 years; the reported rate ranging from 0.3% to 
20.7% 10.
As with SCCHN, treatment of metastatic CSCC may include adjuvant radiotherapy, 
chemotherapy and immune response modifiers 16, 17. Although the efficacy of 
‘biologics’ in this setting has not been fully established they offer exciting new 
opportunities in cancer therapy and are likely to become increasingly important as our 
understanding of cancer cell biology advances in forthcoming years 18.
1.1.3 Vulval squamous cell carcinoma
Vulval SCC (Figure 1.3) is relatively uncommon with approximately 1,000 cases 
diagnosed annually in the UK 19. Aetiologically vulval SCC can be classified into two 
forms. The first is associated with human papillomavirus (HPV) infection and smoking. 
The second is related to chronic vulval dermatoses, in particular lichen sclerosus. Both 
forms are preceded by vulval intraepithelial neoplasia (VIN) 20, 21.
Figure 1.3 Vulval squamous cell carcinoma
Photographs of (a) early and (b) late vulval SCC. Images courtesy 
of Dr Sallie Neill, Consultant Dermatologist, St John’s Institute of 
Dermatology, St Thomas’ Hospital, London. 
b
a
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Vulval SCC arises on the labia of the vulva in the majority of cases and has many 
different growth characteristics. Early lymphatic spread to inguinal lymphatics is 
common being directly related to both the size of the primary lesion and the depth of 
stromal invasion. 
Primary lesions less than 2cm in diameter, with superficial invasion less than 1mm from 
the epithelial stromal junction, can be treated with wide local surgical excision. Lesions 
with stromal invasion greater than 1mm dictate ipsilateral inguinal lymphadenectomy as 
part of the primary resection 22. If the nodes are negative on frozen section a modified 
vulvectomy is performed; if positive the contralateral lymphatic basin is removed 23. 
Total or complete vulvectomy is reserved for bilateral disease but is now largely a 
redundant procedure.
1.1.4 Verrucous carcinoma
Verrucous carcinoma is a variant of well differentiated SCC that was first described by 
Lauren Ackerman in 1947 24. It occurs most frequently on the mucous membranes of 
the oral cavity, larynx and vulva but may also involve any cutaneous site 25, 26.  
Chewing tobacco is the primary aetiological factor for oro-pharyngeal lesions and 
cigarette smoking correlates with laryngeal disease. HPV 16 related DNA sequences 
have been regularly extracted from lesions prompting the suggestion of viral initiated 
oncogenesis 27. 
The diagnosis of verrucous carcinoma is made from its characteristic exophytic, 
papillomatous appearance (Figure 1.4), its indolent clinical behaviour and the 
histological findings of an expansive but locally invasive tumour 28. Microscopically 
broad based, blunted rete ridges composed of well differentiated squamous cells are 
evident. The associated basement membrane appears intact and invariably the 
underlying stroma is mildly inflamed with a lymphocyte predominant infiltrate (Figure 
1.5).
Although locally aggressive, verrucous carcinoma is less likely to metastasise. 
Consequently, surgery is the treatment of choice 29. Primary radiotherapy has previously 
been advocated but concern that this may promote a transition to a more aggressive 
variant has limited its use 30.
ba
Figure 1.4 Verrucous carcinoma: (a) oral and (b) vulval
Photographs of (a) oral and (b) vulval verrucous carcinoma showing the 
exophytic and papillomatous nature of this variant of SCC. Images 
courtesy of (a) Dr Mehri Eghtessad, Honorary Lecturer in Oral Surgery, 
UCL Eastman Dental Institute, London and (b) Dr Sallie Neill, Consultant 
Dermatologist, St John’s Institute of Dermatology, St Thomas’ Hospital, 
London. 
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Figure 1.5  Histopathology of verrucous carcinoma
Photomicrographs of verrucous carcinoma of the tongue. (a) Low power 
view. Magnification 10x. (b) High power view of inset showing broad based, 
blunted rete ridges composed of well differentiated squamous cells. The 
associated basement membrane appears intact. Image magnification 40x. 
Images courtesy of Dr Selvam Thavaraj, Honorary Consultant in Oral 
Pathology, KCL Dental Institute, London.
b
a
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Understanding the signalling mechanisms involved in the regulation of cancer cell 
morphology, motility and invasion has provided new insights into the clinical behaviour 
of tumours and their pattern of spread. Many questions still remain unanswered 
however. In the case of verrucous carcinoma, for example, an obvious one is why is it 
characterised by a collective pushing invasive front with a reduced propensity for 
metastasis compared to typical SCC?  In time, as our knowledge of the process of 
cancer cell invasion improves, such issues will hopefully be resolved. 
1.2 The tumour micro-environment
1.2.1 Tumourigenesis
‘Carcinoma’ is the term used to describe a malignancy derived from epithelial tissue 
which until relatively recently was often regarded as being merely a mass of individual 
cancer cells. Similarly, carcinoma cells had been considered to be transformed 
immortalized keratinocytes with their greater proliferative, invasive and survival 
capacities being attributed solely to genetic or epigenetic changes 31.
Tumours are now recognised as being composed of not only carcinoma cells, but of 
several other cell types capable of interacting with each other within a highly ordered
extra-cellular matrix (ECM). This surrounding stroma has been the focus of 
considerable research in recent years and has given rise to the concept of the tumour 
micro-environment. Tumourigenesis is dependent upon contextual signals between 
cancer cells and their associated stroma 32. Both the epithelial and mesenchymal 
components evolve together and it is now appropriate to consider this micro-
environment of cancer as a single functional unit 33, 34. 
Tissue homeostasis is fundamental for the preservation of normal tissue morphology 
and the identification of multipotent mesenchymal stem cells (MSC) in adult connective 
tissue has provided new insights into this process 35. MSC have the potential to 
differentiate into endothelial cells, fibroblasts, myofibroblasts, smooth muscle cells and 
inflammatory immune cells; all of which are now considered to be key players in 
tumourigenesis 36.
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Epithelial cells can become dysfunctional if tissue homeostasis becomes perturbed but 
the crucial question of which comes first remains unanswered 37, 38. There is no intrinsic 
reason to assume that tumour development begins with epithelial aberrations. Epithelial 
differentiation during embryogenesis, for example, is determined by molecular cues 
from the underlying mesenchyme and recent evidence indicates that genetic changes 
occur in the stroma during the early stages of carcinogenesis 39, 40. This has led to the 
suggestion that a genetically unstable stroma may facilitate tumourigenesis in the 
overlying epithelium 41.
CIS is characterised by connective tissue which bears a close resemblance to that of 
granulation tissue typical of wound healing. This is often referred to as ‘reactive stroma’ 
and its relationship with dysplastic epithelium continues to be an area of considerable 
interest. The sequence of events resulting in the progression of CIS to invasive 
carcinoma is not fully understood 42. Reactive stroma, compared to ‘normal’ tissue, 
contains an enhanced capillary network and increased levels of vascular endothelial 
growth factor (VEGF) 43, 44. VEGF induces micro-vascular changes which favour the 
recruitment of fibroblasts, endothelial cells and inflammatory cells 45. These cells 
secrete ECM rich in type I collagen, fibrin and fibronectin and there by create the 
perfect environment for tumour angiogenesis 43.
Carcinoma is defined by the invasion of cancer cells beyond the ‘constraints’ of the 
epithelial basement membrane into the underlying connective tissue. Expansion of the 
stroma occurs in order to actively support tumour growth and is of vital importance to 
the further progression of the carcinoma 46. Increased deposition of ECM may result in a 
desmoplastic stroma composed of a dense network of fibrillar collagens, fibronectin, 
proteoglycans and tenascin C 47. The latter’s expression correlates with a poor prognosis 
for both breast and bladder cancer and has led to the suggestion that tenascin C may be 
a surrogate marker of cancer cell invasiveness 48, 49.
The regulatory pathways that orchestrate tumour development, growth and spread are 
intricate. It is now clear, however, that stromal cells are not just innocent bystanders but 
assume a very central and active role in tumourigenesis 50. 
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1.2.2 Carcinoma associated fibroblasts (CAF)
Normal fibroblasts constitutively express vimentin and fibroblast-specific protein 1 
(FSP1) 51. When ‘activated’ they express α-smooth muscle actin (αSMA) and are
referred to as myofibroblasts 52. Fibroblast to myofibroblast differentiation is a central 
event in the physiological response to tissue injury and the actions of myofibroblasts 
during wound healing have been extensively studied 53, 54. 
To synthesise abundant ECM proteins, a myofibroblast typically has a large oval 
euchromatic nucleus with several nucleoli, extensive endoplasmic recticulum and a 
prominent Golgi apparatus 42. In addition to ECM proteins, myofibroblasts secrete 
matrix metalloproteinases (MMPs), in particular MMP2, MMP3 and MMP9, which 
facilitate ECM turnover 55. Increased synthesis of growth factors such as epidermal-
growth factor (EGF) and insulin-like growth factor (IGF) induce adjacent epithelial 
cells to proliferate 56. Cytokines, such as interleukin-1 (IL-1), which modulate the 
immune response are also released by myofibroblasts 57.
Under normal circumstances the myofibroblast to fibroblast ratio is reflective of the 
degree of connective tissue remodelling 53, 54. In disorders characterised by excessive 
fibrosis, fibroblasts remain in an activated state being sustained by a self-perpetuating 
autocrine loop 58. Myofibroblasts derived from such tissues are capable of promoting
tumourigenesis when co-cultured with carcinoma cells compared to control fibroblasts 
from normal tissues 59. This observation supports emerging data that tumour derived 
myofibroblasts are genetically and functionally similar to those found in these chronic 
fibrosing conditions and granulation tissue 60.
Carcinoma associated fibroblasts (CAF) have been extracted from a variety of human 
tumours including breast, colon, oesophageal, and pancreatic carcinoma 36, 42. Different 
CAF isolates have different gene expression profiles encoding for a variety of 
cytokines, enzymes, growth factors and ECM-related proteins 61, 62. The origin of these 
differences and their functional significance remain indeterminate with studies 
investigating genetic and epigenetic alterations in CAF being inconclusive 50.
The factors governing the transformation of normal fibroblasts to CAF are not fully 
understood. Epithelial to mesenchymal transition (EMT), in which epithelial cells 
acquire mesenchymal properties, probably accounts for a small proportion of the CAF 
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present in tumours 63, 64. For the origin of tumour myofibroblasts (ie: activated CAF) 
several hypotheses have been proposed (Figure 1.6) 65. The obvious is the 
differentiation of CAF to myofibroblast without the acquisition of any genetic 
alterations, mirroring the situation observed in wound healing 66. The next most 
plausible explanation is that MSC, recruited into the developing tumour, serve as a 
source for a number of stromal cells including the myofibroblast 67. Other explanations 
include clonal expansion of pre-existing tissue myofibroblasts and, as mentioned above, 
possible genetic or epigenetic changes in CAF such as p53 loss 50, 68. 
1.2.3 Carcinoma associated fibroblasts and tumour spread
Intra-vital imaging of experimental tumours has revealed that only 1-5% of tumour cells 
are motile 69. These moving cells are not uniformly distributed but are observed in 
localized areas of the tumour 70.
Several studies have demonstrated the invasive promoting role of activated CAF and 
tumour associated macrophages (TAM) 36, 70, 71. Both cell types are a source of MMPs 
which facilitate cancer cell motility by degrading the ECM 72. CAF also secrete high 
levels of the cytokine stromal cell derived factor 1 (SDF1) which increases carcinoma 
cell proliferation in vivo, via its action on CXCR4, a CXC chemokine receptor 73, 74. 
Furthermore, CXCR4 expression is up-regulated on the surface of cancer cells by high 
levels of transforming growth factor-β (TGFβ) secreted by CAF, there by completing a 
paracrine loop 74, 75, 76. Stromal fibroblasts have also been shown to lead collective 
chains of invading carcinoma cells (which retain their epithelial markers) through a 
collagen-Matrigel® ECM by a combination of force-mediated and protease-mediated 
matrix remodelling 77.
Tumour cell motility requires both intrinsic changes that confer motile competence and 
extrinsic factors that promote invasion. The detection of motility signatures by global 
analyses of primary tumours before the clinical appearance of secondary lesions 
suggests that metastatic potential is determined early in carcinogenesis 78. This 
contradicts the previously held view that invasive cell behaviour is a late acquisition in 
tumour progression. It is, however, not a complete explanation. Desmoplastic tumours 
(which have a high proportion of myofibroblasts), for example, are associated with 
increased  invasion   and   secondary   spread  and  consequently  have  an  unfavourable
Figure 1.6 The multiple origins of tumour myofibroblasts / activated 
carcinoma associated fibroblasts (CAF)
Schematic to illustrate the various hypotheses proposed for the origin of 
tumour myofibroblasts (activated CAF). Multipotent mesenchymal stem cells 
(MSC) have the potential to differentiate into endothelial cells, fibroblasts, 
myofibroblasts, pericytes and inflammatory immune cells; all of which are 
now considered to be key players in tumourigenesis.  
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clinical prognosis 79, 80, 81. It is therefore likely that CAF paracrine signalling also 
facilitates metastasis 73, 74, 82.
Further research is required in order to clarify the molecular mechanisms underlying the 
potential role of CAF in promoting invasion and metastasis. Subsequently, new 
opportunities for therapeutic approaches which target the tumour stroma are likely to 
arise.
1.3 Cancer cell motility
1.3.1 The mechanics of cancer cell motility
Cell migration (Figure 1.7) is a dynamic, cyclical process where by a protrusion is 
formed at the front of the cell (extension) which then attaches to the substrate on which 
the cell is moving (adhesion). This is followed by a contraction which moves the cell 
body in the direction of its leading edge (translocation). Finally, surface attachments at 
the rear of the cell are lost (de-adhesion), the tail retracts and the cell continues 
forwards. Motility is driven by the polymerization of actin monomers into polarized
filaments (F-actin). F-actin associates with myosin II filaments to form a protein 
complex which when phosphorylated powers actin-myosin contraction 83. The 
contractile force generated leads to cytoskeletal reorganization, ECM remodelling and 
cell movement. Optimal cell migration requires the correct synchronization of 
protrusive, adhesive and contractile events 84.
1.3.2 Actin polymerization
Actin polymerization is central to the formation of cell protrusions and cancer cell 
motility. Monomeric globular actin molecules (G-actin) are assembled asymmetrically; 
being added at the barbed end of the filament and subtracted from the pointed end 85. 
Simultaneously, actin-binding proteins regulate a number of processes including: 
capping, nucleating, cross-linking, bundling, severing and depolymerising of filaments.
Figure 1.7 The mechanics of cell motility
(a) Extension. A protrusion is formed at the front of the cell. (b) Adhesion. 
New focal contacts are established between the cell and the substratum. 
(c) Translocation. Actin-myosin contraction moves the cell body in the 
direction of the leading edge. (d) De-adhesion. Surface attachments at the 
rear of the cell are lost, the tail retracts and the cell moves forwards.
Figure adapted from http://www.cytochemistry.net/Cell-Biology.
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Several protein groups and signalling pathways are recognised to be involved in cancer 
cell motility and invasion; notably receptor and non-receptor tyrosine kinases, integrin-
associated proteins and the Rho family of small GTPases. The activation of the Rho 
family GTPases Cdc42 and Rac results in protrusive events by initiating the nucleation 
of new actin filaments. Cdc42 bound to GTP interacts with Wiskott-Aldrich syndrome 
protein (WASP), attenuating WASP auto-inhibition and promoting WASP interaction 
with F-actin 86. WASP also binds with the actin related 2/3 complex (Arp2/3) causing 
branching of actin filaments at a 70º angle 87. WASP-family verprolin-homologous 
protein 1 (WAVE) is another nucleation promoting protein, which when activated by 
GTP-bound Rac, also recruits Arp2/3 to the cell membrane 88. The resulting actin 
polymerization by Arp2/3 initiated at the inner leaflet of the plasma membrane provides 
the internal force to push the membrane forwards and begin cell movement 85, 89. 
1.3.3 Cell protrusions
Several types of cell protrusion have been described, including filopodia, lamellipodia, 
podosomes, invadopodia and membrane blebs. The generation and cycling of these 
structures is dependent either directly or indirectly upon the co-ordinate activity of 
actin-binding and modifying proteins 90.
Filopodia are long, thin cell projections driven by Cdc42 actin bundling at the leading 
edge 91. Straight actin filaments are produced by formins binding to their barbed ends 
promoting lengthening without branching 92.  Ena/VASP proteins also assist in this 
process 91.
Lamellipodia are broad membrane protrusions observed at the front of cells migrating 
across two-dimensional (2D) substrates. Actin polymerization occurs downstream of 
Rac activation 93. They require the nucleation activity of Arp2/3 which sustains the 
propagation of a broad, branching actin network.
The distinction between podosomes and invadopodia is obscure; the former having been 
observed in monocyte-derived cells and the latter noted in carcinoma cells 94, 95, 96. 
Podosomes are actin-rich cell-substrate adhesion sites which are activated by the 
tyrosine kinase Src 97. They correlate with a cancer cell’s ability to cross a basement 
membrane 98.
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Membrane blebbing is thought to be generated by contractile forces which squeeze the 
cell membrane and cause parts of it to detach from the underlying actin cytoskeleton 99. 
It has been observed in carcinoma cells moving in an amoeboid manner in vivo but 
overall, this mechanism of cell protrusion is poorly understood 100, 101, 102.
1.3.4 Focal adhesion dynamics
Tumour cell migration requires the cell to establish stable contacts with the ECM. These 
focal contacts enable contractile forces to be generated which ultimately result in 
translocation of the cell body 103. Focal contacts are composed of integrins coupled to 
the actin cytoskeleton via linker proteins such as paxillin, talin, and vinculin. They are 
dynamic structures, with their assembly and composition being dependent upon the 
rigidity of the substrate 104. The majority of work studying focal adhesion dynamics has 
been performed using cell cultures on either glass or plastic 104. Extrapolating these in 
vitro findings to the tumour micro-environment may therefore be difficult 105. 
Integrins exist as transmembrane heterodimers, consisting of α and β subunits. Different 
integrins regulate focal contact assembly depending on the cell type and the nature of 
the substrate 106. Integrin α5β6, for example, functions as a receptor for fibronectin, 
vitronectin, tenascin and TGFβ. Its distribution is restricted to epithelial cells and it is 
overexpressed in a variety of carcinomas, including SCCHN 107. Signalling downstream 
of the integrins also confers specificity 108. α2β1 integrin binding to collagen is known 
to activate Rho A, where as α3β1 integrin binding to laminin inhibits Rho A but 
stimulates p21-activated kinase 1 (PAK1) 109. The engagement of different integrins 
with the ECM and the cycling of focal contacts are key events in cancer cell motility 
and carcinoma invasion 110.
Focal adhesion kinase (FAK) is an intracellular non-receptor tyrosine kinase that is 
recruited to focal contacts during cell migration 111. Integrin-mediated cell adhesion to 
the ECM results in the phosphorylation and activation of FAK at tyrosine 397 112. This 
creates a docking site for the SH2 phosphotyrosine binding domain of the Src family 
kinases 113. The activated Src-FAK complex induces the downstream phosphorylation 
of paxillin and p130 Crk Associated Substrate (CAS) which in turn stimulates cell 
migration 114.
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Non-integrin cell surface receptors, such as CD44 and CD26 also interact with ECM 
components and affect cell motility. Their precise role in force generation, however, is 
poorly defined 115.
1.3.5 Degradation of the ECM
The degradation of ECM is an integral aspect of tumour cell invasion and metastasis. 
Surface proteases are recruited in a integrin-dependent manner at the leading edge of 
motile cells, resulting in localized proteolysis of matrix components such as collagen, 
fibronectin, and laminin 116. ECM degradation occurs as the advancing cell body gains 
volume, creating space required for further cell expansion and directional movement. 
Consequently, cell migration tracks are generated within the tumour stroma 117.
MMPs are a family of zinc-dependent endopeptidases which are secreted as inactive 
proenzymes and cleaved to their active forms. They are capable of degrading basement 
membrane and ECM components, including fibrillar collagen 118. Over 20 MMPs have 
been characterised, each being classified according to their substrate specificity and 
numbered according to the order of discovery 107. Increased expression and activity of 
MMPs has been demonstrated in a variety of carcinomas. In SCCHN, MMP2 and 
MMP9 has been correlated with invasion, metastasis and poor patient prognosis 119, 120.
Matrix proteases generate chemotactic ECM fragments and promotility neoepitopes that 
engage specific integrins 121. Many of these factors, besides enhancing cell migration, 
influence other cell functions such as cell survival and proliferation.
1.3.6 Cortical actin, stress fibres and actin-myosin contraction
Cross-linked actin networks below the inner leaflet of the cell membrane are termed 
cortical actin (Figure 1.8) 108. Stress fibres, in contrast, consist of elongated cytoplasmic 
bundles of 10-30 actin filaments held together by crosslinking proteins such as α-actinin 
and fascin 104. They are prominent structures in cells cultured on glass and plastic but 
are less evident in cells plated on 3D matrices 101.
Figure 1.8 Cortical actin, stress fibres and cell motility
Cortical actin is comprised of cross-linked actin networks below the inner 
leaflet of the cell membrane. Stress fibres, in contrast, consist of 
elongated cytoplasmic bundles of 10-30 actin filaments. Cell motility is 
dependent on the co-ordinated assembly and disassembly of F-actin as 
well as the generation of contractile forces. The dissociation of cortical 
actin and stress fibre dynamics confers plasticity to cell migration.
Figure adapted from http://www.cellix.imba.oeaw.ac.at.
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Myosin II binding to actin is facilitated by the action of tropomyosin and when 
phosphorylated, induces actin contraction via an increase in ATPase activity. Myosin 
light chain (MLC) can be phosphorylated at two sites, T18 and S19, and the regulation 
of this process is critical to the control of cell contractility 122. Cell motility is dependent 
on the co-ordinated assembly and disassembly of F-actin as well as the generation of 
contractile forces. Inhibition of either actin polymerization with cytochalasin D or 
myosin II ATPase activity with blebbistatin can thus block cell migration 83.
Stress fibre assembly and contraction are governed by the small G-protein Rho through 
its downstream effectors ROCK1 and ROCK2 (generically termed ROCK). ROCK1 
and ROCK2 are serine threonine kinases that increase the availability of phosphorylated 
MLC via several methods. They (a) phosphorylate and inhibit MLC phosphatase, (b) 
potentiate the phosphorylation of MLC through the action of zipper-interacting protein 
kinase (ZIPK) and (c) directly phosphorylate MLC at S19 123, 124. 
Many other downstream effectors of Rho have now been identified. mDia is one such 
protein and is the mammalian homologue of Drosophilia diaphanous. It is a member of 
the formin-homology (FH) family and, by extending the polymerization of actin 
filaments, is associated with the formation of thick stress fibres orientated parallel to 
each other 125, 126.
In contrast to stress fibres, the turnover of cortical actin is regulated by the action of 
myosin light chain kinase (MLCK) 108. This enables the cell to disassociate cortical 
actin and stress fibre dynamics from one another and in doing so confers plasticity to 
cell migration 100. 
1.3.7 The plasticity of cancer cell motility
Several types of tumour cell motility have been identified, the tumour micro-
environment being a key determinant of the mode of cell motility adopted 100. Such 
diversity of movement is a reflection of the molecular repertoire used by cancer cells to 
migrate.
Mesenchymal cell motility is typical of cells derived from connective tissue tumours 
such as fibrosarcomas, but is also observed in carcinomas which have undergone EMT. 
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EMT is estimated to occur in 10-40% of epithelial derived tumours with cells exhibiting 
a fibroblast-like spindle shaped morphology 63. These phenotypic changes are 
accompanied by an alteration in protein expression profiles, which include the loss of 
epithelial cytokeratins and the de novo expression of vimentin 127, 128. Mesenchymal 
motility is dependent on integrin-mediated adhesion dynamics, pericellular proteolysis 
and actin-myosin contraction 108. Cells move at relatively slow speeds (0.1-1µm/min) 
but overall this type of motility represents an efficient mechanism for cancer cell 
dissemination and metastasis 129.
High resolution intra-vital imaging has demonstrated that a small proportion of 
carcinoma cells move at very high speeds (4-20µm/min) with an amoeboid morphology. 
This pattern of ‘amoeboid’ movement is driven by the rapid remodelling of cortical 
actin by Rho and ROCK signalling 100, 108. It does not require the formation of focal 
contacts or ECM degradation and as a result these cells are highly deformable 130. This 
type of cell motility is also used by leucocytes 131.
Collective cell motility, in contrast to both mesenchymal and amoeboid motility, 
involves the movement of clusters or sheets of cells with the maintenance of adherens 
junctions 132. Mechanistically, this is equivalent to a collective form of mesenchymal 
motility 108, 116. Signalling through Cdc42 and MRCK is thought to control the en masse
movement of cells by regulating the contraction of actin-myosin bundles that are 
continuous around the perimeter of the group rather than within individual cells 77. 
In vivo studies have shown that the tumour micro-environment is very heterogeneous 
with regions of motile and non-motile cells 133, 134. The reasons why one cell, or group 
of cells, should be motile and its neighbours not are poorly understood. Cancer cells 
have also been observed switching their mode of motility; indicating that these 
categories of movement are not completely distinct 135. This plasticity in cancer cell 
motility represents a significant obstacle to the development of successful anti-invasive 
drug strategies 33, 108, 115. Small cell lung carcinoma cells, for example, acquire increased 
resistance to cytostatic drugs and irradiation by switching from amoeboid single cell 
motility to collective cell invasion 136, 137.
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1.3.8 The E3 ubiquitin ligase Smurf1 regulates tumour cell plasticity
As previously mentioned the Rho GTPases (Rho A, Rac and Cdc42) are key regulators 
of cell migration. Rho A has been shown to be targeted for degradation at the leading 
edge of motile cells by a HECT domain E3 ubiquitin ligase, Smurf1 138, 139, 140. 
Consequently Rho A activity, which controls actin-myosin contractility, is high at the
back of the cell where it is involved in tail retraction. At the front of the cell, Rho A 
levels are reduced, and Rac along with Cdc42 drive actin polymerization. This localized 
inhibition of contractile forces permits the formation of lamellipodia and the 
establishment of cell polarity necessary for movement 141.
Three dimensional invasion assays and intra-vital imaging indicate that silencing 
Smurf1 increases tumour cell motility by inducing a mesenchymal to amoeboid-like 
transition in cell phenotype 142. This observation, which suggests that ubiquitin type 
modifications are regulators of the actin cytoskeleton and cell movement, formed the 
starting point of my research. A review of the published literature to date reveals that 
current knowledge in this area is limited.
1.4 The ubiquitin-proteasome system
1.4.1 Ubiquitination enzymes
Ubiquitin is a 76 amino acid (8kDa) polypeptide that can be attached to other proteins 
through a process known as ubiquitination 143, 144. This requires the sequential action of 
three enzymes: ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) 
and ubiquitin ligase (E3) (Figure 1.9).
Initially, ubiquitin is activated by E1 in an ATP-dependent reaction. In the second step, 
the activated ubiquitin is transferred to a ubiquitin-conjugating enzyme forming an E2-
ubiquitin thioester. Finally, an E3 ubiquitin ligase mediates the attachment of ubiquitin 
to the ε-amino group of a lysine residue in the target protein via an isopeptide bond. 
Ubiquitin contains seven lysine residues, each of which can be covalently bound to 
another ubiquitin, resulting in the formation of a polyubiquitin chain. The types of 
ubiquitin modifications are diverse, as are their functions 145, 146. Ubiquitin chains linked 
through  lysine-48  (K48)  target   their  substrates  for  proteasomal  degradation  where
Figure 1.9 The ubiquitin-proteasome system
Ubiquitin is a 8kDa polypeptide that can be attached to other proteins (P) by a 
process known as ubiquitination. This typically requires the action of three 
enzymes: ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) 
and ubiquitin ligase (E3). Ubiquitin modifications linked through lysine-48 
target their substrates for proteasomal degradation. Those attached through 
lysine-63 result in functional modulation of their tagged proteins.
Figure adapted from Jesenberger V, Jentsch S. Deadly encounter: ubiquitin
meets apoptosis. Nat Rev Mol Cell Biol 2002; 32: 112-121. 
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as those attached through lysine-63 (K63) typically result in functional modulation of 
their tagged proteins 147.
E3 ligases are primarily responsible for substrate recognition and may be divided into 
two families 148, 149, 150. The RING (really interesting new gene) type contains a series of 
histidine and cysteine residues and can be further classified according to the spatial 
relationship of their RING and substrate binding domains. The HECT (homologous to 
the E6-associated protein C terminus) E3 ligases contain a conserved cysteine residue 
within the HECT domain which allows ubiquitin to be transferred directly to its target 
protein.
1.4.2 Ubiquitin-binding domains
Biochemical and bioinformatic modelling has identified at least 20 different ubiquitin-
binding domains (UBDs). These domains are diverse in both structure and function 
being composed of 50-150 amino acid residues 151. UBDs bind polyubiquitin chains in 
addition to monoubiquitin with relatively low binding affinities 152. When mutated, 
UBDs are unable to correctly handle ubiquitin and consequently protein function in vivo
is impaired. This emphasises the physiological significance of these low-affinity 
interactions and illustrates the important role UBDs have in signal transduction 146.
1.4.3 The proteasome
The proteasome is a large, hollow, cylindrical protein complex which uses ATP to 
degrade ubiquitin-tagged proteins. Its components are referred to by their Svedberg 
sedimentation coefficient (denoted S) 153. The 26S proteasome contains a 20S core 
particle and two 19S regulatory caps 151. The core particle is itself composed of two α 
and two β heptameric rings. The α subunits are structural in nature where as the β
subunits, which form the inner structure of the core, are predominantly catalytic 154.
A target protein must be labelled with at least four ubiquitin molecules for efficient 
binding to the proteasome. Once recognised by the 19S regulatory cap, the substrate 
protein is partially unfolded and de-ubiquitinated prior to being translocated into the 
central channel of the 20S core particle 155. Within the core particle, peptide bonds are 
58
hydrolysed and the protein is digested into short fragments of 3-23 amino acid residues 
in length 156. 
1.4.4 De-ubiquitinating enzymes
Ubiquitination is a reversible process and the human genome encodes for greater than 
100 de-ubiquitinating enzymes (DUBs) 157. DUBs can be classified into cysteine 
proteases and metalloproteases which contain the JAB1/MPN/Mov34 (JAMM) motif. 
The cysteine proteases can be further divided on the basis of their protease domains 
into: (a) ubiquitin-specific proteases (USP), (b) ubiquitin C-terminal hydrolases (UCH), 
(c) ovarian tumour-like proteases (OUT) and (d) Machado-Joseph disease proteases 
(MJD) 151.
Genetic and biochemical evidence suggests that de-ubiquitination is fundamental to 
mammalian physiology 158. DUBs are involved in ubiquitin recycling by the processing 
of ubiquitin precursors, the editing of protein ubiquitination, and the disassembly of 
inhibitory ubiquitin chains. Depending on the cellular circumstances DUBs may act as 
both positive and negative regulators of ubiquitin-linked pathways 159, 160.
1.4.5 Ubiquitin and cancer
Experimental and clinical data implicates the deregulation of ubiquitin-linked pathways 
in oncogenesis (Table 1.1) 146. This is not surprising given the integral role 
ubiquitination has in cell biology. Knowledge of the temporal and spatial dynamics of 
ubiquitin-dependent processes is essential for the understanding of the physiological 
and pathological consequences of ubiquitin signalling in cancer. This, however, is 
complicated by the finding that E3 ligases and DUBs often interact with each other, and 
that both E3 and DUB activity can reside in the same protein 161. Furthermore, cross-
talk between the ubiquitin-proteasome system and several cellular pathways, such as 
p53 and NF-ĸB signalling, is likely to occur simultaneously 162, 163. Key molecules from 
multiple signalling pathways are also subject to a wide array of ubiquitin editing, 
including monoubiquitination, polyubiquitination, neddylation and sumoylation 133. 
Current research is focusing on successfully mapping these complex interactions. 
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Table 1.1 Examples of deregulated ubiquitin-linked pathways implicated 
in oncogenesis
Table adapted from Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like 
proteins in cancer pathogenesis. Nature Rev Cancer 2006; 6: 776-88.
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1.5 NF-ĸB signalling: an overview
1.5.1 NF-ĸB and related proteins
NF-ĸB was first identified in B lymphocytes in 1986 as a regulator of the genes 
encoding for the synthesis of immunoglobulin kappa (ĸ) light chains 164. It was 
originally implicated in oncogenesis through the v-Rel protein of the avian Rev-T 
retrovirus. The latter was shown to induce cell proliferation and confer resistance to 
apoptosis in transformed chicken tumour cells 165. Several NF-ĸB (Rel) transcription 
factors have now been characterised and the family, as a whole, has been linked to the 
expression of over 150 target genes 166.
The NF-ĸB family consists of five members: p65 (RelA), RelB, c-Rel, p50 and p52. All 
individuals can form homo- or heterodimers and each contain an N-terminal Rel-
homology domain (RHD) 167. This motif is approximately 300 amino acid residues in 
length and mediates dimerization, nuclear translocation, DNA binding and interaction 
with the inhibitor of NF-ĸB family (IĸB proteins) 163. 
IĸB proteins are classified as: IĸBα, IĸBβ, IĸBγ, IĸBε, as well as the p105 and p100 
precursors of p50 and p52 respectively. Atypical members function as NF-ĸB co-
activators and include: IĸBζ, IĸBδ (IĸBNS) and B cell lymphoma 3 (BCL-3). All 
individuals contain ankyrin repeat domains which bind to NF-ĸB dimers and retain the 
latter in the cytoplasm under basal conditions 168.
Activation of NF-ĸB occurs through canonical (classical) and non-canonical 
(alternative) pathways. Both involve initiation of all or part of the IĸB kinase (IKK) 
complex. This is composed of: IKKα (IKK1), IKKβ (IKK2) and the regulatory subunit 
NEMO (NF-ĸB essential modulator; also known as IKKγ) 151, 163, 169, 170. 
1.5.2 The canonical NF-ĸB pathway
The canonical or classical NF-ĸB pathway (Figure 1.10) is activated by a variety of 
stimuli, such as the inflammatory cytokines TNFα and interleukin-1 (IL-1) 169. These 
agonists induce the IKK complex to phosphorylate IĸBα at serines 32 and 36. 
Consequently, IĸBα is ubiquitinated and rapidly degraded through the 26S proteasome. 
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Now free of their IĸB binding partners, NF-ĸB p50-p65 dimers translocate to the 
nucleus and mediate gene transcription 151. NF-ĸB p65 also requires phosphorylation, a 
process which appears to involve both IKKα and IKKβ 171.
One of the many genes up-regulated by NF-ĸB is IĸBα itself 151. IĸBα also enters the 
nucleus where it subsequently displaces DNA-bound NF-ĸB; thus establishing a 
negative feedback loop. In the absence of further upstream signalling, NF-ĸB is rapidly 
sequestered by IĸBα and returned back to the cytoplasm. The IĸB proteins, (IĸBα, IĸBβ 
and IĸBε) display temporal differences in their rate of degradation and re-synthesis 
indicating that they do not have entirely overlapping functions 172.
1.5.3 The non-canonical NF-ĸB pathway
The non-canonical or alternative NF-ĸB pathway (Figure 1.11) predominates in B 
lymphocytes in response to stimulation of a subset of TNF-receptor (TNFR) 
superfamily members. These include the receptors for B cell activating factor (BAFF), 
lymphotoxin-β (LTβ) and the CD40 ligand. Activation of this pathway requires IKKα 
but is independent of IKKβ and NEMO 173.
Following cell stimulation, activated NF-ĸB inducing kinase (NIK) leads to IKKα 
dependent processing of RelB-p100 to RelB-p52 174. Nuclear accumulation of RelB-p52 
promotes the expression of several genes important in lymphoid organ development and 
adaptive B-cell mediated immunity 173, 174.
1.5.4 NF-ĸB signalling and tissue homeostasis
NF-ĸB is an important regulator of several cellular processes 169. On one hand, it 
promotes the transcription of key genes involved in the initiation and maintenance of 
inflammatory and immune responses. On the other hand, it is cytoprotective and 
induces the production of a number of anti-apoptotic proteins, including Bcl-XL
175, 
FLIP (FLICE-like inhibitory protein)176 and members of the IAP (inhibitor of apoptosis) 
family 177. This dual role has led to paradoxical observations and provocative theories 
regarding the function of NF-ĸB in normal and diseased tissue.
Figure 1.10  The canonical NF-ĸB pathway
Activation of TNFRs and IL-1Rs induce the IKK complex to phosphorylate
IĸBα. Consequently, IĸBα is ubiquitinated and rapidly degraded through the 
26S proteasome. Now free of their IĸB binding partners, NF-ĸB p50-p65 
dimers translocate to the nucleus and mediate gene transcription.
Figure adapted from Chen ZJ. Ubiquitin signalling in the NF-ĸB pathway. 
Nat Cell Biol 2005; 7: 758-765.
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Figure 1.11  The non-canonical NF-ĸB pathway
The non-canonical NF-ĸB pathway predominates in B lymphocytes and does 
not require IKKβ or NEMO. Following cell stimulation, activated NIK leads to 
IKKα dependent processing of RelB-p100 to RelB-p52. Nuclear accumulation 
of RelB-p52 promotes the expression of several genes important in adaptive 
B-cell mediated immunity.
Figure adapted from Chen ZJ. Ubiquitin signalling in the NF-ĸB pathway. Nat 
Cell Biol 2005; 7: 758-765.
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Genetic mouse models have allowed scientists to investigate the physiological and 
pathological roles of NF-ĸB signalling in vivo 178. Increased NF-ĸB activity, for 
example, can be achieved by either removing IĸB proteins or by overexpressing 
constitutively active IKKβ. Similarly, NF-ĸB signalling can be inhibited by either
depleting NF-ĸB family proteins or expressing degradation-resistant IĸB (IĸB-DR) 
proteins which are unresponsive to the IKK complex 179. Ubiquitous inhibition or 
removal of NF-ĸB results in embryonic or early postnatal death 180, 181. Consequently, 
cell-specific manipulation is required to study the function of NF-ĸB in tissues 169.
Several in vivo mouse studies have demonstrated that NF-ĸB signalling correlates 
positively with tissue inflammation 182, 183, 184. Recently, evidence has emerged in which 
NF-ĸB inhibition in non-immune, epithelial or parenchymal cells also triggers a 
pronounced inflammatory response 185, 186. This observation has led to the hypothesis 
that NF-ĸB activity may contribute to physiological tissue homeostasis via its action on 
tissue-specific immune cells 187. In this setting, normal tissue integrity is maintained by 
balanced NF-ĸB signalling which ensures a measured innate immune response. 
Conversely, an imbalance in epithelial or parenchymal NF-ĸB activation, whether it be 
positive or negative in nature, triggers and sustains a potentially damaging immune-
mediated inflammatory reaction 169. 
1.5.5 NF-ĸB signalling: a link between inflammation and carcinogenesis
Epidemiological studies support the observation that chronic inflammation frequently 
precedes the onset of cancer in adults. This is particularly evident for oesophageal, 
gastric, pancreatic and colorectal cancers 188, 189, 190. Inflammation associated with 
wound healing is self-limiting where as in chronic inflammation the response is 
sustained. Cytokines, principally TNFα and IL-1, which initiate and potentiate the 
inflammatory process also have cardinal effects within the tumour micro-environment. 
The ‘net cytokine effect’ fluctuates throughout the various phases of tumour 
development and is a major determinant of a cancer’s growth and behavioural 
characteristics 191, 192. NF-ĸB signalling is the predominant downstream effector of 
these cytokines and provides a common link between chronic inflammatory disease and 
malignancy. Its deregulation therefore appears to be at the heart of the transition from 
normal to neoplastic tissue.
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1.5.5.1 Incontinentia pigmenti (IP)
Incontinentia pigmenti (IP) is a rare inherited inflammatory disorder of skin 
pigmentation that is associated with ocular, dental and neurological abnormalities 193. Its 
name is derived from the observation that melanin ‘drops out’ of the epidermis and 
forms aggregates within the underlying dermis. IP is now known to be caused by 
mutations in the gene encoding for NEMO on the X chromososome 194. NEMO consists 
of 10 exons and the majority of mutations are deletions which result in a truncated 
protein. Activation of the IKK complex is therefore impaired leading to a reduction in 
NF-ĸB signalling 194. NEMO-deficient mice exhibit an IP phenotype, male embryonic 
lethality and heterozygous females develop inflammatory skin disease 195, 196. 
Collectively, these observations indicate that NF-ĸB regulates epithelial maturation and 
supports the above mentioned hypothesis that a background level of NF-ĸB activity 
contributes to skin homeostasis 169.
1.5.5.2 NF-ĸB deficient epidermal mouse models
Mice with epidermis-specific ablation of transforming growth factor-β-activated kinase 
(TAK1EKO mice) and IKKβ (IKKβEKO mice) develop TNFα-dependent inflammatory 
dermatoses 197, 198. Both TAK1 and IKKβ are required for canonical NF-ĸB signalling. 
In addition, mice expressing a keratinocyte-specific degradation-resistant form of IĸBα 
(k5-IĸBα-DR mice) exhibit inflammatory epidermal hyperplasia shortly after birth and
subsequently develop CSCC 199. When these mice were crossed with TNFR1-deficient 
mice no cutaneous pathology was observed 200. In these studies, the source of TNFα was 
attributed to myeloid-derived cells in the dermis suggesting that keratinocyte and 
stromal ‘communication’ is integral to skin homeostasis and inflammatory responses.
1.5.5.3 Psoriasis
Psoriasis is a chronic inflammatory disorder with characteristic cutaneous features 
(Figure 1.12) and destructive seronegative joint disease 201. It affects 2-3% of people 
worldwide and extensive genome-wide linkage studies have identified 9 psoriasis 
susceptibility loci designated PSORS1-9 202. The histopathological features of psoriatic 
Figure 1.12 Psoriasis vulgaris
Photographs of psoriatic plaques. Lesions are typically (a) red or 
(b) salmon pink in colour and covered by white or silvery scales. 
Plaques are classically distributed symmetrically and involve the 
extensor aspects of the elbows and knees. Images courtesy of 
Dr Fiona Lewis, Consultant Dermatologist, St John’s Institute of 
Dermatology, St Thomas’ Hospital, London. 
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skin include: hyperkeratosis, epidermal acanthosis, angiogenesis and a leucocyte-rich 
dermal  inflammatory infiltrate.  The hyperplastic epidermal changes are associated with
parakeratosis, underexpression of keratinocyte differentiation markers, loss of the 
granular layer, elongation of rete ridges and the presence of Munro microabscesses 203.
The pathogenesis of psoriasis involves epidermal-dermal cytokine interactions which 
induce the expression of surface adhesion molecules, such as inter-cellular adhesion 
molecule 1 (ICAM-1), on keratinocytes. This is a significant factor in the regulation of 
lymphocyte trafficking into psoriatic lesions 204. In addition, this cytokine network co-
ordinates the abnormal dermal vascular proliferation observed in psoriatic plaques and 
sustains the inflammatory reaction 205. TNFα induced pro-inflammatory pathways 
dominate these processes; hence the efficacy of anti-TNFα biological therapies in 
psoriasis 206.
The risk of developing non-melanoma skin cancer is increased in psoriatic patients.  
Whether this is related directly to the underlying chronic inflammatory nature of 
psoriasis or is a consequence of excessive use of phototherapy and systemic 
immunosuppressant drugs remains unclear 207. This scenario is further complicated by 
recent evidence that UV-irradiation induces TNFα mRNA and protein expression in 
both keratinocytes and dermal fibroblasts 208. The nature of the mechanism that senses 
UV light in the TNFα gene promoter is not known 209. Furthermore, IL-1α is also up-
regulated in irradiated skin and has been shown to increase TNFα gene transcription 208. 
It acts synergistically with TNFα in a pro-inflammatory manner through NF-ĸB 
signalling.
1.5.5.4 Inflammatory bowel disease (IBD)
Inflammatory bowel disease (IBD) is a collective term which encompasses the spectrum 
of disease seen in Crohn’s disease and ulcerative colitis (UC). The aetiology of both 
conditions is unknown. Crohn’s disease occurs mainly in Caucasians and may affect 
any part of the gastrointestinal tract, including the mouth. Microscopically, there is 
submucosal chronic non-caseating granulomatous inflammation characterised by multi-
nucleate giant cells. UC, in contrast to Crohn’s disease, most frequently affects the 
lower colon and rectum in people aged 15-40 years. Inflammation and ulceration of the 
superficial layers of the mucosa are followed by pseudopolyp formation. Individuals 
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with poorly controlled UC for longer than 10 years’ duration have a significantly 
increased risk of colorectal carcinoma. Patients with Crohn’s disease are also at an 
increased risk but less so than those with UC 210.
Complications of IBD include weight loss, a normocytic normochromic anaemia, 
gastrointestinal obstruction, perianal fissures, fistulae and abscess formation. Non-
gastrointestinal features include: conjunctivitis, uveitis, iritis, finger clubbing, 
sacroileitis, skin disease (erythema nodosum and pyoderma gangrenosum), liver disease 
(primary sclerosing cholangitis), gallstones and renal calculi 210. All of the above 
manifestations reflect the magnitude and chronicity of unchecked inflammation that 
underlies IBD.
TNFα is a strong stimulus for inflammation in IBD in both mouse models and patients, 
in whom TNFα-targeted treatment is highly effective 211. Furthermore, NF-ĸB 
activation has been shown to be increased in the mucosa of patients with IBD there by 
implicating NF-ĸB pro-inflammatory pathways in the pathogenesis of the disorder 212. 
Supportive of this hypothesis are studies involving mouse models of colitis in which the 
degree of inflammation was reduced by pharmacological inhibition of NF-ĸB signalling 
213, 214. More significant perhaps is the conclusion, from experiments using mice with 
NF-ĸB deficient intestinal epithelium, that NF-ĸB activation is required for the 
maintenance of normal mucosal integrity and immune surveillance 215. This situation 
mirrors that observed in the skin as discussed previously.
Recent experimental evidence suggests that anti-TNFα therapy in mice reduces the 
development of colorectal carcinoma associated with chronic colitis; supporting the 
relationship between TNFα, chronic inflammation and carcinogenesis 216. In this mouse 
model of UC, the administration of azaxymethane (AOM) followed by dextran sodium 
sulphate (DSS) induced severe colitis and multiple colonic cancers 217. Disease 
progression in wild-type (WT) mice was associated with increased TNFα expression 
and a leucocyte-rich inflammatory infiltrate throughout the colonic mucosa and 
submucosa 218. When WT mice were treated with etanercept (a human recombinant 
TNFR-Fc fusion protein) after prior administration of AOM and DSS there was a 
reduction in the number and size of the tumours. The degree of background colitis was 
also lessened 218. The authors concluded that blocking TNFα reversed carcinoma 
progression, even when well established 218. Moreover, they suggested that targeting 
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TNFα may be a useful therapeutic approach for colonic cancers, particularly those 
arising from chronic inflammation in the setting of IBD 218.
1.5.6 NF-ĸB and SCCHN
Molecular profiling studies, using a 15,000 element cDNA microarray, of normal, 
transformed and metastatic keratinocytes from the murine SCC Pam 212 model 
demonstrated that 308 genes were differentially expressed 219. Of those identified, NF-
ĸB regulated greater than 60%. The genes were functionally related to cellular processes 
vital to tumourigenesis such as cell proliferation, cell survival, cell migration, 
angiogenesis and inflammation 219. Furthermore, blocking NF-ĸB signalling by a 
dominant negative IĸBα phosphorylation mutant (IĸBαM) inhibited malignant 
phenotypic features in UM-SCC-9 cells 220. This data indicates that NF-ĸB is an 
important molecular switch for the genotypic and phenotypic changes that are observed 
during the malignant transformation of normal or dysplastic epithelium to SCC. 
NF-ĸB is constitutively active in both SCCHN cell lines and tumour samples 221, 222. Its 
dominant form is the p50-p65 dimer 170, 223. This modulates several genes involved in 
the control of cell cycle progression and apoptosis. One such gene, cyclin D1, is 
overexpressed in 80% of cases and correlates with a poor clinical outcome 224. NF-ĸB 
also inhibits the tumour suppressor p53 by acting upon Mdm2 225. Besides regulating 
anti-apoptotic genes, NF-ĸB signalling confers chemotherapeutic resistance in SCCHN
by inducing γ-glutamylcysteine synthetase; the rate limiting enzyme for glutathione-S-
transferase (GST) synthesis 226. GST overexpression confers resistance to cisplatin 
therapy in patients with SCCHN 227, 228.
A prominent feature of SCCHN is its propensity for local invasion and metastasis. NF-
ĸB regulates many of the proteins involved in the cellular mechanisms that facilitate 
these processes 229, 230, 231. Interleukin-6 (IL-6), interleukin-8 (IL-8), growth-related 
oncogene 1 (GRO-1) and VEGF promote angiogenesis, cell motility and leucocyte 
chemotaxis; all are elevated in SCCHN and all have NF-ĸB DNA binding motifs in 
their promoters. MMP9 is dependent upon NF-ĸB for expression and, as previously 
mentioned in Section 1.3.5, is frequently up-regulated in SCCHN. It correlates 
positively with nodal metastasis and negatively with patient outcome 120. Furthermore, 
NF-ĸB influences the expression of the MMP activator uPA (urokinase plasminogen 
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activator) and reciprocally decreases synthesis of TIMP 1 and 2 (tissue inhibitor of 
MMP) in SCC cells 232.
Although the constitutive activation of NF-ĸB in SCCHN is well established, the 
mechanisms which drive it are not fully understood 170. IL-1α is constitutively expressed 
in SCCHN and serves as an autocrine stimulus for NF-ĸB activation 233. It promotes 
local and systemic inflammatory responses and potentiates the action of TNFα 192. The 
two receptors for TNFα (TNFR1 and TNFR2) are themselves up-regulated in SCCHN, 
compared to normal epithelium and this creates a positive feedback loop which helps to 
sustain NF-ĸB signalling 234. Epidermal growth factor receptor (EGFR) and its high 
affinity ligand tumour growth factor alpha (TGFα) are also overexpressed in 90% of 
cases of SCCHN 235. EGFR stimulation leads to NF-ĸB activation by initiating the 
phosphatidylinositol 3-kinase (PI3K) / Akt protein kinase (Akt) pathway 170. 
Mechanistically, PI3K, Akt and 3-phosphoinositide dependent protein kinase-1 (PDK1) 
collectively activate the IKK complex. Mutations in protein phosphatase and tensin 
homologue (PTEN) are also found in SCCHN 236. Consequently, PTEN suppression of 
Akt activation is impaired which in turn favours NF-ĸB signalling. Other factors which 
activate NF-ĸB in SCC are less well defined. These include infectious agents such as 
Epstein Barr virus (EBV) and environmental cues such as hypoxia 237, 238.
Besides SCCHN, there is cumulative evidence that NF-ĸB is also constitutively active 
in breast, gastric, prostate and colorectal cancers as well as melanoma and lymphoma. It 
therefore seems likely that NF-ĸB pathways are of broad importance to cancer in 
general 239, 240.
1.6 Tumour necrosis factor alpha (TNFα)
1.6.1 TNFα and related proteins
TNFα is a member of the TNF-TNFR cytokine superfamily. Its gene, TNFA, was first 
cloned in 1985 and maps to chromosome 6 (6p21.3) where it spans approximately 3kb. 
TNFα is a 185 amino acid (17kDa) polypeptide chain composed of two anti-parallel β-
pleated sheets 241. It is initially expressed as a 212 amino acid (26kDa) transmembrane 
precursor, pro-TNFα, which is subsequently cleaved at the cell surface by the 
metalloprotease TNFα converting enzyme (TACE) 242, 243, 244. The soluble form of 
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TNFα (sTNFα) is a non-covalently bound trimer of the 17kDa protomer and dissociates 
at concentrations below the nanomolar range, there by losing its bioactivity. TNFα is 
synthesised by a variety of cells including T-lymphocytes, macrophages, dendritic cells, 
endothelial cells, keratinocytes, and fibroblasts 188, 191, 245.
Two TNF receptors (TNFRs) have been identified. TNFR1 (also known as p55/60 or 
CD120a) is ubiquitously expressed and can be activated by both the membrane-bound 
and soluble forms of TNFα 246. TNFR2 (also known as p75/80 or CD120b) is restricted 
to immune and endothelial cells, and responds to the membrane-bound form of sTNFα. 
Both receptors have the same extra-cellular domains but differ in that TNFR1 possesses 
the cytoplasmic death domain (DD) 247, 248.
Ligand binding to TNFR1 initiates signalling through the association of the receptor’s 
DD to TNFR-associated death domain (TRADD) 245. This serves as a platform for 
further binding by three adaptor proteins: TNFR-associated factor 2 (TRAF2); receptor 
interacting protein 1 (RIP1) and Fas-associated-DD (FADD) 249. Recruitment of TRAF2 
and RIP1 triggers NF-ĸB and activator protein 1 (AP1) signalling 249. Binding of FADD 
results in the formation of a cytosolic pro-apoptotic complex containing caspase 8 250. 
Apoptosis mediated through this pathway is reliant on inadequate activation of NF-ĸB 
and is therefore a late response to TNFα. Its significance is relatively minor when 
compared to apoptotic signalling induced by other members of the TNF superfamily 
such as TRAIL (TNF-related apoptosis-inducing ligand) 251. Ligand binding to TNFR2 
leads to activation of several pathways: NF-ĸB, MAPK (mitogen activated protein 
kinase), JNK (c-Jun N-terminal kinase), ERK (extra-cellular signal-regulated kinase) 
and PI3K 252. However, the biological significance of this receptor is not well 
understood.
1.6.2 The biological activities of TNFα
TNFα has a diverse range of biological activities which are central to both innate and 
adaptive immunity 191. In both situations, TNFα orchestrates a complex biological 
cascade involving the production of chemokines, cytokines and the differential 
expression of adhesion molecules across several cell types 253. Release of pre-formed 
TNFα is rapid and occurs early on in the acute phase response 253. In this setting, it acts 
72
in an autocrine manner, activating NF-ĸB and inducing further TNFα production along 
with other cytokines such as IL-1, IL-6, IL-8 and interferon gamma (IFNγ) 245.
Investigations using several animal models, in which local and systemic levels of TNFα 
have been manipulated, indicate that it is critical to experimental inflammatory and 
autoimmune diseases 252. For example, mice in which TNFα mRNA stability has been 
increased develop arthritis, IBD, anti-double stranded DNA antibodies and cachexia 254. 
More importantly perhaps, is the finding that these animal observations are mirrored in 
human disease. The role of TNFα in the pathogenesis of inflammatory dermatoses and 
IBD has already been discussed. Other examples of TNFα driven inflammatory 
disorders include: rheumatoid arthritis, graft versus host disease (GVHD) and TNF 
receptor-associated periodic syndrome (TRAPS) 255. The latter condition is caused by 
mutations in the tumour necrosis factor receptor superfamily member 1A (TNFRSF1A) 
gene and is characterised by altered cell membrane shedding of the TNFR1 complex. 
Consequently, the pro-inflammatory effects of TNFα are enhanced and patients present 
with periodic fevers associated with peritonitis, fasciitis and arthritis 256.
As highlighted in preceding sections, there are several associations between chronic 
inflammatory disease and cancer. Firstly, cancers arise at sites of chronic inflammation 
and the incidence of cancer is increased in chronic inflammatory disease 188, 189, 190. 
Secondly, both the cellular and cytokine components of the inflammatory and tumour 
micro-environments are remarkably similar 188, 191. Finally, interference with or 
inhibition of the cellular and chemical mediators of inflammation have been shown to 
influence cancer progression and spread 245, 257. In view of the above, TNFα has become 
increasingly recognised as being a pivotal chemical mediator within the tumour micro-
environment.
1.6.3 TNFα and cancer
TNFα is not present in plasma or serum of healthy individuals but may be detected in 
cancer patients with advanced disease 252. In prostate cancer, for instance, serum TNFα
levels correlate with the extent of disease and are elevated in cachectic patients 258. 
These findings have also been noted in patients with metastatic breast, pancreatic and 
renal cancer as well as those with chronic lymphocytic leukaemia (CLL) 259, 260, 261, 262. 
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Furthermore, TNFα is regularly detected in the epithelial and stromal compartments of 
human tumour samples 263.
Cancer cell and stromal cell production of TNFα is observed in the development of a 
variety of experimental tumours 191. It is also secreted by both cancer and stromal cell 
lines in vitro along with other cytokines such as IL-1, IL-6 and IL-8. Collectively, this 
phenomenon is responsible for the constitutive activation of NF-ĸB within these cell 
cultures 264. The stimulus for TNFα production in vitro and in vivo, in the absence of 
inflammation, is not entirely clear but may be linked to the expression of endogenous 
molecules such as heat shock proteins 252.
High doses of TNFα are anti-angiogenic and cause haemorrhagic necrosis of tumour 
blood vessels 265. This property of TNFα accurately reflects its name and highlights the 
paradoxical behaviour of TNFα within the tumour micro-environment 257. Diverse 
strategies of TNFα use in cancer therapy have been proposed and, when administered 
locally using an isolated limb perfusion (ILP) circuit, TNFα has proven to be successful 
in the management of advanced extremity soft tissue sarcoma (STS) 266. Furthermore, 
the efficacy of TNFα antagonists in the management of several chronic inflammatory 
disorders has led to interest in the use of biological agents in cancer chemotherapeutics.
1.7 Interleukin 1 (IL-1)
1.7.1 IL-1 and related proteins
The original members of the interleukin-1 (IL-1) superfamily include IL-1α, IL-1β and 
the IL-1 antagonist, IL-1RA. The genes encoding for these three proteins cluster 
together on the long arm of chromosome 2 and span approximately 400kb 192. Six other 
members, (IL-1F5 to IL-1F10), have been added to the IL-1 superfamily in recent years. 
To correspond with this, IL-1α, IL-1β and IL-1RA were reclassified as IL-1F1, IL-1F2 
and IL-1F3 respectively 267.
IL-1α is a 155 amino acid (17kDa) polypeptide chain which is cleaved from its 
precursor molecule, proIL-1α, by a calcium-dependent protease, calpain. An N-terminal 
cleavage product IL-1NTP, the propiece of IL-1α, is created during this process. The 
active membrane form of IL-1α is derived from myristoylation of proIL-1α and is 
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anchored via a mannose-like receptor 268. IL-1β, like IL-1α, is also synthesised as a 
precursor peptide and processed to its mature 153 amino acid (17kDa) form by a 
cysteine protease, IL-1β converting enzyme (ICE). IL-1RA is the physiological 
inhibitor of IL-1, has a signal recognition peptide and is secreted by the endoplasmic 
reticulum and Golgi apparatus 269. With regards to the structural homology of the three 
proteins, IL-1β is more closely related to IL-1RA than to IL-1α. All members of the IL-
1 superfamily have a barrel shaped conformation being composed of 12-14 β-strands. 
IL-1α, IL-1β and IL-1RA are produced by a variety of cells including macrophages, 
monocytes and dendritic cells 188, 190.
IL-1 receptors (IL-1Rs) are ubiquitously expressed and belong to the immunoglobulin 
(Ig) supergene family. IL-1R1 (80kDa) is a signalling receptor where as IL-1R2 
(68kDa) serves as a decoy target 192. Ligand binding to IL-1R1 results in the formation 
of a complex with IL-1R acceptor protein (IL-1RAcP) and the recruitment of IL-1 
receptor-associated kinase (IRAK). Further signal transduction ultimately leads to NF-
ĸB activation. By contrast, the binding of IL-1RA to IL-1R1 or of IL-1 to IL-1R2 does 
not result in a receptor complex with IL-1RAcP. Consequently, IRAK is not recruited 
and further downstream events are inhibited 192. Under physiological conditions, 
membrane bound IL-1R2, soluble IL-1Rs and IL-1RA limit cell responsiveness to IL-1. 
Signalling through IL-1R1 is analogous to the Drosophila Toll pathway 270. IL-1R1 has 
a TIR (Toll-IL-1 receptor) domain in common with other Toll-like receptors (TLRs) 
expressed on immune cells. TLRs recognise pathogen-associated molecular patterns 
(PAMPs) and are integral to the innate immune response 271.
1.7.2 The biological activities of IL-1
Currently, the majority of information regarding the biological activities of IL-1 
originates from studies involving the use of recombinant IL-1α and IL-1β. Extensive 
investigations using in vitro and in vivo experimental systems have demonstrated that in 
their recombinant form, both IL-1α and IL-1β exert the same spectrum of biological 
effects 192. However, the sub-cellular compartments in which IL-1α and IL-1β operate 
differ dramatically. IL-1α is predominantly active intracellularly or in its membrane 
bound form and is only marginally active when secreted. IL-1β, on the other hand, is 
solely active as a secreted product. Its precursor peptide is inactive and IL-1β does not 
exist in a membrane associated state. With these findings in mind, it has been suggested 
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that the localisation of IL-1 molecules, in the context of the cell of origin and its 
surrounding environment, determines the biological function 272.
IL-1α and IL-1β, like TNFα, co-ordinate innate and adaptive immunity 273. Both induce 
the expression of pro-inflammatory genes within immune and stromal cells, leading to 
the cellular and tissue events which typify the inflammatory response. Of particular 
importance to this process, is the ability of IL-1 and TNFα to stimulate their own and 
each other’s production, thus creating an amplification loop. IL-1 has widespread 
effects on the proliferation, differentiation, and behaviour of neutrophils, macrophages 
and natural killer (NK) cells. Many of these actions have been shown to occur indirectly 
and are dependent upon paracrine signalling from neighbouring stromal cells 192. IL-1 is 
also fundamental to the generation of T-cell mediated immune responses and may act as 
an endogenous adjuvant to self-antigens in the pathogenesis of autoimmune disease 274. 
Individuals with mutations in the IL1RN gene do not produce adequate levels of IL-
1RA. Since IL-1 activity is unopposed patients develop pustulosis, periostitis and sterile 
multifocal osteomyelitis. Collectively, this autoimmune inflammatory syndrome is 
termed DIRA (deficiency of the IL-1 receptor antagonist) 275, 276.
1.7.3 IL-1 and cancer
The intra-cellular forms of IL-1α, (proIL-1α and the IL-1NTP) possess a nuclear 
localisation sequence (NLS) 277. They therefore translocate to the nucleus and regulate 
several cellular functions including gene transcription, protein expression and cell 
differentiation 278. In fibroblasts and endothelial cells the accumulation of intracellular 
IL-1α (icIL-1α) correlates with growth arrest and senescence 279, 280. The pathways 
involved in IL-1α intracrine signalling are not well understood but are thought to be 
active in healthy cells. In malignancy, IL-1α is frequently overexpressed and has been 
shown to act in an autocrine manner in several types of cancer 281, 282. What remains 
unanswered, however, is the functional significance of icIL-1α to cancer cell behaviour.
In an experimental mouse model of skin carcinogenesis, tumour formation was induced 
by the application of 12-O-tetradecanoylphorbol-13-acetate (TPA) as a tumour 
promoter, after prior treatment with the initiator, 7,12-dimethylbenzanthracene 
(DMBA). IL-1α expression in the suprabasal keratinocytes was noted and persisted 
throughout tumour development 283. An increase in the concentration of intracellular IL-
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1RA (icIL-1RA) was also detected 284. The relationship between IL-1α and IL-1RA 
expression and its influence in carcinogenesis and tumour progression requires further 
evaluation. 
The importance of TNFα in the tumour micro-environment has been discussed in 
preceding sections. In the model of skin carcinogenesis described above, TPA was 
shown to induce TNFα expression at the site of skin application 285. When TNFα KO 
mice were used residual tumours developed and this was attributed to the actions of   
IL-1 286. Furthermore, IL-1α was up-regulated in the skin of mice treated with DMBA 
alone suggesting its involvement in both tumour initiation and promotion 287.
Co-operation between several oncogenes and membrane bound IL-1 has been described 
in experimental systems of in vitro cell transformation 192. In fibroblasts overexpressing 
v-JUN, IL-1α and TNFα promote anchorage independent growth 288. An IL-1 autocrine 
loop is also involved in Raf-induced transformation of NIH 3T3 cells 289. IL-1β 
expression correlates with mutations of Ras in acute myeloid leukaemia (AML) and 
chronic myeloid leukaemia (CML) 290. In addition, mutant Ras and constitutive IL-1β 
activation has been identified in breast, colon, lung, pancreatic, skin and renal cancers. 
The nature of the relationship between the expression of oncogenes and IL-1 in cancer 
remains undetermined.
Current literature suggests that the in vitro production of IL-1α and IL-1β correlates 
with cancer cell invasiveness. Only rarely have anti-invasive effects been observed 192. 
A diverse group of human cancer cell lines express IL-1 either constitutively or upon 
appropriate stimulation 291. What is less clear, however, is whether IL-1 is integral to 
cell transformation or merely a by-product of the process. Given that normal cells rarely 
secrete IL-1α, it seems likely that IL-1α production by malignant cells is functionally 
significant to tumour progression 233. This statement is supported by the observation that 
in malignant melanoma, IL-1α secreted by melanoma cells correlates with metastasis. In 
this setting, IL-1 was shown to act in an autocrine manner on the tumour cells and to  
have a paracrine influence on neighbouring stromal fibroblasts 292, 293. Moreover, in a 
study of patients with gastric carcinoma, IL-1α positive tumours were associated with 
an increased incidence of liver metastasis and a worse prognosis following resection 294.
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In summary, comparative studies which assess the roles of IL-1α, IL-1β, IL-1RA and 
the IL-1Rs in parallel within the tumour micro-environment are needed. Understanding 
and characterising the intracrine, autocrine and paracrine activities of IL-1 in the context 
of tumour development and progression may lead to the development of novel 
therapeutic strategies.
1.8 Establishing a human tissue bank
1.8.1 The Human Tissue Authority (HTA)
The Human Tissue Authority (HTA) was established on 1st April 2005 under the 
Human Tissue Act (HT Act) 2004 which extends to England, Wales and Northern 
Ireland. It is an Executive Non-Department Public Body (ENDPB) appointed by the 
Secretary of State for Health and consists of a Chair and fourteen members 295. The 
HTA Chair and eight members are lay individuals with a wide range of business, 
commercial and public-sector experience. The remaining six members are medical and 
scientific professionals selected from some of the groups most directly affected by the 
HT Act 296.
The HTA protects the public by licensing and inspecting organisations that store and 
use tissue for research, human application, post-mortem examination, teaching and 
public exhibitions. It also authorises organ and bone marrow donations for the purpose 
of transplantation. The HTA acts under two laws: the HT Act 2004 and the Human 
Tissue (Quality and Safety for Human Application) Regulations 2007.
1.8.2 The Human Tissue Act (HT Act) 2004 
The HT Act 2004 replaced previous legislation (the HT Act 1961, the Anatomy Act 
1984 and the Human Organ Transplants Act 1989) pertaining to England, Wales and 
Northern Ireland. Scotland has its own law, the HT (Scotland) Act 2006 296. 
The fundamental principle of the HT Act relates to the issue of patient consent. This 
must be obtained for the lawful storage and use of bodies, body parts, organs, and 
tissues from the living or the deceased. The HT Act uses the term ‘appropriate consent’ 
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to refer to the person who can give consent which, in most instances, is the individual 
concerned. For the deceased, consent may be sought from the next of kin. The Act 
further stipulates that consent should be given voluntarily by an individual with the 
capacity to make an informed decision. It is regarded as a positive action and may be 
implied, verbal or written depending on the circumstances. A person also retains the 
right to withdraw his or her consent at any time. 
The HT Act prohibits the covert collection of biological samples for genetic analysis, 
but exempts forensic scientific investigations from this offence.
1.8.3 The Human Tissue (Quality and Safety for Human Application)
          Regulations 2007
This latter piece of legislation provides the framework within which the HTA regulates 
the removal, storage and use of human tissue. It stems from a European law, the 
European Union Tissue and Cells Directive (EUTCD) and its remit is the whole of the 
UK, including Scotland. The EUTCD delineates standards for the handling of human 
tissue and cells throughout Europe and enables accurate tracing of samples between 
donors and recipients 295.
1.8.4 The National Research Ethics Service (NRES)
The National Research Ethics Service (NRES) was created in 2006 and is a division of 
the National Patient Safety Agency (NPSA) 297. It consists of the former Central Office 
for Research Ethics Committees (COREC) and the National Health Service Research 
Ethics Committees (NHS RECs) in England 297. NRES aims to deliver a system of 
review that protects the dignity and safety of research participants, whilst promoting 
ethical research. It is responsible for administering training, accreditation and 
overseeing quality assurance for the Research Ethics Service 297. 
RECs review research projects which involve the collection, storage and use of human 
tissue. All are recognised as research ethics authorities for the purpose of the HT Act 
and therefore tissue stored for an ongoing REC approved project does not require an 
HTA licence. When the research project is completed further storage of any residual 
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tissue must be covered by the HTA or the samples destroyed. However, the unnecessary 
destruction of samples donated by patients for research is deemed to be immoral.
1.8.5 The Integrated Research Application System (IRAS)
The Integrated Research Application System (IRAS) was launched in 2008 and was 
developed to streamline the application process required for approval to perform health 
care research within the UK. It significantly reduces the volume of paperwork that was 
previously required by avoiding the duplication of material needed for Site Specific 
Assessment (SSA). Filters are built into IRAS to ensure that the data collected and 
collated is appropriate to the type of study and research approvals required.
1.8.6 The National Institute for Health Research Co-ordinated System for
          gaining NHS Permissions (NIHR CSP)
Any research performed in the NHS requires approval from all the NHS organisations 
involved. The National Institute for Health Research Co-ordinated System for gaining 
NHS Permissions (NIHR CSP) was set up in November 2008 298. It was developed to 
standardise the process of gaining Research and Development (R&D) approval in NHS 
trusts throughout the UK for research studies adopted to the NIHR Clinical Research 
Network Portfolio. An application to the NIHR CSP is made through IRAS.
For non-NIHR Portfolio research, the new IRAS Site Specific Information Form (SSIF) 
is used for R&D management approval. Final R&D authorisation is not normally 
granted until a favourable ethical opinion has been received, funding is in place and a 
‘research sponsor’ has been identified. The sponsor accepts overall responsibility for 
ensuring that the research meets appropriate standards and that arrangements have been 
made to monitor the conduct of the individuals involved. Moreover, a system should be 
in place for the reporting and management of any patient adverse events that arise 
during the course of the study.
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1.8.7 Generic criteria for a human tissue bank
The HTA and the NRES provide guidance for the establishment of human tissue banks 
for the sole purpose of scientific research 295, 297. A summary of these guidelines is 
shown below:
 Prior ethical and R&D approval for the establishment of the Bank should have 
been obtained from the NRES and the NHS trusts involved as outlined above.
 Chief and Principal Investigators must be appointed for the duration of the 
study. The Chief or Principal Investigator at each site of tissue collection should 
assume overall responsibility for data collection, data storage and data analysis 
relevant to participants recruited to the study. All database systems should be 
password protected and subject to audit trail in line with current NHS Trust 
policy.
 The Bank must be stored in a secure facility and its routine handling overseen by 
a single designated Bank Manager.
 Strict criteria for tissue inclusion, exclusion and withdrawal should be defined 
prior to recruiting subjects for donation.
 Informed consent, (ideally written), must be obtained from the individual prior 
to harvesting tissue. Donors should be fully informed of the intended use of their 
tissue for scientific research, the nature of the investigations to be undertaken 
and the length of duration their tissue will be stored for. The donor retains the 
right to withdraw his or her tissue from the bank at anytime without explanation.
 All tissue samples and any associated clinical information pertaining to the 
donor must be anonymous to the researcher at the point of release. Each sample 
should be identified by a unique research number. 
 The use of tissue samples must comply with the terms of the donor consent. Any 
contact with donors should be confined to ethically approved arrangements for 
the feedback of clinically significant information.
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 Any serious adverse event, breach of security or confidentiality relating to the 
Bank which could undermine public confidence in the ethical management of 
the tissue should be reported to the NRES in accordance with the HT Act 2004.
 A Material Transfer Agreement (MTA) which covers the transfer of tissue from 
its source (the NHS Trust) to the site of storage and usage (the Research 
Institute) may be necessary.
 Any substantial amendment to the management of the Bank requires further 
NRES approval prior to its implementation.
Human tissue banks are a valuable asset to cancer research 299. The analysis of tumour 
samples has provided new insights into cancer development and progression. This has 
subsequently led to improved diagnostic techniques and the development of effective 
cancer chemotherapeutic agents.
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1.9 Aims of this work
A defining feature of cancer is its propensity for invasion. Cell motility is central to this 
process and is accompanied by dramatic changes of cell phenotype. This requires 
remodelling of a cell’s actin cytoskeleton as well as dynamic interactions with the 
surrounding ECM.
1.9.1 Hypotheses
 Ubiquitin-linked pathways are key regulators of the actin cytoskeleton.
 Ubiquitin-linked pathways are fundamental to the process of cancer cell 
invasion.
1.9.2 Objectives
 To identify genes regulating ubiquitin and ubiquitin-like proteins which 
influence SCC invasion.
 To improve our understanding of the process of SCC invasion by investigating 
the nature of cellular interactions and signalling pathways at the invasive front.
 To establish a tissue bank of SCCHN tumour specimens, with patient matched 
control tissue samples.
 Having identified ubiquitin-linked regulators of SCC invasion, to examine their 
degree of expression in human tumour samples and assess their potential as 
diagnostic tumour markers.
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Chapter 2
Materials and Methods
2.1 Reagents
2.1.1 Buffers and solutions
Buffers and solutions used regularly throughout these experiments are shown below.
Phosphate buffered saline (PBS):
1.5mM KH2PO4, 8mM Na2HPO4, 2.7mM KCl, 137mM NaCl, pH 7.4
10X Protein buffer
1.92M glycine, 0.25M Trizma® base
1X SDS gel loading buffer
50mM Trizma® HCl pH 6.8, 2% SDS, 10% glycerol, 100mM -mercaptoethanol, 0.2% 
bromophenol blue
SDS running buffer
100ml 10X protein buffer, 10ml 10% SDS, 890ml dH2O
‘Stripping’ buffer
5.5g glycine, 20g SDS, dH2O to 500ml, pH 2.7
10X TBE buffer
108g Trizma® base, 55g Boric acid, 9.3g Na4EDTA, dH2O to 1 litre, pH 8.3
TE buffer
10mM Trizma® HCl pH 7.5, 1mM EDTA
Transfer buffer
100ml 10X protein buffer, 1ml 10% SDS, 699ml dH2O, 200ml Methanol 
84
Trizma® buffered saline (TBS)
137mM NaCl, 2.7mM KCl, 20mM Trizma® HCl, pH 7.4
TBS-Tween20 solution
10ml 20% Tween20 and 990ml 1X TBS 
2.1.2 Chemicals
Commonly used reagents are shown below. Assay specific reagents are listed in their
respective sections. 
Adenosine triphosphate (ATP), ammonium persulphate ((NH4)2S2O8), bromophenol 
blue, bovine serum albumin (BSA), dimethylsulphoxide (DMSO), dithiothreitol (DTT),
ethanol (EtOH), ethylene diamine tetra-acetic acid (EDTA), foetal calf serum (FCS),
glycine (C2H5NO2), hydrochloric acid (HCl), -mercaptoethanol (C2H6OS), Ponceau S, 
potassium chloride (KCl), potassium phosphate (KH2PO4), sodium chloride (NaCl)
sodium deoxycholate, sodium orthovanadate (NaVO4), sodium phosphate (Na2HPO4),
sodium pyrophosphate (Na4P2O7), tetramethylethylenediamine (TEMED), Triton® X-
100, Trizma base, Trizma HCl, Tween20, nonyl phenoxylpolyethoxylethanol (NP-
40), were all purchased from Sigma-Aldrich®, UK.
Acetic acid (CH3COOH), acrylamide solution, boric acid (H3BO3), glycerol
(C3H5(OH)3), magnesium chloride (MgCl2), methanol (MeOH) and sodium dodecyl
sulphate (SDS) were purchased from Thermo Fisher Scientific Inc., UK.
BD MatrigelTM basement membrane matrix and rat-tail collagen type I was purchased 
from BD Biosciences, Europe.
2.2 Mammalian cell culture techniques
2.2.1 Cell lines
A431 cells are human vulval SCC cells and were grown in DMEM with 10% FCS in 
10% CO2 at 37ºC 
300. SCC12 cells (a human CSSC cell line) were cultured in FAD 
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medium supplemented with 10% FCS, 5µg/ml insulin (Invitrogen, UK), 0.5µg/ml 
hydrocortisone (Sigma-Aldrich®, UK) and 10ng/ml EGF (Sigma-Aldrich®, UK) 
hereafter referred to as complete media, in 5% CO2 at 37ºC 
301. Human HNCAF (head 
and neck carcinoma-associated fibroblasts) were cultured in DMEM with 10% FCS and 
insulin-transferrin-selenium (Invitrogen, UK) in 10% CO2 at 37ºC.
2.2.2 Cell culture
DMEM was made to the following protocol in house by media production services.
E4 - Dulbecco's Modification of Eagles Medium (DMEM) mg/litre
Inorganic Salts 
  CaCl2.2H2O 265.00 
  Fe(NO3)3 0.10
  KCl 400.00 
  MgSO4. 7H2O 200.00 
  NaCl 6400.00 
  NaH2PO4.2H2O 140.00 
Amino Acids 
  L- Arginine mono.HCl 84.00 
  L-Cystine 48.00 
  L-Histidine mono.HCl 42.00 
  L-Glutamine 584.00 
  Glycine 30.00 
  L-Isoleucine 104.80 
  L-Leucine 104.80 
  L-Lysine mono.HCl 146.20 
  L-Methionine 30.00 
  L-Phenylalanine 66.00 
  L-Serine 42.00 
  L-Threonine 95.20 
  L-Tryptophan 16.00 
  L-Tyrosine 72.40 
  L-Valine 93.60 
  Inositol 7.00 
Vitamins 
  Choline Chloride 4.00 
  Folic acid 4.00 
  Nicotinamide 4.00 
  DL-pantothenic acid, Ca salt 4.00 
  Pyridoxal HCl 4.00 
  Riboflavin 0.40 
  Thiamine HCl (aneurine) 4.00 
Other Compounds 
  D-Glucose 4500.00 
  Phenol red 15.00 
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  NaHCO3 3700.00 
  Penicillin 100,000 units 
  Streptomycin Sulphate 100.00 
  Sodium pyruvate 110.00 
  Antimycotic (Butyl-p-hydroxybenzoate) 0.20
FAD medium was also made in house, being a 3:1 formulation of DMEM and Ham’s 
F12.
Cells were sub-cultured every 5-7 days when approximately 90% confluent. After 
decanting the culture medium, cultures were washed with PBS. The cells were then 
enzymatically detached by incubating with 0.1% trypsin and 0.02% versene for 5 
minutes at 37ºC. The trypsin was subsequently neutralised by adding 10ml of the 
appropriate culture medium containing 10% FCS.
2.2.3 Storage and retrieval of cells
Stocks of cells were maintained in liquid nitrogen. Cells were frozen in 1.5ml of 
DMEM with 20% FCS and 10% DMSO in cryotubes containing no more than 107 cells. 
At the time of freezing, cells were typically split 1:10 and cooled in a -80ºC freezer for 
12-24 hours before being transferred to liquid nitrogen for long-term storage at -196ºC.
Cells were retrieved from the liquid nitrogen storage facility by rapid thawing of the 
cryotubes in a 37ºC water bath; the cells were then transferred to 10ml of culture 
medium. After centrifuging at 12,000rpm for 5 minutes at room temperature, the 
supernatant was discarded and the cell pellet re-suspended in culture medium before 
being transferred to the appropriate sized tissue culture flask. Cells were maintained in 
culture as described previously (Section 2.2.2).
2.2.4 Transient DNA transfections
2 x 105 A431 cells were seeded per well in 6 well plates the day before transfection in 
DMEM with 10% FCS. 100µl of Opti-MEM® (Invitrogen, UK) was mixed with 6µl of 
FuGENE® 6 transfection reagent (Roche, UK). The contents were left for 15 minutes 
before adding 1µg of DNA and leaving for a further 15 minutes. Cells were washed 
once with PBS before being covered with 800µl of Opti-MEM®. The DNA-liposome 
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mix was then pipetted onto the cells and swirled briefly. After 5 hours of incubation in 
10% CO2 at 37ºC the transfection mix was removed, the cells washed with PBS and 
fresh DMEM with 10% FCS added. Cells were subsequently recovered for analysis by 
immunofluorescence (IMF) or immunohistochemistry (IHC).
2.2.5 siRNA transfections
siRNA duplexes were purchased from Dharmacon® or Qiagen® and stock solutions of 
20µM made. For the initial A431 screen, Dharmacon® provided SMARTpool siRNA 
libraries in a 96 well format with each SMARTpool consisting of 4 individual siRNA 
duplexes per gene. The concentration of oligonucleotides in the libraries was 2.5µM 
(0.625µM of each duplex). 
Cells were cultured in standard conditions. A431 and SCC12 cells were transfected 
using DharmaFECT™ 2 (Dharmacon®, UK). HNCAF were transfected using 
DharmaFECT™ 1 (Dharmacon®, UK). The final concentration of siRNA in all 
transfections was 100nM. 
2.2.5.1 siRNA transfections per well (48 well plate)
1 x 104 A431 cells or 8 x 103 HNCAF cells were plated per well 12-24 hours prior to 
transfection.  
Depending on the stock concentration of the siRNA solution, either transfection mixture 
A or transfection mixture B was used.
Transfection Mixture A (siRNA stock concentration 2.5µM)
1. 10µl of 2.5µM siRNA solution was mixed with 15µl of Opti-MEM®.
2. 0.5µl of DharmaFECT™ transfection reagent with 24.5µl of Opti-MEM®.
Transfection Mixture B (siRNA stock concentration 20µM)
1. 12.5µl of 2µM siRNA solution was mixed with 12.5µl of Opti-MEM®.
2. 0.5µl of DharmaFECT™ transfection reagent with 24.5µl of Opti-MEM®.
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After 5 minutes 1 and 2 were mixed together and left for a further 20 minutes at room 
temperature to allow siRNA-liposomal complexes to form.  During this time cells were 
washed with PBS and covered with 200µl of Opti-MEM® with 5% FCS. Subsequently, 
the 50µl siRNA-DharmaFECT™ transfection reagent mix was added.  A further 250µl 
of Opti-MEM® with 5% FCS was then added following 24 hours of standard 
incubation. Depending on the nature of the experiment, transfections were stopped at 
48, 72 or 96 hours.
2.2.5.2 siRNA transfections per well (24 well plate)
1 x 104 A431 cells were plated per well 12-24 hours prior to transfection.  
Transfection Mixture (siRNA stock concentration 20µM)
1. 25µl of 2µM siRNA solution was mixed with 25µl of Opti-MEM®.
2. 1µl of DharmaFECT™ transfection reagent with 49µl of Opti-MEM®.
After 5 minutes 1 and 2 were mixed together and left for a further 20 minutes at room 
temperature to allow siRNA-liposomal complexes to form.  During this time cells were 
washed with PBS and covered with 400µl of Opti-MEM® with 5% FCS. The 100µl 
siRNA-DharmaFECT™ transfection reagent mix was then added to constitute a final 
transfection volume of 500µl. A further 500µl of Opti-MEM® with 5% FCS was then 
added following 24 hours of standard incubation. 
2.2.5.3 siRNA transfections per well (6 well plate)
2 x 105 A431 cells, 3 x 105 SCC12 cells or 2 x 105 HNCAF were plated per well 12-24 
hours prior to transfection.  
Transfection Mixture (siRNA stock concentration 20µM)
1. 50µl of 2µM siRNA solution was mixed with 50µl of Opti-MEM®.
2. 2µl of DharmaFECT™ transfection reagent with 98µl of Opti-MEM®.
After 5 minutes 1 and 2 were mixed together and left for a further 20 minutes at room 
temperature to allow siRNA-liposomal complexes to form.  During this time cells were 
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washed with PBS and covered with 800µl of Opti-MEM® with 5% FCS. The 200µl 
siRNA-DharmaFECT™ transfection reagent mix was then added to constitute a final 
transfection volume of 1ml. 
2.2.6 siRNA screening
Dharmacon® SMARTpool siRNA libraries targeting 289 E3 ubiquitin ligases and 137 
de-ubiquitinating enzymes (DUBs) were used to screen for their potential role in SCC 
invasion by initially assessing their ability to regulate the actin cytoskeleton of A431 
cells. 
2.2.6.1 siRNA screening in A431 cells
As detailed in Section 2.2.5, siRNA libraries were presented in a 96 well plate format 
with each SMARTpool consisting of 4 individual siRNA duplexes per gene. Each plate 
also contained empty wells and non-targeting siRNA controls. In addition, siRNA 
duplexes targeting Integrin β1 and Rho A were included. These acted as positive
transfection controls since both generate reproducible and characteristic changes in the 
cytoskeleton of A431 cells. The gene symbols and Dharmacon® catalogue numbers 
follow.
E3 Ubiquitin Ligase Library
Plate 1
ANKIB1 M-028950-01 ANKRD11 M-027299-01
ARIH2 M-020104-01 MARCH7 M-007055-01
BAZ1A M-006941-00 BBAP M-007143-01
BIRC2 M-004390-02 BIRC3 M-004099-02
BIRC4 M-004098-01 C17ORF27 M-023324-02
CBL M-003003-02 CBLB M-003004-02
CBLC M-006962-00 CBLL1 M-007069-00
CCNB1IP1 M-019251-01 CDC26 M-017290-00
CHD5 M-009878-00 RFWD2 M-007049-01
CUL7 M-017673-00 DCST1 M-016740-01
DET1 M-019393-00 DKFZP547C195 M-026520-01
DKFZP564A022 M-007078-01 DKFZP761H1710 M-007082-00
DPF1 M-031779-01 DTX3 M-007156-01
DTX4 M-026663-01 DZIP3 M-006910-00
EGFL9 M-014254-00 FANCL M-021486-00
FBXL14 M-015718-00 FBXL17 M-024385-00
FBXO17 M-013128-00 FBX018 M-017404-00
FBXO27 M-018558-00 C1ORF164 M-021044-01
FLJ12875 M-007062-02 FLJ20186 M-020685-01
FLJ20315 M-007004-02 FLJ23749 M-007108-01
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FLJ30092 M-027115-00 FLJ31951 M-007146-01
FLJ35757 M-007150-02 FLJ36180 M-007174-01
FLJ45273 M-027218-02 FLJ46380 M-032070-01
HACE1 M-007193-01 HECTD2 M-007198-00
FLJ21156 M-027468-03 NEDL1 M-007186-01
HECW2 M-007192-00 HERC2 M-007180-02
HOZFP M-021465-00 HRD1 M-007090-00
HUWE1 M-007185-01 IBRDC2 M-025119-00
ITCH M-007196-01 KIAA0317 M-007184-02
KIAA0804 M-023668-00 KIAA1333 M-007014-00
KIAA1542 M-026727-00 KIAA1991 M-032290-00
KIAA2025 M-021878-00 LNX2 M-007164-01
LOC285498 M-008019-00 LOC389822 M-029504-00
LOC442247 M-032292-01 LOC493829 M-032293-00
LOC51136 M-010205-01 LOC51255 M-006985-00
LRSAM1 M-007103-01 MAPKBP1 M-022225-00
FLJ20668 M-007006-02 LOC51257 M-006986-00
MARCH3 M-007116-02 MARCH9 M-015561-01
MDM2 M-003279-04 MGRN1 M-022620-00
LOC142678 M-015287-00 MID2 M-006938-00
Plate 2
MKRN1 M-006959-00 MKRN2 M-006960-01
MKRN3 M-006581-01 MNAB M-020453-02
MYCBP2 M-006951-01 MYLIP M-006976-00
MYST3 M-019849-01 NEDD4 M-007178-02
NHLRC1 M-027323-00 NSMCE1 M-007157-01
PDZRN3 M-023265-01 PHF7 M-019179-00
PJA1 M-007045-01 PJA2 M-006916-00
PRP19 M-004668-02 RCHY1 M-006966-01
RFPL1 M-006553-01 RFPL2 M-006935-01
RFPL3 M-006934-00 RFWD3 M-017095-01
RKHD1 M-031965-00 RKHD2 M-006989-00
RKHD3 M-022292-00 RNF10 M-006918-01
RNF103 M-006594-00 RNF11 M-006971-01
RNF111 M-007002-01 RNF12 M-006982-01
RNF121 M-007011-02 RNF122 M-007068-00
RNF123 M-007041-00 RNF125 M-007005-01
RNF126 M-007015-01 RNF127 M-007067-01
RNF128 M-007061-01 TRIM60 M-007153-00
RNF13 M-006944-01 RNF130 M-007021-00
RNF133 M-007155-00 PCGF6 M-007084-01
RNF135 M-007087-01 RNF137 M-007007-01
RNF138 M-006991-01 RNF141 M-006980-00
RNF146 M-007080-00 RNF148 M-010758-00
RNF149 M-007169-00 RNF150 M-010713-01
RNF151 M-030777-00 RNF152 M-007160-00
MARCH5 M-007001-00 RNF157 M-022965-01
RNF159 M-007089-00 RNF166 M-007119-00
RNF167 M-006967-00 FLJ35794 M-007152-00
RNF17 M-007026-00 LOC285533 M-007170-00
RNF18 M-007030-00 LOC285671 M-017714-00
MGC33993 M-007162-00 MGC4734 M-007134-00
FLJ10546 M-020828-00 FLJ38628 M-007107-00
FLJ20225 M-006999-00 RNF187 M-021939-00
RNF19 M-006965-00 RNF2 M-006556-00
RNF20 M-007027-00 RNF24 M-006943-00
RNF25 M-007047-00 RNF26 M-007060-00
RNF28 M-007093-00 TRIM55 M-007092-00
RNF3 M-006926-00 TRIM54 M-007032-00
RNF34 M-007072-00 RNF36 M-007137-00
RNF39 M-007074-00 RNF40 M-006913-00
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Plate 3
RNF41 M-006922-00 RNF44 M-006947-00
RNF5 M-006558-00 RUFY1 M-016355-00
SH3MD2 M-007037-00 SH3RF2 M-007145-00
SHPRH M-007167-00 SIAH1 M-012598-01
SIAH2 M-006561-01 SMC4L1 M-006837-00
SMURF1 M-007191-00 SMURF2 M-007194-00
STUB1 M-007201-01 SUGT1 M-012877-00
MARCH6 M-006925-00 TMEPAI M-010501-00
TRAF7 M-007086-00 TRIM10 M-006920-00
TRIM11 M-007075-00 TRIM15 M-007102-00
TRIM17 M-006981-00 TRIM2 M-006955-00
TRIM25 M-006585-00 TRIM3 M-006931-00
TRIM31 M-006939-00 TRIM34 M-006997-00
TRIM35 M-006952-01 TRIM36 M-007012-00
TRIM38 M-006929-00 TRIM39 M-007028-00
TRIM4 M-007101-00 TRIM40 M-007129-00
TRIM41 M-007105-00 TRIM42 M-007173-00
TRIM43 M-007127-00 TRIM45 M-007073-00
TRIM46 M-007071-00 TRIM47 M-007106-00
TRIM48 M-007059-00 TRIM5 M-007100-00
TRIM50A M-007130-00 TRIM50C M-031736-00
TRIM52 M-007095-00 TRIM56 M-007079-00
TRIM6 M-007121-00 FLJ10759 M-007010-00
LOC201292 M-018490-00 TRIM67 M-032288-00
TRIM7 M-007077-00 TRIM9 M-012974-00
TTC3 M-006570-00 UBE2L6 M-008569-00
UBE2N M-003920-01 UBQLN2 M-013566-00
VPS11 M-007022-00 VPS41 M-006972-00
KIAA1374 M-023638-00 FLJ36175 M-007203-00
WSB1 M-013015-00 WSB2 M-017223-00
WWP1 M-004251-00 WWP2 M-004252-01
ZC3HDC5 M-022950-00 ZFPL1 M-019375-00
ZFYVE19 M-017961-00 ZNF179 M-006588-00
ZNF183 M-006590-00 ZNF183L1 M-007135-00
ZNF294 M-006968-00 ZNF313 M-007024-00
ZNF364 M-006974-00 ZNF598 M-007104-00
FLJ25735 M-007148-00 ZNF650 M-016653-00
ZNRF1 M-007098-00 ZNRF2 M-007165-00
FLJ12747 M-010747-00 ZNRF4 M-007141-00
ZSWIM2 M-007142-00
Plate 4
ARIH1 M-019984-00 HERC4 M-021426-00
HERC5 M-005174-01 HERC6 M-005175-02
UBE3C M-007183-00 UBE3B M-007197-01
UBE3A M-005137-00 MID1 M-006537-00
SSA1 M-006563-02 TRIM28 M-005046-01
TRIM32 M-006950-00 TRIM37 M-006538-01
TRIM23 M-006523-00 TRIM33 M-005392-02
TRAF6 M-004712-00 UHRF1 M-006977-00
UHRF2 M-007117-00 UBCE7IP5 M-006949-00
AMFR M-006522-00 DTX2 M-007114-01
MID1 M-006537-00 PJA2 M-006916-00
RNF139 M-006942-00 RNF144 M-006912-00
RNF14 M-006906-01 RNF7 M-006907-01
RNF8 M-006900-00 RNF6 M-006559-00
RBX1 M-004087-01 LRSAM1 M-007103-00
UBAP1 M-017474-00 UBAP2 M-013168-00
ANUBL1 M-017760-00 UBL3 M-012786-00
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UBL4 M-020658-00 UBL5 M-014320-00
BARD1 M-003873-00 MDM4 M-006536-01
UBR1 M-010691-01 UBR2 M-006954-00
EDD1 M-007189-01 CHFR M-007018-01
TRIAD3 M-017305-00 PARK2 M-003603-00
NEDD4L M-007187-01 NEDD8 M-020081-00
SAE1 M-006402-00 UBA2 M-005248-00
PML M-006547-00 RFP M-006552-00
De-ubiquitinating Enzyme Library
Plate 1
ATXN3L M-024927-00 BAP1 M-005791-00
COPS5 M-005814-01 CXORF53 M-005798-02
CYLD M-004609-00 DUB1A M-028352-00
DUB3 M-027332-00 LOC391622 M-028355-00
FBX07 M-013606-00 FBX08 M-012435-00
FLJ14981 M-018630-00 JOSD1 M-017674-00
MJD M-012013-00 MYSM1 M-005905-01
OTUB1 M-021061-00 OTUB2 M-010983-00
OTUD1 M-026487-00 OTUD4 M-009927-00
OTUD5 M-013823-00 OTUD6B M-008553-00
OTUD7A M-008841-00 PARP11 M-016115-00
PRPF8 M-012252-01 PSMD14 M-006024-00
SBBI54 M-015500-00 SENP2 M-006033-00
SHFM3P1 M-009706-01 STAMBP M-012202-00
STAMBPL1 M-005783-01 TNFAIP3 M-009919-00
UBE1 M-004509-00 UBE1C M-005249-00
UBE1DC1 M-006405-00 UBE1L M-019759-00
UBE2A M-009424-00 UBE2B M-009930-00
UBE2C M-004693-01 UBE2D1 M-009387-01
UBE2D2 M-010383-01 UBE2D3 M-008478-00
UBE2E1 M-008850-01 UBE2E2 M-031782-00
UBE2E3 M-008845-00 UBE2G1 M-010154-01
UBE2G2 M-009095-01 UBE2H M-009134-00
UBE2I M-004910-00 UBE2J1 M-007266-00
UBE2J2 M-008614-00 UBE2L3 M-010384-01
UBE2L6 M-008569-00 UBE2M M-004348-00
UBE2N M-003920-01 UBE2NL M-031625-00
UBE2Q M-008631-01 UBE2R2 M-009700-01
UBE2S M-009707-00 UBE2V2 M-008823-00
UBE3A M-005137-00 UBE3B M-007197-01
UBE4A M-007200-00 UBE4B M-007202-01
UBL3 M-012786-00 UBL4 M-020658-00
UBL5 M-014320-00 UBR1 M-010691-01
UBTD1 M-018385-00 UCHL1 M-004309-00
UCHL3 M-006059-00 UCHL5 M-006060-01
UEV3 M-008494-00 UFD1L M-017918-00
USP1 M-006061-01 USP10 M-006062-01
USP11 M-006063-00 USP12 M-027148-00
USP13 M-006064-00 USP14 M-006065-01
USP15 M-006066-00 USP16 M-006067-00
Plate 2
USP18 M-004236-02 USP19 M-006068-01
USP2 M-006069-00 USP20 M-006070-01
USP21 M-006071-00 USP22 M-006072-00
USP24 M-006073-01 USP25 M-006074-01
USP26 M-006075-01 USP28 M-006076-01
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USP29 M-006077-00 USP3 M-006078-01
USP30 M-021294-02 USP31 M-022513-00
USP32 M-006080-01 USP33 M-006081-00
USP34 M-006082-00 USP35 M-006083-01
USP36 M-006084-01 USP37 M-006086-01
USP38 M-006086-01 USP39 M-006087-00
USP4 M-004974-01 USP40 M-006088-00
USP41 M-031434-00 USP42 M-006089-00
USP43 M-023019-00 USP44 M-006091-00
USP45 M-010054-00 USP46 M-006092-02
USP47 M-006093-00 USP48 M-006079-01
TRFP M-006094-00 USP5 M-006095-00
USP50 M-031837-00 USP51 M-032247-00
USP52 M-021192-00 USP53 M-027186-00
USP54 M-016853-00 USP6 M-006096-02
USP7 M-006097-00 USP8 M-005203-01
USP9X M-006099-01 USP9Y M-006100-01
VCPIP1 M-019137-00 YOD1 M-027369-00
ZA20D1 M-008670-00 ZRANB1 M-009270-00
SENP8 M-004071-00 SENP5 M-005946-01
SENP3 M-006034-00 SENP1 M-006357-00
PSMD7 M-009621-01 LOC220594 M-016888-01
MGC5306 M-014314-01 EIF3S3 M-003883-00
COPS8 M-015831-01
Controls
CTRL #1 D-001210-01 CTRL #2 D-001210-02
ITGB1 #1 D-004506-01 RHOA #1 D-003860-04
For each 96 well plate, 1 x 104 A431 cells were seeded per well in two 48 well plates 
and transfected as previously described (Section 2.2.5.1). Forty-eight hours after 
transfection, the cells were trypsinised and plated in 250µl of standard media on 
deformable collagen-Matrigel® gels (Section 2.2.7) in 8 well Lab-Tek™ II chambered 
coverglasses (NUNC™, UK). Cells were allowed to adhere for a further 24 hours 
before fixing with 4% paraformaldehyde (PFA) for 10 minutes.
For visualisation, cells were permeabilised with 0.25% Triton® X-100 for 10 minutes, 
blocked in 3% BSA in PBS for 1 hour and then stained with TRITC phalloidin (Sigma-
Aldrich®, UK)  and DAPI (Sigma-Aldrich®, UK).
Screening of cell phenotypes was done blindly, in duplicate and scored independently 
by three individuals.
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2.2.6.2 De-convolution of siRNA SMARTpools
SMARTpool upgrade kits were purchased from Dharmacon® and individual siRNA
duplexes reconstituted to stock solutions of 20µM. The oligonucleotides were then 
arranged in a 96 well plate format at a concentration of 2µM to facilitate screening as 
outlined above. 
The gene symbols, gene descriptions and Dharmacon® catalogue numbers of the 
SMARTpool upgrade kits are shown below. 
E3 Ubiquitin Ligases
CDC26 Cell division cycle 26 MU-017290-00
DKFZp761H1710 Hypothetical protein DKFZp761H1710 MU-007082-00
FLJ20315 Hypothetical protein FLJ20315 MU-007004-00
LOC389822 Hypothetical protein LOC389822 MU-029504-00
MARCH3 Membrane-associated ring finger 3 MU-007116-00
MKRN2 Makorin, ring finger protein 2 MU-006960-00
PJA1 Praja 1 MU-007045-00
RFWD3 Ring finger and WD repeat domain 3 MU-017095-00
RKHD2 Ring finger and KH domain containing 2 MU-006989-00
RNF11 Ring finger protein 11 MU-006971-00
RNF12 Ring finger protein 12 MU-006982-00
RNF123 Ring finger protein 123 MU-007041-00
RNF126 Ring finger protein 126 MU-007015-00
FLJ10546 Hypothetical protein FLJ10546 MU-020828-00
RNF2 Ring finger protein 2 MU-006556-00
RNF41 Ring finger protein 41 MU-006922-00
RNF44 Ring finger protein 44 MU-006947-00
RNF5 Ring finger protein 5 MU-006558-00
SUGT1 SGT1, suppressor of G2 allele of SKP1 MU-012877-00
TRIM11 Tripartite motif-containing 11 MU-007075-00
TRIM3 Tripartite motif-containing 3 MU-006931-00
TRIM4 Tripartite motif-containing 4 MU-007101-00
VPS11 Vacuolar protein sorting 11 MU-007022-00
ZNF364 Zinc finger protein 364 MU-006974-00
ZNF598 Zinc finger protein 598 MU-007104-00
FLJ12747 Novel C3HC4 type zinc finger MU-010747-00
HERC4 Hect domain and RLD 4 MU-021426-00
HERC6 Hect domain and RLD 6 MU-005175-02
UBE3A Ubiquitin protein ligase E3A MU-005137-00
TRIM33 Tripartite motif-containing 33 MU-005392-02
TRAF6 TNF receptor-associated factor 6 MU-004712-00
RNF14 Ring finger protein 14 MU-006906-01
Mdm4 Mdm4 MU-006536-01
SAE1 SUMO-1 activating enzyme subunit 1 MU-006402-00
De-ubiquitinating Enzymes
BAP1 BRCA1 associated protein-1 MU-005791-00
DUB1A De-ubiquitinating enzyme 1A MU-028352-00
DUB3 De-ubiquitinating enzyme 3 MU-027332-00
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OTUD7A OTU domain containing 7A MU-008841-00
FLJ14981 Hypothetical protein FLJ14981 MU-018630-00
USP12 Ubiquitin specific protease 12 MU-027148-00
USP2 Ubiquitin specific protease 2 MU-006069-00
TRFP Trf-proximal homolog MU-006094-00
ZA20d1 Zinc finger, A20 domain containing 1 MU-008670-00
USP6 Ubiquitin specific protease 6 MU-006096-02
PSMD7 Proteasome 26S subunit, non-ATPase 7 MU-009621-01
2.2.6.3 siRNA screening in HNCAF
Two individual siRNA duplexes were selected for each ‘2nd Round’ gene hit and 
arranged in a 96 well plate at a concentration of 2µM. 8 x 103 HNCAF were plated per 
well in two 48 well plates and screening carried out as previously described (Sections 
2.2.5.1 and 2.2.6.1). If both duplexes produced a consistent phenotype the gene was 
retained for further study and was designated a ‘CAF’ hit. 
The target gene, oligonucleotide name and Dharmacon® catalogue number for each 
siRNA duplex included in this screen is listed below.
E3 Ubiquitin Ligases
       CDC26 CDC26 #2 D-017290-02
CDC26 #4 D-017290-04
       MARCH3 MARCH3 #1 D-007116-01
MARCH3 #3 D-007116-03
       MKRN2 MKRN2 #1 D-006960-01
MKRN2 #4 D-006960-04
       PJA1 PJA1 #2 D-007045-02
PJA1 #4 D-007045-04
       RFWD3 RFWD3 #2 D-017095-02
RFWD3 #4 D-017095-04
       RKHD2 RKHD2 #1 D-006989-01
RKHD2 #4 D-006989-04
       RNF12 RNF12 #3 D-006982-03
RNF12 #4 D-006982-04
       RNF126 RNF126 #1 D-007015-01
RNF126 #3 D-007015-03
       FLJ10546 FLJ10546 #3 D-020828-03
FLJ10546 #4 D-020828-04
       RNF2 RNF2 #1 D-006556-01
RNF2 #3 D-006556-03
       RNF41 RNF41 #3 D-006922-03
RNF41 #4 D-006922-04
       SUGT1 SUGT1 #3 D-012877-03
SUGT1 #4 D-012877-04
       TRIM11 TRIM11 #2 D-007075-02
TRIM11 #3 D-007075-03
       ZNF598 ZNF598 #2 D-007104-02
ZNF598 #3 D-007104-03
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       HERC4 HERC4 #3 D-021426-03
HERC4 #4 D-021426-04
       HERC6 HERC6 #3 D-005175-04
HERC6 #4 D-005175-06
       TRAF6 TRAF6  #2 D-004712-02
TRAF6  #3 D-004712-03
       RNF14 RNF14 #3 D-006906-03
RNF14 #4 D-006906-04
       Mdm4 Mdm4 #2 D-006536-03
Mdm4 #3 D-006536-04
       SAE1 SAE1 #1 D-006402-01
SAE1 #4 D-006402-04
De-ubiquitinating Enzymes
        BAP1 BAP1 #2 D-005791-02
BAP1 #4 D-005791-04
        DUB1A DUB1A #2 D-028352-02
DUB1A #3 D-028352-03
        FLJ14981 FLJ14981 #2 D-018630-02
FLJ14981 #3 D-018630-03
        USP12 USP12 #3 D-027148-03
USP12 #4 D-027148-04
        USP2 USP2 #1 D-006069-01
USP2 #4 D-006069-04
        TRFP TRFP #2 D-006094-02
TRFP #4 D-006094-04
        ZA20d1 ZA20d1 #1 D-008670-01
ZA20d1 #3 D-008670-03
        USP6 USP6 #2 D-006096-07
USP6 #3 D-006096-08
        PSMD7 PSMD7 #3 D-009621-03
PSMD7 #4 D-009621-05
        
Controls
             - CTRL #1 D-001210-01
- CTRL #2 D-001210-02
        ITGB1 ITGB1 #1 D-004506-01
        RHOA RHOA #1 D-003860-04
2.2.6.4 Qiagen® siRNA screen
For the genes identified as potential candidates for detailed study four further siRNA 
duplexes were obtained. These were used initially to assess the validity of the cell 
phenotypes already observed in the A431 cells following gene silencing. 
Individual siRNA duplexes were purchased from Qiagen® and reconstituted to stock 
solutions of either 10µM or 20µM dependent upon their formulation. The 
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oligonucleotides were then arranged in a 48 well plate format at a concentration of 2µM 
and screened in A431 cells as previously discussed (Section 2.2.6.1). 
The target gene, oligonucleotide name and Qiagen® catalogue number for each siRNA 
duplex included in this screen is listed below.
E3 Ubiquitin Ligases
       RKHD2 RKHD2 #A S100703696
RKHD2 #B S103028487
RKHD2 #C S100703675
RKHD2 #D S100764862
       TRAF6 TRAF6 #A S103046043
TRAF6 #B S103050145
TRAF6 #C S100066101
TRAF6 #D S100066122
De-ubiquitinating Enzymes
       ZA20d1 ZA20d1 #A S100764869
ZA20d1 #B S100764876
ZA20d1 #C S100764855
ZA20d1 #D S100764862
       USP6 USP6 #A S102633442
USP6 #B S103032715
USP6 #C S100064512
USP6 #D S100064519
2.2.7 Collagen-Matrigel® matrix
The collagen-Matrigel® gel mix which formed the three-dimensional extra-cellular 
matrix used throughout the stages of siRNA screening consisted of rat tail collagen type 
1 (typically 9.03mg/ml) mixed with 5X αMEM containing sodium bicarbonate, 20% 
Matrigel® (typically 11.2mg/ml) and 10% FCS.  The volume was made up with 
standard media depending on the cell line being used in the assay (Section 2.2.1). The 
gel mix was then applied to 8 well Lab-Tek™ II chambered coverglasses using a sealed 
glass pipette; 45µl of gel being sufficient to cover a surface area of 0.7cm2 per well. 
Finally, each gel was left to polymerise for 20 minutes at 37ºC to allow the collagen-
Matrigel® matrix to be fully formed prior to seeding cells onto its surface.
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2.2.8 Organotypic invasion assays
2.2.8.1 The organotypic culture system
The organotypic culture system was set up as previously described 77. The constituents 
of a single organotypic collagen gel are listed below:
Organotypic collagen gel mix       µl
      Matrigel® (11.2mg/ml)       200
      Rat tail collagen type I (9.03mg/ml)       400
      5X αMEM with sodium bicarbonate        80
      FCS       100
      FAD medium with 10% FCS       120
      5 x 105 HNCAF suspended in FAD medium with 10% FCS       100
                                                               _____
      Total Volume      1000
The collagen gel mix was prepared on ice and 900µl of this solution aliquoted into wells 
of a 24 well plate and allowed to polymerise for 30 minutes at 37ºC.  The final collagen 
concentration and Matrigel® concentration per gel was 3.612mg/ml and 2.24mg/ml 
respectively. Once the gels were set, 1ml of complete media was added per well and the 
gels left to equilibrate at 37ºC for 24 hours before changing the media daily thereafter. 
A fibroblast-free collagen gel mix was also used to coat sterile nylon discs (Millipore, 
UK). After incubating at 37ºC for 20 minutes, the gel coated discs were fixed in 1% 
glutaraldehyde for 1 hour, washed four times in PBS, twice in complete media and then 
stored at 4ºC.
At 72 hours, 5 x 105 SCC12 cells were seeded on to each gel in complete media. The 
next day, the gels were lifted on to individual collagen coated nylon discs resting on 
stainless steel bridges placed in 6 well plates. Sufficient complete media was then added 
to feed each organotypic culture from beneath the bridge thus allowing the epithelial 
layer to grow at an air-liquid interface. Media was changed daily throughout the 
duration of the assay.
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One week following gel preparation, the cultures were fixed in either 4% 
paraformaldehyde (PFA) with 0.25% gluteraldehyde in PBS or 10% normal buffered 
formalin (NBF). After 4 hours, specimens were bisected, transferred to 70% EtOH and 
embedded in paraffin wax on their cut edge. 4µm sections taken at 50µm intervals were 
stained with haematoxylin and eosin (H&E) for quantitative analysis (Section 2.10.2). 
The processing, embedding and staining of samples was performed by the Cancer 
Research UK Experimental Histopathology Laboratory.
2.2.8.2 SCC invasion screen
SCC12 cells were transfected as outlined in Section 2.2.5.3 and after 24 hours plated on 
to organotypic collagen gels as above. Two individual siRNA duplexes were selected 
for each gene hit. The siRNA oligonucleotides included in this screen were those listed 
in Section 2.2.6.3. 
Previous work from our group has established Cdc42 to be a key regulator of SCC12 
carcinoma invasion in this system 77. siRNA targeting Cdc42 was therefore used to 
assess the effect of gene knockdowns on invasion and acted as a positive control for 
transfection efficiency. Organotypic cultures in which SCC12 cells had either been 
transfected with a non-targeting siRNA duplex or were not transfected were also 
included. A collagen gel without fibroblasts was set up routinely in each assay.
Controls
             - CTRL #1 D-001210-01
         CDC42 Cdc42 #2 HOOSA-000009
This screen was carried out over several months and assays which identified genes as 
being possible regulators of carcinoma invasion were repeated.
2.2.8.3 Inhibition of SCC invasion by HNCAF interference
To assess the influence of the ‘CAF’ gene hits on the ability of stromal fibroblasts to 
promote SCC invasion, a  modified  two-stage  organotypic  invasion  assay  was  used. 
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This assay was performed twice and involved knocking down the genes of interest in 
HNCAF as described in Section 2.2.5.3. The next day, organotypic collagen gels were 
constructed as outlined in Section 2.2.8. After a further 5 days, the gels were 
photographed to document the degree of matrix contraction (Section 2.10.3) before 
being incubated in complete media with puromycin (5µg/ml) for 48 hours at 37ºC to kill 
the fibroblasts. Complete media was used to wash the gels four times; each wash being 
greater than 1 hour. 5 x 105 SCC12 cells were then plated on top of each gel and the 
organotypic cultures proceeded as usual.
Inhibition of ROCK in fibroblast-SCC co-cultures is known to reduce carcinoma 
invasion due to insufficient fibroblast-mediated matrix remodelling 77. Hence, siRNA 
targeting ROCK1 and ROCK2 was selected as the positive transfection control. The 
target gene, oligonucleotide name and Dharmacon® or Qiagen® catalogue number for 
each siRNA duplex used in this assay is listed below. 
E3 Ubiquitin Ligases
       MKRN2 MKRN2 #1 D-006960-01
MKRN2 #4 D-006960-04
       RKHD2 RKHD2 #1 D-006989-01
RKHD2 #4 D-006989-04
       HERC4 HERC4 #3 D-021426-03
HERC4 #4 D-021426-04
       TRAF6 TRAF6  #2 D-004712-02
TRAF6  #3 D-004712-03
        Mdm4 Mdm4 #2 D-006536-03
Mdm4 #3 D-006536-04
        SAE1 SAE1 #1 D-006402-01
SAE1 #4 D-006402-04
De-ubiquitinating Enzymes
       
        ZA20d1 ZA20d1 #1 D-008670-01
ZA20d1 #3 D-008670-03
        USP6 USP6 #2 D-006096-07
USP6 #3 D-006096-08
Controls
             - CTRL #4 D-001210-04
- CTRL #Q     1027280
        ROCK1 ROCK #1 D-003536-05
        ROCK2 ROCK #2 D-004610-05
101
2.2.8.4 Validation of candidate genes as regulators of SCC invasion
Serial organotypic cultures as described in Section 2.2.8.1 were carried out using the 
siRNA oligonucleotides shown below: 
TRAF6
   TRAF6 #1   GGAGAAACCUGUUGUGAUUUU D-004712-01
   TRAF6 #2  GGACAAAGUUGCUGAAAUCUU D-004712-02
   TRAF6 #3   GUUCAUAGUUUGAGCGUUAUU  D-004712-03
   TRAF6 #B  UACGCGAACGUGGAAGUCAAU S103050145
   TRAF6 #C  GUCCCUACUCAAAUUUGGGAU S100066101
   TRAF6 #D  GUCGCGACACGUUUGAUAUAU S100066122
ZA20d1
   ZA20d1 #1 GGACAUGGAUGCUGUUCUGUU D-008670-01
   ZA20d1 #2 GAAUCUAUCUGCCUUUGGAUU D-008670-02
   ZA20d1 #3 GAAGGAGAAUACCAAGGAAUU D-008670-03
   ZA20d1 #A UUCCUCCGAUUUGUUUCAAUU S100764869
   ZA20d1 #B GGCCGCCUUCCUCUUCAGUUU S100764876
   ZA20d1 #C UUCCUCCAAGAGUCAGUUAUU S100764855
Controls
  CTRL #1 UAGCGACUAAACACAUCAA D-001210-01
   CTRL #Q Sequence not specified    1027280
   Cdc42 #2 AGACUCCUUUCUUGCUUGUUU HOOSA-000009
In experiments where cells were depleted of both TRAF6 and ZA20d1, siRNA duplexes 
were added in equal concentration in the transfection mix. The final concentration of 
siRNA was 100nM.
2.2.8.5 A431 organotypic cultures
Organotypic assays were performed with A431 cells. Compared to SCC12 cells, A431 
cells were intrinsically less invasive in this system and therefore the duration of the 
assays were lengthened to 2 weeks. Organotypic collagen gels were set up as described 
in Section 2.2.8 and allowed to remodel for 7 days before adding 5 x 105 A431 cells.  
The cultures then proceeded as normal until fixation on Day 14. 
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2.2.8.6 Investigating NF-ĸB signalling in SCC invasion
NF-ĸB signalling in our organotypic system was investigated using several cytokines 
and small molecule inhibitors. These were added to the medium which was changed 
daily throughout the duration of the assay. Doses varied according to the assay 
performed and are specified in the relevant section. The cytokines, inhibitors and their 
targets are listed below:
Cytokine / Inhibitor      Target          Source
Tumour Necrosis Factor alpha    TNFα TNFRs First Link UK Ltd.
Interleukin 1 alpha    IL-1α IL-1Rs / TLRs Calbiochem®, UK
IKK Inhibitor II    IKKI-II IKKα / IKKβ Calbiochem®, UK
IKK-2 Inhibitor    IKKI-2 IKKβ Calbiochem®, UK
IKK Inhibitor III    IKKI-III IKKβ Calbiochem®, UK
IKK Inhibitor X    IKKI-X IKK complex Calbiochem®, UK
* Vehicles: IL-1α ~ BSA (0.1%) and IKK Inhibitors ~ DMSO (>99%)
Organotypic cultures were also performed with the daily addition of infliximab 
(Centocor BV, The Netherlands), a monoclonal antibody to TNFα in clinical use. This 
was a gift from Professor Martin Gore (The Royal Marsden Hospital, London).
2.3 Bacterial techniques
2.3.1 Bacterial media and plates
Escherichia coli (E.coli) bacteria were grown in suspension in either Luria-Bertani 
medium (LB) or Terrific Broth (TB) containing the appropriate antibiotic to select for 
the DNA construct of interest. Similarly, transformations were plated on to 10cm dishes 
with agar containing either ampicillin (50µg/ml), blasticidin (50µg/ml) or kanamycin 
(50µg/ml).
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2.3.2 Bacterial strains
Novablue Competent Cells™ (Novagen®, UK) were used for transformations of all 
plasmids. Competent E.coli bacteria were generated as follows.
E.coli were grown overnight in 20ml LB medium at 37 C. The next day 5ml of the 
20ml culture was added to 500ml of fresh LB medium and the culture re-incubated at 
37C on a rotary shaker. When the optical density of the culture (measured at a 
wavelength of 600nm) reached 0.6, the flask was chilled on ice and centrifuged at 
4,000rpm for 20 minutes at 4ºC. The supernatant was discarded and the pelleted 
bacteria re-suspended in 100ml of sterile Transformation Buffer 1 (TFB1).  
The bacteria were again centrifuged at 4,000rpm at 4C for 20 minutes, the supernatant 
removed and the pellet re-suspended in 20ml of chilled sterile Transformation Buffer 2 
(TFB2). The bacterial suspension was kept on ice for 15 minutes before being aliquoted 
into 1.5ml Eppendorf tubes. The samples were then snap frozen in dry ice and placed in 
a -80ºC freezer for long-term storage. 
Transformation Buffer 1 (TFB1)
     Potassium acetate (CH3COOK) 30mM
     Manganese chloride (MnCl2) 50mM
     Potassium chloride (KCl) 100mM
     Calcium chloride, (CaCl2) 10mM
     Glycerol 15 %
Transformation Buffer 2 (TFB2)
     4-morpholinepropanesulfonic acid (MOPS) 10mM
     Calcium chloride (CaCl2) 76mM
     Potassium chloride (KCl) 10mM
     Glycerol 15 %
     pH 7.0
2.3.3 Bacterial transformation
Competent E.coli bacteria were thawed on ice for 15 minutes. 130µl of bacterial 
suspension was mixed with 1µg of plasmid DNA and incubated on ice for a further 15 
minutes. The competent cell-DNA mix was then heated in a water bath at 42ºC for 
exactly 90 seconds and returned to ice for 2 minutes. 800µl of LB was added to the 
bacteria before incubating them again for another 45 minutes at 37ºC. After centrifuging 
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at 4,000rpm for 5 minutes, the bacterial pellet was re-suspended in 200µl of LB. This 
bacterial suspension was spread over an agar plate containing the appropriate antibiotic 
and incubated overnight at 37ºC. The next day the plate was inspected for colony 
formation.  
2.4 Plasmids
2.4.1 pUNO-hTRAF6-HA
The plasmid pUNO-hTRAF6-HA was purchased from InvivoGen™, (Autogen Bioclear 
UK Ltd.) and contained the hTRAF6 gene fused to the influenza haemagglutinin 
epitope tag (YPYDVPDYA x 3) at the 3’ end. Features of the pUNO expression vector 
included: the human EF-1α / HTLV hybrid promoter, a multiple cloning region with 
convenient restriction enzyme sites, a polyadenylation signal, and the blasticidin 
resistance gene (bsr) driven by the SV40 promoter in tandem with the bacterial EM7 
promoter.
2.5 Nucleic acid methods
2.5.1 Preparation of plasmid DNA
The preparation and purification of plasmid DNA from small volume overnight 
bacterial cultures was performed using the QIAfilter Plasmid Midi Kit (Qiagen®, UK). 
All buffers were supplied with the kit and all the steps were carried out at room 
temperature unless otherwise indicated. 
Single colonies of E.coli bacteria transformed with the pUNO-hTRAF6-HA construct 
were inoculated into 50ml of InvivoGen™ BLAS TB medium (Autogen Bioclear UK 
Ltd.) and left to incubate overnight in 5% CO2 at 37ºC. The next day pelleted bacteria 
were re-suspended in 4ml of Buffer P1, mixed with 4ml of Buffer P2 and left to stand 
for 5 minutes. After adding 4ml of chilled Buffer P3 the mixture was inverted gently 
105
and left on ice for 20 minutes. The sample was then centrifuged at full speed at 4ºC for 
30 and 15 minutes respectively.
After each centrifugation the DNA containing supernatant was removed and placed into 
a QIAGEN-tip which had previously been equilibrated with Buffer QBT. The tip was 
then washed twice with two 10ml aliquots of Buffer QC following which the DNA was 
eluted with 5ml of Buffer QF. DNA, precipitated by the subsequent addition of 3.5ml of 
isopropanol, was pelleted by centrifuging at 10,000rpm at 4ºC for 30 minutes. After 
washing with 2ml of 70% EtOH and a final centrifugation at 10,000rpm at 4ºC for 10 
minutes, the DNA was air dried for 10 minutes and then dissolved in 500µl distilled 
water.
Buffer P1
     Trizma® HCl 50mM
     EDTA 10mM
     RNase A 100µg/ml
     pH 8.0
Buffer P2
     Sodium hydroxide (NaOH ) 200mM
     SDS 1%
Buffer P3
     Potassium acetate (CH3COOK) 3M
     pH 5.5
     
Buffer QBT
     Sodium chloride (NaCl) 750mM
     4-morpholinepropanesulfonic acid (MOPS) 50mM
     Isopropanol (C3H7OH) 15%
     Triton® X-100 15%
     pH 5.5
     
Buffer QC
     Sodium chloride (NaCl) 1M
     4-morpholinepropanesulfonic acid (MOPS) 50mM
     Isopropanol (C3H7OH) 15%
     pH 7.0
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Buffer QF
     Sodium chloride (NaCl) 1.25M
     Trizma® HCl 50mM
     Isopropanol (C3H7OH) 15%
     pH 8.5
2.5.2 Nucleic acid quantification
The concentration of nucleic acid from Midipreps was determined using a NanoDrop™ 
spectrophotometer (Thermo Fisher Scientific Inc., UK) which measures the absorbance 
of a 1µl sample at a wavelength of 260nm.
2.5.3 Preparation of RNA
The preparation and purification of RNA from cells grown in culture was performed 
using the RNeasy Mini Kit (Qiagen®, UK). All buffers were supplied with the kit and 
all the steps were carried out at room temperature unless otherwise stated. RNase-free 
tubes and pipette tips were used.
Typically 3 x 105 cells in a single well of a 6 well plate were lysed directly by the 
addition of 600µl of Buffer RLT containing 6µl of β-mercaptoethanol (β-ME). The 
lysate was homogenised in an RNase-free tube by passing it through a 20-gauge needle 
(0.9mm diameter) 15 times and 600µl of 70% EtOH was added. Up to 700µl of the 
sample was loaded into an RNeasy spin column and centrifuged at 10,000rpm for 15 
seconds. The flow through was discarded and this step repeated until the whole sample 
had been transferred to the spin column. The column membrane was now washed by 
centrifuging with 350µl of Buffer RW1 at 10,000rpm for 15 seconds.
To reduce the risk of genomic DNA contamination, DNase digestion was carried out for 
15 minutes on the column according to the manufacturer’s instructions using the 
RNase-Free DNase Set (Qiagen®, UK). Following this, the membrane was washed 
again with Buffer RW1 as described above.
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Finally, 500µl of Buffer RPE was spun through the column at 10,000rpm for 15 seconds 
twice. Once dry, the RNA was eluted in 50µl of RNase-free water and quantified using 
a NanoDrop™ spectrophotometer (Section 2.5.2).
Buffer RLT
     Proprietary buffer containing guanindine thiocyanate (C2H6N4S).
     
Buffer RW1
     Proprietary buffer containing EtOH and guanindine thiocyanate (C2H6N4S).
Buffer RPE
     Proprietary buffer of unspecified composition.
2.5.4 Preparation of cDNA
Complementary DNA (cDNA) was prepared by reverse transcription as follows:
    µg
      RNA template  2.0
      Random Primer Mix (500µg/ml) *  1.0
The RNA-random primer mix was made up to a total volume of 14µl using nuclease-
free water before heating to 75ºC for 5 minutes. After cooling on ice for a further 5 
minutes, the following were added.
    µl
      5X M-MLV Reverse Transcriptase Buffer *  5.0
      dNTPs (10µM) *  5.0
      M-MLV Reverse Transcriptase *  1.0
                        ____
      Reaction Volume 25.0
* Purchased from Promega, UK
The reaction mixture was allowed to equilibrate at room temperature for 10 minutes, 
before being heated to 40ºC for 50 minutes. 75µl of nuclease-free water was then added 
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to the resultant cDNA solution to a total volume of 100µl. cDNA samples were stored at 
-20ºC.
2.5.4.1 Generating a cDNA library
cDNA was generated from A431 gene depleted cells as described in Sections 2.2.5.2, 
2.5.3 and 2.5.4. The siRNA oligonucleotides used for gene depletion are listed below:
E3 Ubiquitin Ligases
       RKHD2 RKHD2 #1, #2, #3, #4, #A, #B, #C and #D
       TRAF6 TRAF6 #1, #2, #3, #4, #A, #B, #C and #D
       
De-ubiquitinating Enzymes
       ZA20d1 ZA20d1 #1, #2, #3, #4, #A, #B, #C and D
       
Controls
        MOCK       -
             - CTRL #1
        RHOA RHOA #1
2.5.5 Polymerase chain reaction (PCR)
Polymerase chain reactions (PCRs) were carried out using a GeneAmp PCR System 
2700 thermal cycler (Applied Biosystems, UK) with the protocol detailed below. 
PCR mix     µl
      5X Phusion™ GC Buffer containing 7.7mM MgCl2 **  5.0
      dNTPs (10µM) *  2.0
      DNA template (10ng)         0.5
      Phusion™ DNA Polymerase **  0.5
      Forward primer (10µM)  5.0
      Reverse primer (10µM)  5.0
      dH2O  7.0
            ____
      Reaction Volume  25.0
* Purchased from Promega, UK. ** Purchased from Finnzymes Inc., USA.
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PCR temperature cycles
      95ºC 5 minutes      
25-28 cycles of:
      95ºC 1 minute Denaturing
      54ºC 1 minute Annealing              
      72ºC 1 minute Extension 
      
      72ºC 10 minutes
        4ºC Hold
2.5.5.1 Primer design
Primer 3 software (Whitehead Institute for Biomedical Research, USA) was used to 
design forward and reverse DNA primers which would generate gene products of 150-
250 base pairs. A BLAST search for each oligonucleotide sequence was conducted 
against the human genome to assess gene specificity prior to ordering it from Sigma-
Aldrich®, UK.  At least 2 pairs of primers were constructed for each gene of interest 
and their respective PCR products verified by agarose gel electrophoresis (Section 
2.5.7). The details of regularly used primers are shown below.
E3 Ubiquitin Ligases
Gene          Primer           Sequence            TmºC   Product Size (bp)
RKHD2 1F   GGAGAAAGAGCGTCAACACC 59.85 190
1R   GCCATGGCAACATCTTCTTT 60.08
2F   GGAGAAAGAGCGTCAACACC 59.85 248
2R   GTTTCGAGATGCACGAATCA 59.81
TRAF6 1F   CTGCAAAGCCTGCATCATAA     59.98 224
1R   GGGGACAATCCATAAGAGCA 59.89
2F   TGCCATGAAAAGATGCAGAG 59.95 174
2R   AAGGCGACCCTCTAACTGGT 60.13
De-ubiquitinating Enzymes
Gene          Primer           Sequence            TmºC   Product Size (bp)
ZA20d1 1F   CACGTCTTTGTCCTTGCTCA 60.02 202
1R   TGGACACGAGTGCAGAAAAG 60.02
2F CATTTGCCCCTATTCCCTTT 60.14 195
2R   GCAAGGGCAGCAGCTTATAC 60.01
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Control
Genes          Primer           Sequence            TmºC   Product Size (bp)
GAPDH 1F   CGACCACTTTGTCAAGCTCA 60.02 203
1R   AGGGGAGATTCAGTGTGGTG 59.96
2F ACGGATTTGGTCGTATTGGGC 65.17 157
2R   TTGACGGTGCCATGGAATTTG 66.10
RHOA 1F   AAGGACCAGTTCCCAGAGGT 59.97 228
1R   TTCTGGGGTCCACTTTTCTG 60.08
2F   GTGCCCACAGTGTTTGAGAA 59.73 171
2R   ACTATCAGGGCTGTCGATGG 60.10
DNA oligonucleotides were reconstituted to stock solutions of 100µM using Milli-Q™ 
water according to the manufacturer’s instruction. For PCR, 10µM secondary stock 
solutions were used.
2.5.6 Quantitative PCR (qPCR)
Platinum® SYBR® Green qPCR SuperMix-UDG with ROX (Invitrogen, UK) was used 
for the amplification and detection of DNA in real-time quantitative PCR (qPCR) in 
conjunction with the 7900HT Fast Real-Time PCR System (Applied Biosystems™, 
UK).  
Platinum® SYBR® Green qPCR SuperMix-UDG with ROX
     Platinum® Taq DNA polymerase
     SYBR® Green I dye
     Trizma® HCl
     Potassium chloride (KCl)
     Magnesium chloride (MgCl2) 6mM
     dGTP 400µM
     dATP 400µM
     dCTP 400µM
     dUTP 800µM
     Uracil DNA glycosylase (UDG)
     ROX Reference Dye 1µM
     Stabilizers
  
All real-time polymerase chain reactions (qPCRs) were carried out in an ABI Prism
96 well optical reaction plate (Applied Biosystems, UK) and were set up on ice. The 
protocol for a single reaction is detailed below. 
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qPCR mix     µl
      DNA template (10ng)         0.5
      Platinum® SYBR® Green qPCR SuperMix-UDG with ROX 12.5
      Forward primer (10µM)  0.5
      Reverse primer (10µM)  0.5
      Milli-Q™ H2O 11.0
            ____
      Reaction Volume  25.0
PCR temperature cycles
      50ºC 2 minutes UDG incubation
      95ºC 2 minutes
40 cycles of:      
      95ºC 15 seconds Denaturing              
      60ºC 30 seconds Annealing / Extension
        4ºC Hold
2.5.7 Agarose gel electrophoresis
DNA samples (10µl) were mixed with 5µl of 6X gel loading buffer (0.25% 
bromophenol blue and 0.25% xylene cyanol in 30% glycerol) and loaded into the lanes 
of an agarose gel. 0.8% to 2% agarose gels were selected according to the size of the 
DNA fragments being separated. Ethidium bromide (Sigma-Aldrich®, UK), at a final 
concentration of 5µg/ml, was added to the agarose during the gel casting process and 
gel electrophoresis was performed in 0.5X TBE buffer at 70 volts for 1-2 hours. The 
DNA was visualised using a UV transilluminator with a wavelength of 254nm.
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2.5.8 Purification of DNA from agarose gels
DNA bands cut from agarose gels were purified using an illustra™ GFX™ PCR DNA 
and Gel Band Purification Kit (GE Healthcare UK Ltd.) according to the manufacturer’s 
instructions. 
In summary, the agarose band containing DNA was dissolved in 300l of Capture 
Buffer Type 3 by heating to 60ºC for 15 minutes before being transferred to an 
assembled GFX MicroSpin™ column and collection tube. After centrifugation at 
13,000rpm for 30 seconds, the column was washed with 500l of Wash Buffer Type 1. 
Once dry, the DNA was eluted in 20-50µl of distilled water and quantified using a 
NanoDrop™ spectrophotometer (Section 2.5.2).
Capture Buffer Type 3
     Proprietary buffer of unspecified composition containing a pH indicator to visually
     identify the optimal time for DNA binding to the silica membrane of the column.
Wash Buffer Type 1
     Proprietary buffer of unspecified composition containing EtOH.
2.5.9 DNA sequencing
DNA constructs were sequenced using the Big Dye® Terminator (BDT) Kit (Applied 
Biosystems™, UK) in accordance with the manufacturer’s instructions. Each 
sequencing reaction consisted of:
Sequencing mix     µl
      DNA template (100ng)         1.0
      BDT reaction mix  8.0
      Primer (3.2pmol)  1.0
      dH2O 10.0
            ____
      Reaction Volume 20.0
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Sequence temperature cycles
      95ºC 1 minute
25 cycles of:      
      96ºC 10 seconds Denaturing              
      61ºC 5 seconds Annealing 
      60ºC 4 minutes Extension
        4ºC Hold
Sequencing reactions were purified using PERFORMA® DTR Gel Filtration Cartridges 
(EdgeBio,USA). After air drying at room temperature, the DNA was analysed by an in 
house research services laboratory (Cancer Research UK Equipment Park).
2.6 Protein methods
2.6.1 Preparation of cell lysates for Western blotting
Cells were cultured in 6 well plates. After washing once with PBS on ice, cells were 
lysed directly by the addition of 150-250µl of 1X SDS gel loading buffer per well. 
Lysates were sonicated three times for 5 seconds each and heated to 95ºC for 5 minutes 
prior to being stored at -80ºC.
2.6.2 SDS-PAGE gel electrophoresis 
Samples were separated by electrophoresis under reducing conditions using 1.5mm 10% 
SDS-polyacrylamide mini-gels constructed as follows:
Running Gel Layer                  µl
     SDS   10%   100
     Trizma® HCl at pH 8.8   1M 3,750
     Acrylamide   40% 2,500
     Ammonium persulphate   20%    50
     TEMED    10
     dH2O 3,590
 ____
     Total Volume            10,000
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Once poured, the running gel was overlaid with water and allowed to polymerise for 20 
minutes. When set, a 5% stacking gel was prepared as shown below:
Stacking Gel Layer                  µl
     SDS   10%    50
     Trizma® HCl at pH 6.8   1M   625
     Acrylamide   40%   625
     Ammonium persulphate   20%    25
     TEMED     5
     dH2O 3,670
 ____
     Total Volume             5,000
The overlay water was decanted and the stacking gel poured. A 10 or 15 well comb was 
then inserted into the stacking gel mix, being careful not to introduce any air bubbles. 
The stacking gel layer was allowed to set over 45 minutes.
The comb was removed and the wells rinsed with distilled water. The SDS-PAGE mini-
gel was now transferred to a running tank (Bio-Rad Laboratories Ltd., UK) which was 
in turn filled with SDS running buffer (Section 2.1.1). Each well was loaded with up to 
25µl of sample and one lane was used to run a pre-stained protein ladder with the range 
of 10-200kDa (Benchmark™, Invitrogen, UK). Gels were run at 25mA for 2 hours.
2.6.3 Western blotting 
After protein separation was complete and having removed the stacking gel layer, the 
SDS-PAGE mini-gel was allowed to equilibrate in transfer buffer (Section 2.1.1) for 15 
minutes. The Protran™ nitrocellulose membrane (Whatman, UK) on to which the 
proteins were to be blotted was also equilibrated for a similar period. 
The membrane, closely apposed to the gel, was placed between two sheets of 3MM 
chromatography paper (Whatman, UK) and two fibre pads. This ‘gel sandwich’ was 
positioned in a transfer cassette and loaded into a Mini Trans-Blot® electrophoretic 
transfer cell (Bio-Rad Laboratories Ltd., UK). A frozen Bio-Ice cooling unit was put in 
the transfer tank which was then filled with chilled transfer buffer. Electrophorectic 
transfer was performed at 100volts over 90 minutes on ice.
115
The uniformity and overall effectiveness of the transfer of protein from the gel to the 
membrane was assessed by staining the membrane with Ponceau S solution (0.1% 
Ponceau S and 5% acetic acid). This was then removed by washing with distilled water 
before blocking the membrane for 1 hour in 5% milk (Marvel™, Cadbury, UK) + TBS-
Tween20 solution (Section 2.1.1) at room temperature. Primary antibodies, generally 
used at a dilution of 1:1000 in 5% BSA + TBS-Tween20 solution, were applied to the 
membrane by incubating overnight at 4ºC. 
The next day, the membrane was washed three times in TBS-Tween20 solution (5 
minutes per wash) and incubated for a further hour at room temperature with an HRP-
conjugated secondary antibody (Thermo Fisher Scientific Inc., UK). Secondary 
antibodies were diluted 1:50,000 in 5% milk + TBS-Tween20 solution. After three 
further washes as above, the membrane was rinsed for 5 minutes in 2ml of either ‘West 
Dura’ or ‘West Pico’ SuperSignal® Chemiluminescent Substrate (Thermo Fisher 
Scientific Inc., UK). Finally, the blot was developed by exposing the membrane to 
chemiluminescent film (GE Healthcare UK Ltd.).
2.6.4 Primary antibodies used for Western blotting
Antibody / Target               Mol Wt*    Dilution       Species             Source
TRAF6 64     1:2000          Rabbit Abcam®
Phospho-NF-ĸB p65 (Ser536) 65     1:1000          Rabbit Cell Signaling Technology®
Phospho-IĸBα (Ser32) 41     1:1000          Rabbit Cell Signaling Technology®
Phospho-IKKα/β          85 / 87     1:1000          Rabbit Cell Signaling Technology®
NF-ĸB p65 65     1:1000          Rabbit Cell Signaling Technology®
IĸBα 39     1:1000          Mouse Cell Signaling Technology®
IKKα        85     1:1000          Rabbit Cell Signaling Technology®
β-Tubulin 1 55   1:200000        Mouse        Sigma-Aldrich®
* Molecular Weight in kilodaltons (kDa)
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2.6.5 Secondary probing of Western blots
Nitrocellulose membranes were “stripped” of antibodies by washing for 10 minutes 
twice with stripping buffer (Section 2.1.1). After washing two times in TBS-Tween20 
solution (5 minutes per wash), the ‘stripped’ membrane was blocked for 1 hour in 5% 
milk + TBS-Tween20 solution at room temperature and then re-probed with primary 
antibody as outlined above. 
2.7 Immunohistochemistry (IHC)
The following techniques were performed in conjunction with Emma Nye (Operational 
Head of the Cancer Research UK Experimental Histopathology Laboratory).
2.7.1 Optimisation of antibodies
A431 cell pellets were used to optimise antibodies for immunohistochemistry (IHC). 
Dependent upon the antibody, cells were gene depleted / DNA transfected or cytokine 
stimulated / inhibited prior to pelleting.
For a single cell pellet approximately 1 x 106 A431 cells were washed with PBS before 
being gently lifted and pipetted into an Eppendorf tube. After centrifugation at 
10,000rpm for 1 minute, the cells were fixed in 500µl of 10% NBF for 30 minutes. The 
NBF was then replaced by 70% EtOH and the pellet embedded in paraffin wax for 
processing by standard methods thereafter.
2.7.2 Paraffin sections
Paraffin embedded specimens (4µm thick) were mounted on poly-L-lysine coated slides 
before being de-waxed in xylene and dehydrated by passage through graded alcohols to 
water. Endogenous peroxidase activity was blocked using 1.6% hydrogen peroxide 
(H2O2) in PBS for 10 minutes followed by washing in distilled water. Antigen retrieval 
was performed by immersing samples in sodium citrate buffer and microwaving three 
times for 5 minutes at full power. Sections were then cooled to room temperature in 
running water and washed in PBS prior to blocking in goat serum diluted to 10% in 1% 
BSA for 30 minutes. This step was included to reduce non-specific staining. 
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Slides were incubated with primary antibody (Section 2.7.3) in 1% BSA for 1 hour at 
room temperature. After washing in PBS-Tween20 solution for 1 minute, biotinylated 
goat anti-rabbit secondary antibody (1:250 in 1% BSA) was then applied to the sections 
for 45 minutes, also at room temperature. Samples were washed as above and developed 
microscopically with VECTASTAIN® Elite ABC Reagent and Vector DAB substrate 
(Vector Laboratories Ltd., UK). A final wash in water was performed before the 
sections were counterstained lightly with haematoxylin, dehydrated, cleared and 
mounted.
Omission of the primary antibody acted as a negative control. Positive controls varied 
according to the nature of the assay and are specified in the relevant sections. A single 
section of all samples was routinely stained with H&E.
Sodium Citrate Buffer
     Sodium Citrate 10mM
     Tween20 0.05%
     pH 6.0
PBS-Tween20 solution
10ml 20% Tween20 and 990ml 1X PBS 
2.7.3 Primary antibodies used for IHC (paraffin sections)
Antibody / Target            Dilution               Species              Source
TRAF6 1:20             Rabbit  Abcam®
NF-ĸB p65 1:50             Rabbit Cell Signaling Technology®
IĸBα 1:20    Mouse Cell Signaling Technology®
Vimentin 1:200    Rabbit  Abcam®  
Pan-cytokeratin AE1 / AE3 1:100    Mouse   Dako
2.7.4 Frozen sections
Frozen sections (5µm thick) were cut on to poly-L-lysine coated glass slides and stored 
at -80ºC. Staining was performed at room temperature unless otherwise indicated and 
all steps were separated by three 5 minute washes with PBS. 
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Once thawed, sections were fixed in 4% PFA for 10 minutes and permeabilised with 
0.2% Triton® X-100 for a further 10 minutes. Samples were then treated with sodium 
borohydride 2mg/ml (Sigma-Aldrich®, UK) for 5 minutes and blocked for 1 hour with 
3% BSA. 
Following blocking, slides were incubated with primary antibody (Section 2.7.5) in 3% 
BSA overnight at 4ºC. For visualisation, Alexa Fluor® secondary antibodies 
(Invitrogen, UK), TRITC phalloidin and DAPI each diluted to a concentration of 1:500 
in 3% BSA were applied to the sections over 2 hours in darkness. After three final 
washes, the tissue samples were mounted and imaged by confocal microscopy. 
Omission of the primary antibody acted as a negative control. As with paraffin 
embedded specimens, a single section of all frozen tissue samples was routinely stained 
with H&E.
2.7.5 Primary antibodies used for IHC (frozen sections)
Antibody / Target                  Dilution              Species             Source
TRAF6  1:100             Rabbit Abcam®
Collagen IV           1:100            Mouse Abcam®
2.7.6 Commercial tissue microarrays
To investigate the clinical relevance of TRAF6 as a potential biological marker and 
therapeutic target, paraffin embedded tissue microarrays were purchased from US 
Biomax Inc. for immunohistochemical analysis. These are listed below.
Tissue Microarray     Cores       Cases             Catalogue No.
            Tumour          Normal
       SCCHN        63          20 3            BC34011
        OSCC       60      50             10 OR601
    Vulval SCC        24      10 2 UV241
        CSCC        48      40 8 SK483
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Microarrays were bought in triplicate and processed as outlined in Section 2.7.2. 
Paraffin embedded A431 cell pellets with and without TRAF6-HA expressing cells 
(Section 2.7.1) acted as positive controls and were stained alongside the tissue arrays. 
The analysis of and quantification of TRAF6 expression in these samples is described in 
Section 2.10.5. Several cores were missing from the supplied arrays and therefore the 
number of samples included in the final analysis of each array differed from that listed 
above.
2.8 Human tissue banking
Ethical and R&D approval was obtained for the establishment of a human tissue bank of 
SCCHN specimens with patient matched control tissue samples.  The process of setting 
up the tissue bank and its management are described in detail in Chapter 8, Section 8.2.
2.9 Microscopy techniques
2.9.1 Immunofluorescence (IMF)
Approximately 1 x 104 A431 cells were seeded on to glass coverslips in 24 well plates. 
Twenty-four hours later the cells were washed once with PBS and fixed in 4% PFA for 
20 minutes on ice. After being permeabilised with 0.2% Triton® X-100 for 10 minutes, 
the cells were washed three times with PBS and blocked for 1 hour with 2% BSA. 
Following blocking, the cells were incubated with primary antibody (Section 2.9.2) in 
2% BSA for 2 hours at room temperature. For visualisation, Alexa Fluor® secondary 
antibodies (1:300), TRITC phalloidin (1:500) and DAPI (1:500) in 2% BSA were 
applied over 2 hours in darkness. After three further washes, the coverslips were 
mounted using Mowiol® medium (Sigma-Aldrich®, UK) and imaged by confocal 
microscopy. Omission of the primary antibody acted as a negative control. 
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2.9.2 Primary antibodies used for IMF
Antibody / Target                  Dilution              Species              Source
TRAF6  1:50             Rabbit  Abcam®
TRAF6  1:50             Rabbit         Santa Cruz Biotechnology, Inc
NF-ĸB p65  1:50             Rabbit           Cell Signaling Technology®
Integrin β1      1:250    Mouse        Santa Cruz Biotechnology, Inc
2.9.3 Imaging
A Nikon TE2000-S equipped with a Nikon DS-5M camera was used for routine 
viewing of cell cultures and to capture images of H&E and immunostained sections. All 
other imaging was performed using a Zeiss LSM 510 inverted confocal microscope.
2.9.4 Confocal imaging of human tissue samples
Frozen sections of SCCHN and matched normal tissue samples were prepared for 
confocal microscopy as described in Section 2.7.4. GFP, TRITC and Cy5 fluorophores 
were imaged using standard lasers and filter sets. DAPI was imaged using two-photon 
excitation in response to an 840nm pulsed titanium sapphire laser.
2.10 Data analysis
2.10.1 Assessment of cell morphology
Gene silencing in A431 cells and HNCAF was accompanied by a variety of cell 
phenotypes compared to control cells. These included cell rounding, cell elongation, 
actin-rich micro-spikes, lamellipodial extensions and membrane blebbing. For the 
siRNA screens previously described, cell morphology was assessed qualitatively and 
scored descriptively by at least two independent observers. Each screen was blind and 
performed twice. Genes were retained for further study if there was a high degree of 
concordance with respect to the cytoskeletal changes recorded amongst observers. 
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Representative confocal images were taken of the cell phenotypes induced by gene 
silencing at successive rounds of screening. Zeiss LSM Image Browser was used to 
examine the F-actin cytoskeleton and cell morphology of gene knockdowns more 
closely but a detailed quantitative morphometric analysis was not undertaken.
2.10.2 The Invasion Index
Carcinoma cell invasion in the organotypic gel culture system was assessed using an 
Invasion Index as previously described 77, 302. 
H&E stained sections of organotypic cultures were viewed at 20x magnification and 5 
areas of each gel captured. The digital images were loaded into Image J software 
(NIMH, USA) and for each image the ‘invading’ and non-invading areas measured. The 
‘invading’ area included both the region of SCC dispersion within the gel and the 
surface or ‘epithelial’ layer of non-invading cells. 
The Invasion Index was defined as 1 - (Non-invading Area / Invading Area) where a 
value of 0 represented no invasion. For each organotypic culture, the Invasion Index 
was an average of 5 measurements. 
2.10.3 The Contraction Index
For two-stage organotypic assays (Section 2.2.8.3) gels were photographed after 5 days 
of matrix remodelling just prior to the removal of HNCAF with puromycin. The degree 
of gel contraction was then assessed by using Image J software to measure the surface 
area of the gel relative to its well. The Contraction Index was subsequently calculated 
by using the formula 1 - (Gel Area / Well Area) where a value of 0 represented no 
contraction 303. 
2.10.4 Apoptotic counts in gene depleted cells
DAPI stained siRNA gene depleted A431 cells on collagen-Matrigel® gels were 
imaged at 20x magnification 72 hours following transfection. Five images per sample 
were captured and the percentage of apoptotic cells per visual field calculated. 
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2.10.5 Quantitative analysis of TRAF6 IHC
TRAF6 immunostained sections were viewed at 20x magnification and 3 images per 
sample captured. Digital images were loaded into NIS Elements software (Nikon UK 
Ltd) and 10 representative immunostained areas were selected for analysis per sample. 
TRAF6 immunostaining was cytosolic in nature and therefore cell nuclei were not 
included in the regions analysed to avoid positively skewing the data. The mean 
absolute pixel intensity within each region of interest was measured and normalised to a 
‘white balanced’ area of the image by subtracting the background pixel intensity. This 
normalised value was then expressed on a scale of 0 to 1, with 0 representing absolute 
whiteness and 1 absolute blackness. The mean and standard error of the 10 
measurements was calculated to give an overall measure of mean pixel intensity for 
TRAF6 immunostained regions per sample. Neither the relative proportion of TRAF6 
positive cells nor their distribution within each sample was recorded.  
2.10.6 Statistical analysis
NCSS Statistical Power & Analysis software was used to perform: 
(a) ANOVA for randomized block design tests to assess statistical significance of 
differences in carcinoma cell invasion within single and between duplicate organotypic 
assays. p values were Bonferroni corrected depending on the nature of the assay and 
ranged from p < 0.007 to p < 0.05.
(b) Kruskal-Wallis non-parametric ANOVA to assess statistical significance of the 
percentage of apoptotic cells following siRNA gene depletion compared to mock 
transfected samples; p value < 0.05 (Chapter 5, Section 5.4.5).
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Chapter 3
Morphological siRNA screening
3.1 Introduction
Cancer cell invasion and cell motility are accompanied by dramatic changes of cell 
phenotype as well as dynamic interactions with the surrounding ECM. To test the 
hypothesis that ubiquitin-linked pathways are key regulators of the actin cytoskeleton a 
series of morphological screens using siRNA targeting 289 E3 ubiquitin ligases and 137 
DUBs were performed. This chapter details the results of this screening process.
3.2 Morphological siRNA screening
3.2.1 Screening for regulators of cortical actin organization in SCC cells
Dharmacon® SMARTpool siRNA libraries targeting 289 E3 ubiquitin ligases and 137 
DUBs were used to screen for their potential role in SCC invasion by initially assessing 
their ability to regulate the actin cytoskeleton. Transfected A431 cells were plated on 
deformable collagen-Matrigel® gels and after 24 hours stained with DAPI and TRITC 
phalloidin to visualise the F-actin cytoskeleton. Gene silencing was accompanied by a 
variety of cell phenotypes compared to control cells. These included cell rounding, cell 
elongation, actin-rich spikes, membrane blebs, and a disrupted actin cell cortex. Cell 
morphology was assessed qualitatively and scored descriptively by three independent 
observers. A SMARTpool was retained for further investigation if it achieved a score of 
at least 5 out of 6 for altered cell morphology compared to the control. Each screen was 
blind and performed twice. Descriptions of the cell phenotypes observed for the highest 
scoring gene knockdowns are shown in Tables 3.1-3.6. 
Control, non-targeting siRNA transfected cells (Figure 3.1b) were phenotypically 
indistinguishable from non-transfected cells (Figure 3.1a). siRNA duplexes targeting 
Integrin β1 and Rho A were included as positive controls since both generated 
reproducible and characteristic changes in the cytoskeleton of A431 cells. Integrin β1 
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gene depletion produced rounded cells (Figure 3.1c) where as Rho A knockdown 
resulted in elongated cells with a thickened actin cortex (Figure 3.1d).
Figures 3.2-3.4 show representative images of the various cell phenotypes observed. 
Knocking down RKHD2, for example, resulted in elongated cells with prominent 
cortical actin (Figure 3.2c). In contrast to this, silencing SUGT1 caused the cells to 
cluster with a rounded morphology (Figure 3.2f). Several gene knockdowns led to the 
formation of actin-rich spikes (Figures 3.3c, 3.3d and 3.3e) where as membrane blebs 
were less frequently seen (Figure 3.3f). Interference with a number of other genes, such 
as TRIM11 and MARCH3, produced a flattened cell phenotype (Figures 3.4c and 3.4d). 
Occasionally, the actin cytoskeleton appeared to be disrupted (Figures 3.4e and 3.4f).
Tables 3.7 and 3.8 list the symbol, description and accession number of each of the 45 
genes identified. These ‘1st Round’ hits were subsequently de-convoluted.
3.2.2 De-convolution of siRNA SMARTpools
To confirm that the cell phenotypes observed in my initial round of screening were not 
‘off-target’ phenomena; the respective 45 SMARTpools were de-convoluted in A431 
cells using individual siRNA duplexes. If at least two of the four duplexes comprising 
the SMARTpool produced the same phenotype, the gene was retained for further study. 
This screen was blind, performed twice and scored by two independent observers.
Figures 3.5, 3.6 and 3.7 illustrate the de-convolution of siRNA SMARTpools targeting 
SAE1, USP12 and Mdm4 respectively. In these examples, gene silencing with at least 
three of the four siRNA duplexes of each SMARTpool produced the phenotype 
originally observed in the ‘1st Round’. Knocking down SAE1 resulted in rounded cells. 
USP12 gene depletion was characterised by flat, elongated cells and interference with 
Mdm4 led to cells with pronounced actin-rich spikes. 
Following SMARTpool de-convolution, 29 genes emerged as ‘2nd Round’ hits. These 
are listed in Table 3.9.
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Screen 1 Screen 2
GENE
Scorer 1 Scorer 2 Scorer 3 Scorer 1 Scorer 2 Scorer 3
SCORE
DKFZ-
p761H1710
single
rounded
clusters
rounded
rounded
single
rounded
control
single
rounded
5
MARCH3 elongated
spikes
elongated control
elongated
flat
elongated elongated 5
CDC26 elongated
spikes
control elongated
elongated
flat
disrupted
disrupted
flat
5
LOC-
389822
elongated
spikes
control elongated spikes spikes spikes 5
FLJ20315 elongated elongated elongated elongated collapsed elongated 6
Table 3.1 Screening for regulators of cortical actin organization in A431 
cells with Dharmacon® SMARTpool siRNA: E3 ubiquitin ligases Plate 1
Cells were plated on deformable collagen-Matrigel® gels, fixed at 72 hours 
following transfection and stained with TRITC phalloidin. Each screen was blind 
and performed twice. Cell phenotype was assessed qualitatively and scored 
descriptively by three independent observers. A SMARTpool was retained for 
de-convolution if it achieved a score of at least 5 out of 6 for altered cell 
morphology compared to the control. 
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Screen 1 Screen 2
GENE
Scorer 1 Scorer 2 Scorer 3 Scorer 1 Scorer 2 Scorer 3
SCORE
RNF123 single
rounded
spikes
spikes
rounded
single
rounded
control rounded 5
MKRN2 elongated
spikes
elongated
spikes
bipolar spikes spikes
elongated
spikes
6
RKHD2 elongated bipolar bipolar bipolar bipolar
spikes
flat
6
PJA1 spikes spikes spikes spikes spikes spikes 6
RNF126 spikes control spikes spikes spikes spikes 5
FLJ10546 elongated
spikes
flat elongated flat control
elongated
flat
5
RNF11 spikes
rounded
spikes
single
spikes
spikes
rounded
spikes spikes 6
RNF12 elongated elongated elongated elongated elongated elongated 6
RNF2 spikes spikes spikes spikes control spikes 5
RFWD3 spikes
rounded
single
spikes
spikes spikes spikes spikes 6
Table 3.2 Screening for regulators of cortical actin organization in A431 
cells with Dharmacon® SMARTpool siRNA: E3 ubiquitin ligases Plate 2
Cells were plated on deformable collagen-Matrigel® gels, fixed at 72 hours 
following transfection and stained with TRITC phalloidin. Each screen was blind 
and performed twice. Cell phenotype was assessed qualitatively and scored 
descriptively by three independent observers. A SMARTpool was retained for 
de-convolution if it achieved a score of at least 5 out of 6 for altered cell 
morphology compared to the control. 
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Screen 1 Screen 2
GENE
Scorer 1 Scorer 2 Scorer 3 Scorer 1 Scorer 2 Scorer 3
SCORE
RNF41 elongated
spikes
spikes elongated
elongated
spikes
control flat 5
TRIM4 elongated
blebs
control spikes spikes spikes spikes 5
ZNF364 elongated
spikes
control spikes spikes spikes
bipolar
spikes
5
RNF44 spikes clusters spikes
clusters
spikes
control spikes 5
ZNF598 bipolar bipolar elongated elongated control
elongated
flat
5
RNF5 clusters
rounded
rounded single
clusters
rounded
control mixed 5
SUGT1 single
rounded
rounded
single
rounded
single
rounded
single
rounded
rounded 6
TRIM3 control spikes spikes spikes spikes spikes 5
VPS11 spikes spikes spikes spikes spikes spikes 6
FLJ12747 spikes spikes spikes spikes spikes spikes 6
TRIM11 elongated
spikes
elongated
spikes
bipolar spikes control flat 5
Table 3.3 Screening for regulators of cortical actin organization in A431 
cells with Dharmacon® SMARTpool siRNA: E3 ubiquitin ligases Plate 3
Cells were plated on deformable collagen-Matrigel® gels, fixed at 72 hours 
following transfection and stained with TRITC phalloidin. Each screen was blind 
and performed twice. Cell phenotype was assessed qualitatively and scored 
descriptively by three independent observers. A SMARTpool was retained for 
de-convolution if it achieved a score of at least 5 out of 6 for altered cell 
morphology compared to the control. 
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Screen 1 Screen 2
GENE
Scorer 1 Scorer 2 Scorer 3 Scorer 1 Scorer 2 Scorer 3
SCORE
HERC4 single
rounded
control
single
rounded
single
rounded
spikes rounded 5
HERC6 elongated
flat
control blebs
elongated
flat
bipolar bipolar 5
TRIM33 elongated
spikes
spikes
elongated
spikes
spikes control disrupted 5
TRAF6 elongated
flat
control
elongated
flat
elongated flat elongated 5
RNF14 elongated
spikes
spikes bipolar flat elongated control 5
UBE3A single
rounded
single
single
rounded
single
rounded
rounded rounded 6
SAE1 spikes
disrupted
cortex
single
rounded
single
rounded
clusters rounded 6
Mdm4 spikes spikes spikes spikes control spikes 5
Table 3.4 Screening for regulators of cortical actin organization in A431 
cells with Dharmacon® SMARTpool siRNA: E3 ubiquitin ligases Plate 4
Cells were plated on deformable collagen-Matrigel® gels, fixed at 72 hours 
following transfection and stained with TRITC phalloidin. Each screen was blind 
and performed twice. Cell phenotype was assessed qualitatively and scored 
descriptively by three independent observers. A SMARTpool was retained for 
de-convolution if it achieved a score of at least 5 out of 6 for altered cell 
morphology compared to the control. 
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Screen 1 Screen 2
GENE
Scorer 1 Scorer 2 Scorer 3 Scorer 1 Scorer 2 Scorer 3
SCORE
FLJ14981 flat blebs disrupted flat flat flat 6
OTUD7A clusters
spikes
spikes spikes
rounded
blebs
spikes spikes 6
BAP1 rounded
spikes
clusters
spikes
spikes
rounded
spikes
spikes spikes 6
DUB1A flat
spikes
spikes spikes
flat
spikes
flat flat 6
USP12 elongated elongated elongated elongated control elongated 5
DUB3 elongated
blebs
spikes spikes
clusters
spikes
spikes spikes 6
Table 3.5 Screening for regulators of cortical actin organization in A431 
cells with Dharmacon® SMARTpool siRNA: De-ubiquitinating enzymes 
Plate 1
Cells were plated on deformable collagen-Matrigel® gels, fixed at 72 hours 
following transfection and stained with TRITC phalloidin. Each screen was blind 
and performed twice. Cell phenotype was assessed qualitatively and scored 
descriptively by three independent observers. A SMARTpool was retained for 
de-convolution if it achieved a score of at least 5 out of 6 for altered cell 
morphology compared to the control. 
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Screen 1 Screen 2
GENE
Scorer 1 Scorer 2 Scorer 3 Scorer 1 Scorer 2 Scorer 3
SCORE
USP2 elongated
spikes
spikes spikes
elongated
spikes
elongated disrupted 6
TRFP elongated elongated elongated
elongated
spikes
elongated elongated 6
PSMD7 single
rounded
single
rounded
rounded
single
rounded
few cells
single
rounded
6
ZA20d1 spikes spikes spikes
elongated
spikes
spikes spikes 6
USP6 elongated
blebs
clusters
blebs
control elongated elongated elongated 5
Table 3.6 Screening for regulators of cortical actin organization in A431 
cells with Dharmacon® SMARTpool siRNA: De-ubiquitinating enzymes 
Plate 2
Cells were plated on deformable collagen-Matrigel® gels, fixed at 72 hours 
following transfection and stained with TRITC phalloidin. Each screen was blind 
and performed twice. Cell phenotype was assessed qualitatively and scored 
descriptively by three independent observers. A SMARTpool was retained for 
de-convolution if it achieved a score of at least 5 out of 6 for altered cell 
morphology compared to the control. 
Mock Control
Rounded Elongated
Figure 3.1 ‘Reference’ F-actin phenotype categories in A431 
cells: Integrin β1 and Rho A gene depletion
Cells were plated on deformable collagen-Matrigel® gels and 
fixed 72 hours following transfection. Cells stained with TRITC 
phalloidin. (a) Mock; (b) Control siRNA; (c) Integrin β1 siRNA and 
(d) Rho A siRNA. Scale bar indicates 20µm.
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Figure 3.2 Examples of F-actin phenotype categories in A431 
cells: bipolar, elongated and rounded
Cells were plated on deformable collagen-Matrigel® gels and fixed 72 
hours after transfection with Dharmacon® SMARTpool siRNA libraries. 
Cells stained with TRITC phalloidin. (a) Mock; (b) Control siRNA;        
(c) RKHD2 siRNA and (d) HERC6 siRNA; (e) DKFZp761H1710 siRNA 
and (f) SUGT1 siRNA. Scale bar indicates 20µm.
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Actin-rich spikes
C
Mock
a
Control
b
Membrane  blebs
Actin-rich spikes 
d
e
Actin-rich spikes
Figure 3.3 Examples of F-actin phenotype categories in A431 
cells: actin-rich spikes and membrane blebs
Cells were plated on deformable collagen-Matrigel® gels and fixed 72 
hours after transfection with Dharmacon® SMARTpool siRNA 
libraries. Cells stained with TRITC phalloidin. (a) Mock; (b) Control 
siRNA; (c) OTUD7A siRNA and (d) DUB1A siRNA; (e) RNF2 siRNA 
and (f) PSMD7 siRNA. Scale bar indicates 20µm.
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Figure 3.4 Examples of F-actin phenotype categories in A431 
cells: flat and disrupted cortex
Cells were plated on deformable collagen-Matrigel® gels and fixed 72 
hours after transfection with Dharmacon® SMARTpool siRNA 
libraries. Cells stained with TRITC phalloidin. (a) Mock; (b) Control 
siRNA; (c) TRIM11 siRNA and (d) MARCH3 siRNA; (e) ZNF598 
siRNA and (f) RNF14 siRNA. Scale bar indicates 20µm.
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Plate 1
NM_005500SUMO-1 activating enzyme subunit 1SAE1
NM_002393Mdm4Mdm4
NM_004290Ring finger protein 14RNF14
NM_004620TNF receptor-associated factor 6TRAF6
NM_015906Tripartite motif-containing 33TRIM33
NM_000462Ubiquitin protein ligase E3AUBE3A
NM_017912Hect domain and RLD 6HERC6
NM_015601Hect domain and RLD 4HERC4
XM_290972Novel C3HC4 type zinc fingerFLJ12747
NM_178167Zinc finger protein 598ZNF598
NM_014455Zinc finger protein 364ZNF364
NM_021729Vacuolar protein sorting 11VPS11
NM_033017Tripartite motif-containing 4TRIM4
NM_006458Tripartite motif-containing 3TRIM3
NM_145214Tripartite motif-containing 11TRIM11
NM_006704SGT1, suppressor of G2 allele of SKP1SUGT1
NM_006913Ring finger protein 5RNF5
NM_014901Ring finger protein 44RNF44
NM_005785Ring finger protein 41RNF41
NM_007212Ring finger protein 2RNF2
NM_018133Hypothetical protein FLJ10546FLJ10546
NM_017876Ring finger protein 126RNF126
NM_022064Ring finger protein 123RNF123
NM_016120Ring finger protein 12RNF12
NM_014372Ring finger protein 11RNF11
NM_016626Ring finger and KH domain containing  2RKHD2
NM_018124Ring finger and WD repeat domain 3RFWD3
NM_022368Praja 1PJA1
NM_014160Makorin ring finger protein 2MKRN2
NM_178450Membrane-associated ring finger 3MARCH3
XM_372169Hypothetical protein LOC389822LOC389822
NM_017763Hypothetical protein FLJ20315FLJ20315
NM_031297Hypothetical protein DKFZp761H1710DKFZp761H1710
NM_139286Cell division cycle 26CDC26
AccessionGene DescriptionGene Symbol
Plate 2
Plate 3
Plate 4
Table 3.7 Regulators of cortical actin organization in A431 cells: 
‘1st Round’ Dharmacon® SMARTpool hits
E3 Ubiquitin Ligases
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Plate 1
Plate 2
Table 3.8 Regulators of cortical actin organization in A431 cells: 
‘1st Round’ Dharmacon® SMARTpool hits
NM_02811Proteasome 26S subunit, non-ATPase 7PSMD7
NM_004505Ubiquitin specific protease 6USP6
NM_020205Zinc finger, A20 domain containing 1ZA20d1
NM_004275Trf-proximal homologTRFP
NM_004205Ubiquitin specific protease 2USP2
NM_182488Ubiquitin specific protease 12USP12
NM_130901OTU domain containing 7AOTUD7A
NM_032868Hypothetical protein FLJ14981FLJ14981
NM_201402De-ubiquitinating enzyme 3DUB3
XM_377830De-ubiquitinating enzyme 1ADUB1A
NM_004656BRCA1 associated protein-1BAP1
AccessionGene DescriptionGene Symbol
De-ubiquitinating Enzymes
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Figure 3.5 Example of de-convolution of Dharmacon® SMARTpool
siRNA in A431 cells: ‘rounded’ cell phenotype
Knockdown of SAE1 with the individual siRNA duplexes comprising the 
SMARTpool results in a rounded cell phenotype. Cells stained for F-actin 
with TRITC phalloidin 72 hours after transfection. Collagen-Matrigel® matrix 
imaged by reflectance. Scale bar indicates 20µm.
F-actin Reflectance Merge
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Figure 3.6 Example of de-convolution of Dharmacon® SMARTpool siRNA 
in A431 cells: ‘elongated’ cell phenotype
Knockdown of USP12 with the individual siRNA duplexes comprising the 
SMARTpool results in an elongated cell phenotype. The phenotype induced  by 
duplex 4 is less impressive compared to that observed with the other three 
oligonucleotides. Cells stained for F-actin with TRITC phalloidin 72 hours after 
transfection. Collagen-Matrigel® matrix imaged by reflectance. Scale bar 
indicates 20µm.
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Figure 3.7 Example of de-convolution of Dharmacon® SMARTpool
siRNA in A431 cells: ‘spiky’ cell phenotype
Knockdown of Mdm4 with the individual siRNA duplexes comprising the 
SMARTpool results in cells with prominent actin-rich spikes. Cells stained for 
F-actin with TRITC phalloidin 72 hours after transfection. Collagen-Matrigel®
matrix imaged by reflectance. Scale bar indicates 20µm.
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roundedSUMO-1 activating enzyme subunit 1SAE1
spikyMdm4Mdm4
elongatedRing finger protein 14RNF14
elongatedTNF receptor-associated factor 6TRAF6
elongatedHect domain and RLD 6HERC6
roundedHect domain and RLD 4HERC4
elongatedZinc finger protein 598ZNF598
elongatedTripartite motif-containing 11TRIM11
roundedSGT1, suppressor of G2 allele of SKP1SUGT1
elongatedRing finger protein 41RNF41
spikyRing finger protein 2RNF2
elongatedHypothetical protein FLJ10546FLJ10546
spikyRing finger protein 126RNF126
elongatedRing finger protein 12RNF12
elongatedRing finger and KH domain containing  2RKHD2
spikyRing finger and WD repeat domain 3RFWD3
spikyPraja 1PJA1
spikyMakorin, ring finger protein 2MKRN2
elongatedMembrane-associated ring finger 3MARCH3
elongatedCell division cycle 26CDC26
Predominant 
Phenotype
Gene DescriptionGene Symbol
Table 3.9 De-convolution of Dharmacon® SMARTpool siRNA in 
A431 cells: ‘2nd Round’ gene hits
The 45 ‘1st Round’ SMARTpool hits were de-convoluted. If at least two 
of the four individual duplexes comprising the SMARTpool produced 
the same phenotype the gene was retained for further study.  
elongatedUbiquitin specific protease 12USP12
roundedProteasome 26S subunit, non-ATPase 7PSMD7
elongatedUbiquitin specific protease 6USP6
spikyZinc finger, A20 domain containing 1ZA20d1
elongatedTrf-proximal homologTRFP
spikyUbiquitin specific protease 2USP2
elongatedHypothetical protein FLJ14981FLJ14981
spikyDe-ubiquitinating enzyme 1ADUB1A
spikyBRCA1 associated protein-1BAP1
De-ubiquitinating Enzymes
E3 Ubiquitin Ligases
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3.2.3 Screening for regulators of cortical actin organization in HNCAF
The importance of stromal interactions with epithelial cells is well established in 
carcinogenesis and although the characteristics of activated CAF are not completely 
understood their tumour promoting role is well documented 50, 66.
To further test my 29 ‘2nd Round’ gene hits as regulators of the actin cytoskeleton and 
to investigate their potential role in CAF function an additional siRNA screen was 
undertaken. This screen was blind, performed twice and scored by two independent 
observers. Eight ‘CAF’ hits were identified (Table 3.10) and representative images of 
the cell phenotypes observed are shown in Figures 3.8-3.12.
siRNA duplexes targeting Integrin β1 and Rho A were again included as positive
controls (Figure 3.8). Integrin β1 knockdown caused loss of the bipolar appearance 
typical of CAF, whilst Rho A depletion resulted in the formation of prominent stress 
fibres (Figure 3.13a). The majority of CAF hits (MKRN2, RKHD2, TRAF6, Mdm4, 
SAE1, ZA20d1 and USP6) were characterised by abnormal cell bodies which had fewer 
stress fibres and an increased spread area (Figure 3.13c). In ‘normal’ CAF, stress fibres 
were orientated parallel to each other and the long axis of the cell (Figure 3.13b). 
Knocking down HERC4 led to a dramatic rounding of cells which still retained some 
capacity to contract their associated ECM (Figure 3.11).
Stromal fibroblasts are able to alter their surrounding ECM via a combination of force-
mediated and protease-mediated matrix remodelling 77. Figure 3.14 shows reflectance 
imaging of collagen-Matrigel® gels after 24 hours of fibroblast remodelling. Holes in 
the matrix are clearly visible. Transmission Electron Microscopy (TEM) has 
demonstrated that these structures represent migration tracks, being devoid of matrix at 
their centre and composed of thick collagen bundles at their periphery 77. They are also 
associated with the deposition of matrix components such as fibronectin and tenascin-C 
Remodelled ECM facilitates the collective invasion of carcinoma cells, where as naïve 
unconditioned matrix does not 77.
Table 3.10 Regulators of cortical actin organization in HNCAF: 
‘CAF’ hits
Screening in HNCAF was undertaken with two siRNA duplexes per 
‘2nd Round’ gene hit to further investigate their role as regulators of 
the actin cytoskeleton. The screen was blind, performed twice and 
scored by two independent observers. Eight ‘CAF’ hits were 
identified in which gene depletion by both oligonucleotides resulted 
in an abnormal cell phenotype.
De-ubiquitinating Enzymes
E3 Ubiquitin Ligases
NM_002393Mdm4Mdm4
NM_004620TNF receptor-associated factor 6TRAF6
NM_004505Ubiquitin specific protease 6USP6
NM_020205Zinc finger, A20 domain containing 1 ZA20d1
NM_005500SUMO-1 activating enzyme subunit 1SAE1
NM_015601Hect domain and RLD 4HERC4
NM_016626Ring finger and KH domain containing  2 RKHD2
NM_014160Makorin, ring finger protein 2MKRN2
AccessionGene DescriptionGene Symbol
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Figure 3.8 ‘Reference’ F-actin phenotypes in HNCAF: Integrin β1 and 
Rho A gene depletion
Cell phenotypes observed in HNCAF following siRNA gene depletion. 
Arrows indicate abnormal cell bodies. Cells stained for F-actin with TRITC 
phalloidin 72 hours after transfection. Collagen-Matrigel® matrix imaged by 
reflectance. The scale bars represent 50µm.
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Figure 3.9 F-actin phenotypes in HNCAF: MKRN2 and RKHD2 gene 
depletion
Cell phenotypes observed in HNCAF following siRNA gene depletion. 
Arrows indicate abnormal cell bodies. Cells stained for F-actin with TRITC 
phalloidin 72 hours after transfection. Collagen-Matrigel® matrix imaged by 
reflectance. The scale bars represent 50µm.
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Figure 3.10 F-actin phenotypes in HNCAF: TRAF6 and Mdm4 gene 
depletion
Cell phenotypes observed in HNCAF following siRNA gene depletion. 
Arrows indicate abnormal cell bodies. Cells stained for F-actin with TRITC 
phalloidin 72 hours after transfection. Collagen-Matrigel® matrix imaged by 
reflectance. The scale bars represent 50µm.
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Figure 3.11 F-actin phenotypes in HNCAF: HERC4 and SAE1 gene 
depletion
Cell phenotypes observed in HNCAF following siRNA gene depletion. 
Arrows indicate abnormal cell bodies. Cells stained for F-actin with TRITC 
phalloidin 72 hours after transfection. Collagen-Matrigel® matrix imaged by 
reflectance. The scale bars represent 50µm.
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Figure 3.12 F-actin phenotypes in HNCAF: ZA20d1 and USP6 gene 
depletion
Cell phenotypes observed in HNCAF following siRNA gene depletion. 
Arrows indicate abnormal cell bodies. Cells stained for F-actin with TRITC 
phalloidin 72 hours after gene depletion. Collagen-Matrigel® matrix imaged 
by reflectance. The scale bars represent 50µm.
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Figure 3.13 F-actin phenotypes in HNCAF: stress fibres.
Cell phenotypes observed in HNCAF based upon the effect on the actin 
cytoskeleton. Arrows indicate stress fibres. A decrease in stress fibres was 
associated with an increase in cell spread area. Cells stained for F-actin with 
TRITC phalloidin 72 hours after transfection. The scale bars represent 
50µm.
F-actin
Increased stress fibres
Normal
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Figure 3.14 Examples of matrix remodelling and track generation by 
carcinoma-associated fibroblasts
Reflectance images of collagen-Matrigel® extra-cellular matrix (white) after 
24 hours of fibroblast remodelling. Fibroblasts stained with TRITC phalloidin
(red) shown in insets. Arrows indicate holes generated in the matrix. Circles 
indicate areas of remodelled matrix. The scale bars represent 50µm.
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3.3 Summary
 Dharmacon® SMARTpool siRNA libraries targeting 289 E3 ubiquitin ligases 
and 137 DUBs were used to screen for their potential role in SCC invasion by 
assessing their ability to regulate the actin cytoskeleton of A431 cells. Forty-five 
‘1st Round’ hits were identified.
 To confirm that the cell phenotypes observed in the initial morphological screen
were not ‘off-target’ phenomena, the SMARTpools of the 45 ‘1st Round’ hits 
were de-convoluted using individual siRNA duplexes. From this screen in A431 
cells, 29 genes emerged as ‘2nd Round’ hits.
 To further test my 29 ‘2nd Round’ gene hits as regulators of the actin 
cytoskeleton, an additional siRNA screen in stromal fibroblasts was performed. 
Eight genes (MKRN2, RKHD2, TRAF6, Mdm4, HERC4, SAE1, ZA20d1 and 
USP6) when individually depleted in fibroblasts resulted in markedly abnormal 
cell phenotypes. These were designated ‘CAF’ hits. 
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Chapter 4
Functional siRNA screening
4.1 Introduction
To investigate the role of my 29 ‘2nd Round’ gene hits (Chapter 3, Table 3.9) on SCC 
invasion a functional siRNA screen using an organotypic culture system was performed 
(Figure 4.1). This system involved culturing carcinoma cells (SCC12) over a matrix 
predominantly composed of Type I collagen. Each culture was supported by a metal 
bridge which enabled the epithelial layer to develop at an air-liquid interface. Media
was changed daily throughout the duration of the assay. When HNCAF were 
introduced, the collagen-Matrigel® ECM was remodelled and carcinoma cells invaded 
as collective chains without having undergone an EMT 77. The extent of SCC invasion 
was reproducibly assessed by calculating the Invasion Index 302.
Matrix remodelling by fibroblasts is an important aspect of several physiological and 
pathological processes such as wound healing and tissue fibrosis. It is also critical to 
carcinoma invasion 304, 305. Fibroblast-mediated remodelling of the ECM can be 
visualised microscopically by reflectance imaging and TEM 77. Fibroblasts also have 
the ability to contract collagen gels; a phenomenon that can be observed at the 
macroscopic level 303, 306. Furthermore, a good correlation between the degree of 
macroscopic gel contraction and the extent of microscopic matrix remodelling exists 77. 
Given that our organotypic system is fibroblast-dependent and that a remodelled 
conditioned ECM is necessary to support SCC invasion, I also investigated the 
influence of my 8 ‘CAF’ gene hits (Chapter 3, Table 3.10) on the ability of stromal 
fibroblasts to promote SCC invasion and gel contraction. 
Figure 4.1 Organotypic culture system for studying SCC invasion
(a) Photograph and diagram showing experimental set-up. This system 
involved culturing carcinoma cells over a collagen-Matrigel® matrix 
supported by a collagen coated nylon filter resting on a stainless steel 
bridge. Sufficient medium was added to feed the culture from beneath the 
bridge thus allowing the epithelial layer to develop at an air-liquid interface. 
(b) Photomicrograph of an H&E section showing invasion of carcinoma 
cells. When carcinoma-associated fibroblasts are introduced into the matrix 
the SCC cells invade as collective chains and retain the expression of 
epithelial markers.
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Wire mesh
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4.2 Functional siRNA screening
4.2.1 SCC invasion screen
Cdc42 is a key regulator of SCC12 invasion in our organotypic system 77. siRNA 
targeting Cdc42 was therefore used as a positive control for transfection efficiency and 
to assess the effect of gene depletion on invasion. Organotypic cultures in which SCC12 
cells had been transfected with a non-targeting siRNA duplex or were not transfected 
were also included. In addition, a collagen gel without fibroblasts was set up routinely 
in each assay to act as a negative control. Two individual siRNA oligonucleotides were 
selected for each of the 29 ‘2nd Round’ gene hits per assay. Serial assays were 
performed and the genes assessed with respect to the degree of inhibition of carcinoma 
invasion observed following their depletion. Silencing 21 of the 29 genes identified as 
cytoskeletal regulators had no obvious functional effect on SCC invasion (data not 
shown).
Figures 4.2-4.9 illustrate the results of the organotypic assays of the genes which 
emerged as potential candidates for further study. Each figure consists of (a) 
photomicrographs of H&E sections demonstrating the degree of carcinoma infiltration 
into the underlying matrix, (b) quantification of carcinoma invasion using the Invasion 
Index and (c) randomized block ANOVA statistical analysis. Depletion of RKHD2 
(Figure 4.3), TRAF6 (Figure 4.4), and ZA20d1 (Figure 4.8) achieved statistically 
significant inhibition of carcinoma invasion with at least one of the two targeting siRNA 
duplexes chosen.
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Figure 4.2 SCC organotypic invasion screen: MKRN2 gene depletion
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Quantification of carcinoma 
invasion in organotypic gels in the absence of stromal fibroblasts, in the 
presence of stromal fibroblasts and with Cdc42 or MKRN2 inhibited by siRNA 
in SCC12 cells. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Cdc42 siRNA RKHD2 siRNA #1 RKHD2 siRNA #4 
Do not reject0.370949Control vs Control siRNA
Do not reject0.092371Control siRNA vs RKHD2 siRNA #4
Reject0.019921Control siRNA vs RKHD2 siRNA #1
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.3 SCC organotypic invasion screen: RKHD2 gene depletion
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Quantification of carcinoma 
invasion in organotypic gels in the absence of stromal fibroblasts, in the 
presence of stromal fibroblasts and with Cdc42 or RKHD2 inhibited by siRNA 
in SCC12 cells. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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SCC12 alone SCC12 + HNCAF Control siRNA 
Cdc42 siRNA TRAF6 siRNA #2 TRAF6 siRNA #3 
Do not reject0.945694Control vs Control siRNA
Reject0.000006Control siRNA vs TRAF6 siRNA #3
Reject0.000010Control siRNA vs TRAF6 siRNA #2
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.4 SCC organotypic invasion screen: TRAF6 gene depletion
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Quantification of carcinoma 
invasion in organotypic gels in the absence of stromal fibroblasts, in the 
presence of stromal fibroblasts and with Cdc42 or TRAF6 inhibited by siRNA 
in SCC12 cells. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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SCC12 alone SCC12 + HNCAF Control siRNA 
Cdc42 siRNA Mdm4 siRNA #2 Mdm4 siRNA #3 
Do not reject0.086477Control vs Control siRNA
Do not reject0.061711Control siRNA vs Mdm4 siRNA #3
Do not reject0.076099Control siRNA vs Mdm4 siRNA #2
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.5 SCC organotypic invasion screen: Mdm4 gene depletion 
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Quantification of carcinoma 
invasion in organotypic gels in the absence of stromal fibroblasts, in the 
presence of stromal fibroblasts and with Cdc42 or Mdm4 inhibited by siRNA 
in SCC12 cells. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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SCC12 alone SCC12 + HNCAF Control siRNA 
Cdc42 siRNA HERC4 siRNA #3 HERC4 siRNA #4 
Do not reject0.086477Control vs Control siRNA
Do not reject0.167189Control siRNA vs HERC4 siRNA #4
Do not reject0.029069Control siRNA vs HERC4 siRNA #3
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.6 SCC organotypic invasion screen: HERC4 gene depletion
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Quantification of carcinoma 
invasion in organotypic gels in the absence of stromal fibroblasts, in the 
presence of stromal fibroblasts and with Cdc42 or HERC4 inhibited by siRNA 
in SCC12 cells. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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SCC12 alone SCC12 + HNCAF Control siRNA 
Cdc42 siRNA SAE1 siRNA #1 SAE1 siRNA #4 
Do not reject0.953404Control vs Control siRNA
Do not reject0.037713Control siRNA vs SAE1 siRNA #4
Do not reject0.069820Control siRNA vs SAE1 siRNA #1
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.7 SCC organotypic invasion screen: SAE1 gene depletion
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Quantification of carcinoma 
invasion in organotypic gels in the absence of stromal fibroblasts, in the 
presence of stromal fibroblasts and with Cdc42 or SAE1 inhibited by siRNA in 
SCC12 cells. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Cdc42 siRNA ZA20d1 siRNA #1 ZA20d1 siRNA #3 
Do not reject0.858188Control vs Control siRNA
Reject0.022693Control siRNA vs ZA20d1 siRNA #3
Do not reject0.040391Control siRNA vs ZA20d1 siRNA #1
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.8 SCC organotypic invasion screen: ZA20d1 gene depletion 
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Quantification of carcinoma 
invasion in organotypic gels in the absence of stromal fibroblasts, in the 
presence of stromal fibroblasts and with Cdc42 or ZA20d1 inhibited by siRNA 
in SCC12 cells. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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SCC12 alone SCC12 + HNCAF Control siRNA 
Cdc42 siRNA USP6 siRNA #2 USP6 siRNA #3 
Do not reject0.858188Control vs Control siRNA
Do not reject0.031790Control siRNA vs USP6 siRNA #3
Do not reject0.027850Control siRNA vs USP6 siRNA #2
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.9 SCC organotypic invasion screen: USP6 gene depletion
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Quantification of carcinoma 
invasion in organotypic gels in the absence of stromal fibroblasts, in the 
presence of stromal fibroblasts and with Cdc42 or USP6 inhibited by siRNA 
in SCC12 cells. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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4.2.2 Inhibition of SCC invasion by HNCAF interference
To assess the influence of the 8 ‘CAF’ cytoskeletal gene hits on the ability of stromal 
fibroblasts to promote SCC invasion, a modified two-stage organotypic assay was used 
as described in Chapter 2, Section 2.2.8.3. 
This assay was performed twice and involved the construction of collagen-Matrigel® 
gels containing siRNA gene depleted HNCAF. After 5 days of matrix remodelling, the 
fibroblasts were extracted and SCC12 seeded on to the conditioned ECM. The 
organotypic cultures were then allowed to proceed to completion and the extent of 
carcinoma invasion quantified. Inhibition of ROCK in fibroblast-SCC co-cultures has 
been shown to reduce carcinoma invasion by impairing fibroblast-dependent force-
mediated matrix contraction 77. siRNA targeting ROCK1 and ROCK2 was therefore 
chosen as the positive transfection control.
The results of this invasive screen are displayed in Figures 4.10-4.12. Five genes, 
(MKRN2, RKHD2, TRAF6, ZA20d1 and USP6), when individually depleted in stromal 
fibroblasts impaired their ability to promote SCC invasion.
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Figure 4.10 Inhibition of SCC invasion by HNCAF interference. (a) ‘Control’
gels and (b) siRNA gene depleted HNCAF gels
Quantification of carcinoma invasion in organotypic gels that previously 
contained gene depleted stromal fibroblasts. ROCK, MKRN2, RKHD2, TRAF6, 
Mdm4, HERC4, SAE1, ZA20d1 and USP6 function inhibited by siRNA in 
HNCAF. Gels treated with puromycin (5µg/ml) daily for 48 hours after 5 days of 
matrix remodelling and fibroblasts removed prior to the addition of SCC12 cells. 
The average of 10 visual fields from 2 experiments is shown. The error bars 
represent the s.e. 
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Do not reject0.367520MOCK vs Control siRNA
Do not reject0.155424Control vs MOCK
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.11 Inhibition of SCC invasion by HNCAF interference.   
(a) ‘Control’ gels and (b) randomized block ANOVA statistical 
analysis
(a) Scatter plot displaying quantification of carcinoma invasion in the 
‘control’ gels of the organotypic assay illustrated in Figure 4.10. 
Individual experimental blocks are illustrated. The average of 5 visual 
fields is shown and error bars represent the s.e. (b) Randomized block 
ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Reject0.003008Control siRNA vs USP6 siRNA #1 + #3
Reject0.009604Control siRNA vs ZA20d1 siRNA #1 + #3
Do not reject0.096878Control siRNA vs SAE1 siRNA #1 + #4
Do not reject0.034362Control siRNA vs HERC4 siRNA #3 + #4
Do not reject0.0820224Control siRNA vs Mdm4 siRNA #2 + #3
Reject0.008562Control siRNA vs TRAF6 siRNA #2 + #3
Reject0.003809Control siRNA vs RKHD2 siRNA #1+ #4
Reject0.006113Control siRNA vs MKRN2 siRNA #1+ #4
Decision p<0.025p ValueRandomized Block ANOVA
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Figure 4.12 Inhibition of SCC invasion by HNCAF interference.   
(a) siRNA gene depleted HNCAF gels and (b) randomized block 
ANOVA statistical analysis
(a) Scatter plot displaying quantification of carcinoma invasion in the gene 
depleted HNCAF gels of organotypic assay illustrated in Figure 4.10. 
Individual experimental blocks are illustrated. The average of 5 visual fields 
is shown and error bars represent the s.e. (b) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
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4.3 Fibroblast-dependent collagen-Matrigel® matrix remodelling
4.3.1 The Contraction Index
The collagen-Matrigel® gels constructed for the assays detailed in Section 4.2.2 were 
photographed after 5 days of fibroblast-mediated matrix remodelling (Figures 4.13a and 
4.15a) and the Contraction Index for each gel calculated (Figures 4.13b and 4.15b). 
Figures 4.14a and 4.16a show scatter plots of the individual experimental blocks for the 
‘Control’ gels and the siRNA gene depleted HNCAF gels respectively. 
Gels containing HNCAF transfected with non-targeting siRNA contracted to a similar 
degree to those with mock transfected or non-transfected stromal fibroblasts (Figure 
4.14b). As expected, fibroblast-deficient gels did not contract. 
Predictably, ROCK depleted HNCAF exhibited a noticeably reduced ability to contract 
their ECM (Figure 4.15). The contraction indices of the siRNA gene depleted HNCAF 
gels were not statistically different when compared to the control (Figure 4.16b). 
4.3.2 The relationship between SCC invasion and collagen-Matrigel®
          matrix contraction
Figure 4.17 shows scatterplots of the mean Invasion Index and the mean Contraction 
Index for the two-stage organotypic assays investigating the functional significance of 
my 8 ‘CAF’ cytoskeletal gene hits (Section 4.2.2). The relationship between these two 
parameters for my genes of interest was inconsistent. 
00.1
0.2
0.3
0.4
0.5
0.6
C
o
n
tr
ac
ti
o
n
 I
n
d
ex
 (
A
U
)
Ctrl Ctrl MOCK
CTRL      
siRNA
--HNCAF
Day 5 & 6 - Puromycin (5µg/ml)
Figure 4.13 Assessment of fibroblast-dependent collagen-Matrigel®
matrix contraction: ‘Control’ gels 
(a) Images of organotypic gels after 5 days of matrix remodelling prior to 
the removal of HNCAF from the organotypic assay described in Figure 
4.10. The dotted line represents the area of the gel. (b) Quantification of 
the degree of matrix remodelling. The Contraction Index was calculated 
using the formula 1 - (Gel Area / Well Area). The average of 2 
experiments is shown and error bars represent the s.e. 
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Figure 4.14 Assessment of fibroblast-dependent collagen-Matrigel®
matrix contraction: ‘Control’ gels. (a) Scatter plot and (b) randomized 
block ANOVA statistical analysis
(a) Scatter plot displaying the Contraction Index of the ‘Control’ gels 
illustrated in Figure 4.13. Individual experimental blocks are shown. 
*Denotes an expanded Y-axis. (b) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 4.15 Assessment of fibroblast-dependent collagen-Matrigel®
matrix contraction: siRNA gene depleted HNCAF gels
(a) Images of organotypic gels after 5 days of matrix remodelling prior to 
the removal of HNCAF from the organotypic assay illustrated in Figure 4.10 
The dotted line represents the area of the gel. (b) Quantification of the 
degree of matrix remodelling. The Contraction Index was calculated using 
the formula 1 - (Gel Area / Well Area). The average of 2 experiments is 
shown and error bars represent the s.e. 
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Do not reject0.177399Control siRNA vs USP6 siRNA #1 + #3
Do not reject0.310840Control siRNA vs ZA20d1 siRNA #1 + #3
Do not reject0.585704Control siRNA vs SAE1 siRNA #1 + #4
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Figure 4.16 Assessment of fibroblast-dependent collagen-Matrigel®
matrix contraction: siRNA gene depleted HNCAF gels. (a) Line plot 
and (b) randomized block ANOVA statistical analysis
(a) Scatter plot displaying the Contraction Index of the siRNA gene 
depleted HNCAF gels illustrated in Figure 4.15. Individual experimental 
blocks are shown. *Denotes an expanded Y-axis. (b) Randomized block 
ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
Block 1
Block 2
*
170
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
TRAF6     
siRNA
Ctrl 
siRNA
ROCK 
siRNA
RKHD2 
siRNA
MKRN2 
siRNA
Mdm4 
siRNA
HERC4 
siRNA
SAE1 
siRNA
ZA20d1  
siRNA
USP6 
siRNAHNCAF
Day 5 & 6 - Puromycin (5µg/ml)
Invasion Index
Contraction Index
b
A
rb
it
ra
ry
 U
n
it
s 
(A
U
)
a
Figure 4.17 Relationship between SCC invasion and collagen-Matrigel®
matrix contraction
Scatter plots displaying the relationship between mean carcinoma invasion 
(blue) and mean gel contraction (red) of the organotypic assay illustrated in 
Figure 4.10. (a) ‘Control’ gels and (b) siRNA gene depleted HNCAF gels. Error 
bars represent the s.e.
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4.4 Summary of siRNA screening
A summary of the results of the various morphological and functional screens described 
in Chapters 3 and 4 is presented diagrammatically in Figure 4.18.
4.4.1 Gene hits
Five genes: 3 E3 ubiquitin ligases (MKRN2, RKHD2, and TRAF6) and 2 de-
ubiquitinating enzymes (ZA20d1 and USP6) were identified as potential candidate 
genes for detailed study.
A431 Cytoskeletal Screen
‘1st Round’
‘2nd Round’
Gene Library
Dharmacon® SMARTpool Hits
De-convoluted SMARTpool Hits
HNCAF Cytoskeletal Hits
RKHD2 
TRAF6 
ZA20d1 
SCC12 Interference HNCAF Interference
45
426
29
3
8
5Inhibition of SCC Invasion
Figure 4.18 Summary of siRNA screening
Diagrammatic representation of the morphological and functional 
screens undertaken to identify regulators of SCC invasion using 
Dharmacon® SMARTpool siRNA libraries targeting 289 E3 ubiquitin
ligases and 137 de-ubiquitinating enzymes. 
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4.5 Summary
 To investigate the role of my 29 ‘2nd Round’ gene hits on SCC invasion a 
functional siRNA screen using an organotypic culture system was performed. 
Three genes, (RKHD2, TRAF6 and ZA20d1), when individually depleted in 
SCC12 cells were associated with a statistically significant reduction in 
carcinoma invasion.
 To assess the influence of my 8 ‘CAF’ gene hits on the ability of stromal 
fibroblasts to promote carcinoma invasion, a modified two-stage organotypic 
assay was conducted. Five genes, (MKRN2, RKHD2, TRAF6, ZA20d1 and 
USP6), when individually depleted in HNCAF impaired their ability to promote 
SCC invasion.
 Previous work from our group has shown a good correlation between the extent 
of collagen-Matrigel® matrix contraction and the ability of stromal fibroblasts to 
promote carcinoma invasion 77. The relationship between these two parameters 
for my genes of interest was inconsistent.
 Following morphological and functional screening, 3 E3 ubiquitin ligases 
(MKRN2, RKHD2 and TRAF6) and 2 de-ubiquitinating enzymes (ZA20d1 and 
USP6), emerged from the original 426 siRNA gene library as potential 
candidates for detailed study. 
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Chapter 5
Validation of gene hits and candidate genes
5.1 Introduction
Of the 5 genes identified from the various cytoskeletal and functional screens outlined 
in Chapters 3 and 4, RKHD2, TRAF6, ZA20d1 and USP6 were selected for further 
validation. At this stage, results suggested that RKHD2, TRAF6 and ZA20d1 were 
functionally important to carcinoma invasion in both SCC12 cells and HNCAF. 
MKRN2 was ‘dropped’ at this time on the basis of its poor performance in the SCC 
organotypic invasion screen compared to that of USP6 (Chapter 4, Figures 4.2 and 4.9).
The results of this validation process, the selection of candidate genes and their 
subsequent confirmation as regulators of carcinoma invasion are presented here.
5.2 Validation of gene hits
5.2.1 Qiagen® siRNA screen 
For each of RKHD2, TRAF6, ZA20d1 and USP6 four additional siRNA duplexes were 
purchased from Qiagen®. These oligonucleotides were screened in A431 cells (as 
described in Chapter 3, Section 3.2.1) to assess the legitimacy of the morphological 
changes previously noted following gene depletion. Figures 5.1 and 5.2 show 
representative images of the cell phenotypes observed. 
The results of this cytoskeletal screen were consistent with those obtained using 
Dharmacon® siRNA. The predominant cell phenotypes observed following gene 
depletion in A431 cells were: RKHD2 - elongated, TRAF6 - elongated, ZA20d1 - spiky 
and USP6 - elongated.  
Figure 5.1 Qiagen® siRNA screen in A431 cells: RKHD2 and 
TRAF6 gene depletion
Phenotypes of A431 cells on deformable collagen-Matrigel® gels 72 
hours following transfection with control,  Integrin β1, Rho A, RKHD2, 
and TRAF6 siRNA duplexes. Arrows indicate examples of elongated 
cells. Cells stained with TRITC phalloidin. Scale bar represents 50µm.
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Figure 5.2 Qiagen® siRNA screen in A431 cells: ZA20d1 and USP6 
gene depletion
Phenotypes of A431 cells on deformable collagen-Matrigel® gels 72 
hours following transfection with control,  Integrin β1, Rho A, ZA20d1 
and USP6 siRNA duplexes. Arrows indicate examples of actin-rich 
spikes. Cells stained with TRITC phalloidin. Scale bar represents 20µm.
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5.2.2 Quantitative polymerase chain reaction (qPCR)
For RKHD2, TRAF6 and ZA20d1 quantitative polymerase chain reaction (qPCR) 
assays were performed to assess the knockdown efficiency of each siRNA duplex for its 
target gene. USP6 was ‘dropped’ at this stage since I was unable to design a functional 
set of forward and reverse DNA primers necessary to generate the desired PCR product.
RNA was extracted from A431 cells 72 hours following transfection and mRNA 
transcriptional output correlated to the cell phenotype observed on a collagen-Matrigel® 
gel. qPCR assays were performed in triplicate and normalised to GAPDH which was 
chosen as a house-keeping gene. 
Figure 5.3 illustrates the elongated cell phenotypes observed in A431 cells following 
RKHD2 gene depletion. Figures 5.4a and 5.4b show the relative knockdown 
efficiencies of the Dharmacon® and Qiagen® siRNA duplexes respectively. All eight 
oligonucleotides resulted in approximately 60% or greater reduction in mRNA 
transcriptional output compared to the mock sample. Figures 5.4c and 5.5 confirm 
transfection efficiency.
Figure 5.6 illustrates the elongated cell phenotypes observed in A431 cells following 
TRAF6 gene depletion. Figures 5.7a and 5.7b show the relative knockdown efficiencies 
of the Dharmacon® and Qiagen® siRNA duplexes respectively. Four of the eight 
oligonucleotides, #1, #2, #3 and #B, resulted in approximately 50% or greater reduction 
in mRNA transcriptional output compared to the mock sample. Figures 5.7c and 5.8 
confirm transfection efficiency.
Figure 5.9 illustrates the actin-rich spikes observed in A431 cells following ZA20d1 
gene depletion. Figures 5.10a and 5.10b show the relative knockdown efficiencies of the 
Dharmacon® and Qiagen® siRNA duplexes respectively. All of the oligonucleotides, 
other than #4, resulted in approximately 50% or greater reduction in mRNA 
transcriptional output compared to the mock sample. Figures 5.10c and 5.11 confirm 
transfection efficiency.
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Figure 5.3 Validation of Dharmacon® and Qiagen® RKHD2 siRNA
duplexes: A431 cell phenotypes
Phenotypes of A431 cells on deformable collagen-Matrigel® gels 72 
hours following transfection with control,  Integrin β1, Rho A and 
RKHD2 siRNA duplexes. Arrows indicate examples of elongated cells. 
Cells stained with TRITC phalloidin. Scale bar represents 20µm.
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Figure 5.4 Validation of Dharmacon® and Qiagen® RKHD2 siRNA
duplexes:  quantitative polymerase chain reaction (qPCR)
qPCR assays were performed to assess mRNA transcriptional output in 
A431 cells 72 hours following siRNA transfection. Values were normalised 
to GAPDH which was selected as a house-keeping gene. The average 
value of 3 independent experiments is shown and error bars indicate the 
s.e. (a) Dharmacon® RKHD2 siRNA duplexes. (b) Qiagen® RKHD2 
siRNA duplexes. (c) Rho A siRNA duplex. This was included as a positive 
transfection control.
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Figure 5.5 Validation of Dharmacon® and Qiagen® RKHD2 siRNA
duplexes: Integrin β1 immunofluoresence
Immunofluoresence staining of A431 cells on glass 72 hours following 
transfection with Integrin β1 siRNA confirming gene knockdown 
efficiency. This acted as an additional positive transfection control. 
Cells also stained with TRITC phalloidin. Scale bar represents 50µm.
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Figure 5.6 Validation of Dharmacon® and Qiagen® TRAF6 siRNA
duplexes: A431 cell phenotypes
Phenotypes of A431 cells on deformable collagen-Matrigel® gels 72 
hours following transfection with control,  Integrin β1, Rho A and TRAF6 
siRNA duplexes. Arrows indicate examples of elongated flat cells. Cells 
stained with TRITC phalloidin. Scale bar represents 20µm.
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Figure 5.7 Validation of Dharmacon® and Qiagen® TRAF6 siRNA
duplexes:  quantitative polymerase chain reaction (qPCR)
qPCR assays were performed to assess mRNA transcriptional output in 
A431 cells 72 hours following siRNA transfection. Values were normalised 
to GAPDH which was selected as a house-keeping gene. The average 
value of 3 independent experiments is shown and error bars indicate the 
s.e. (a) Dharmacon® TRAF6 siRNA duplexes. (b) Qiagen® TRAF6 siRNA 
duplexes. (c) Rho A siRNA duplex. This was included as a positive 
transfection control.
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Figure 5.8 Validation of Dharmacon® and Qiagen® TRAF6 siRNA
duplexes: Integrin β1 immunofluoresence
Immunofluoresence staining of A431 cells on glass 72 hours following 
transfection with Integrin β1 siRNA confirming gene knockdown 
efficiency. This acted as an additional positive transfection control. 
Cells also stained with TRITC phalloidin. Scale bar represents 50µm.
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Figure 5.9 Validation of Dharmacon® and Qiagen® ZA20d1 siRNA
duplexes: A431 cell phenotypes
Phenotypes of A431 cells on deformable collagen-Matrigel® gels 72 
hours following transfection with control,  Integrin β1, Rho A and 
ZA20d1 siRNA duplexes. Arrows indicate examples of actin-rich spikes. 
Cells stained with TRITC phalloidin. Scale bar represents 20µm.
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Figure 5.10 Validation of Dharmacon® and Qiagen® ZA20d1 siRNA
duplexes:  quantitative polymerase chain reaction (qPCR)
qPCR assays were performed to assess mRNA transcriptional output in 
A431 cells 72 hours following siRNA transfection. Values were normalised 
to GAPDH which was selected as a house-keeping gene. The average 
value of 3 independent experiments is shown and error bars indicate the 
s.e. (a) Dharmacon® ZA20d1 siRNA duplexes. (b) Qiagen® ZA20d1 
siRNA duplexes. (c) Rho A siRNA duplex. This was included as a positive 
transfection control.
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Figure 5.11 Validation of Dharmacon® and Qiagen® ZA20d1 
siRNA duplexes: Integrin β1 immunofluoresence
Immunofluoresence staining of A431 cells on glass 72 hours following 
transfection with Integrin β1 siRNA confirming gene knockdown 
efficiency. This acted as an additional positive transfection control. 
Cells also stained with TRITC phalloidin. Scale bar represents 50µm.
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5.2.3 TRAF6 immunofluoresence (IMF)
Of my potential candidate genes, RKHD2, TRAF6 and ZA20d1, antibodies were only 
available commercially for TRAF6. Anti-TRAF6 antibodies were therefore purchased 
from Abcam® and Santa Cruz Biotechnology Inc.
Figure 5.12 demonstrates IMF staining for TRAF6 in A431 cells on glass 72 hours 
following transfection with the pUNO-hTRAF6-HA construct. Images were captured to 
optimally show TRAF6-HA positive cells. TRAF6 expression was cytosolic.
The rabbit monoclonal antibody manufactured by Abcam® was considered to be the 
better of the two anti-TRAF6 antibodies and was further validated in TRAF6-HA 
positive cells using 12CA5, a HA-tag antibody (Figure 5.13).
5.3 The selection of candidate genes
5.3.1 TRAF6 and ZA20d1
At this stage of my research, a review of the scientific literature indicated that TRAF6 
and ZA20d1 were positive and negative regulators of canonical NF-ĸB signalling in 
epithelial cells 163, 307. Co-immunoprecipitation studies also suggested that ZA20d1 was 
the complementary DUB to TRAF6 and that its interaction with TRAF6 was critical to 
downstream signalling events following TNFR and IL-1R activation 308. In view of this, 
and given the importance of NF-ĸB pathways in the pathogenesis of SCC, TRAF6 and 
ZA20d1 were selected as candidate genes for detailed study.
5.3.2 RKHD2
RKHD2 was not selected as a candidate gene for detailed study. Currently there is no 
experimental data regarding its function other than a single study which speculatively 
links its E3 ligase activity to the pathogenesis of essential hypertension 309. 
CONTROL MOCK TRAF6-HA
Figure 5.12 TRAF6 immunofluoresence
Immunofluoresence staining of A431 cells on glass 72 hours following 
transfection with the pUNO-hTRAF6-HA construct. Cells stained with 
rabbit anti-TRAF6 (1:50) and mouse anti-TRAF6 (1:50) antibodies. 
Cells also stained with TRITC phalloidin. Scale bar represents 50µm.
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Figure 5.13 TRAF6-HA positive A431 cells
Immunofluoresence staining of A431 cells on glass 72 hours 
following transfection with the pUNO-hTRAF6-HA construct. Cells 
stained with rabbit anti-TRAF6 (1:50) and mouse 12CA5 (1:50) 
antibodies. 12CA5  is a HA-tag antibody. Cells also stained with 
TRITC phalloidin. Scale bar represents 50µm.
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5.4 Functional validation of candidate genes
Having chosen TRAF6 and ZA20d1 as candidate genes, I sought to validate their 
function as regulators of carcinoma invasion in SCC12 cells by performing organotypic 
assays using six targeting siRNA duplexes for each gene. These were selected on the 
basis of their ability to knockdown TRAF6 (Figure 5.7) and ZA20d1 (Figure 5.10) 
respectively.  
5.4.1 TRAF6 is required in SCC12 cells for carcinoma invasion in vitro
Figure 5.14a consists of representative photomicrographs of H&E sections from these 
assays. Silencing of TRAF6 with each of the six siRNA oligonucleotides inhibited 
carcinoma invasion compared to the control samples, evident by the reduced number of 
cancer cells infiltrating the ECM. Figure 5.14b shows the quantification of carcinoma 
invasion. A scatter plot of the individual experimental blocks is presented in Figure 
5.15a. The reduction in carcinoma invasion observed following TRAF6 gene depletion 
was statistically significant for all six duplexes (Figure 5.15b).
Figure 5.16 demonstrates the efficacy of TRAF6 siRNA gene depletion in SCC12 cells 
72 hours following transfection. Cell lysates were made in parallel with Block 1 of the 
organotypic assay illustrated in Figure 5.14.
5.4.2 ZA20d1 is required in SCC12 cells for carcinoma invasion in vitro
Figure 5.17a consists of representative photomicrographs of H&E sections from these 
assays. Silencing of ZA20d1 with each of the six siRNA oligonucleotides inhibited 
carcinoma invasion compared to the control samples, evident by the reduced number of 
cancer cells infiltrating the ECM. Figure 5.17b shows the quantification of carcinoma 
invasion. A scatter plot of the individual experimental blocks is also presented in Figure 
5.18a. The reduction in carcinoma invasion observed following ZA20d1 gene depletion 
was statistically significant for five of the six duplexes (Figure 5.18b).
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Figure 5.14 SCC12 organotypic invasion assay: TRAF6 gene 
depletion 
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Quantification of 
carcinoma invasion in organotypic gels in the absence of stromal
fibroblasts, in the presence of stromal fibroblasts and with Cdc42 or 
TRAF6 inhibited by siRNA in SCC12 cells. The average of 15 visual 
fields from 3 experiments is shown. The error bars represent the s.e.
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Reject0.003054Control siRNA vs TRAF6 siRNA #D
Reject0.000006Control siRNA vs TRAF6 siRNA #C
Reject0.000066Control siRNA vs TRAF6 siRNA #B
Reject0.00034Control siRNA vs TRAF6 siRNA #3
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Figure 5.15 TRAF6 is required in SCC12 cells for carcinoma 
invasion in vitro
(a) Scatter plot displaying quantification of carcinoma invasion of the  
organotypic assay illustrated in Figure 5.14. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error 
bars represent the s.e. (b) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.007.
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Figure 5.16 Western blot demonstrating the efficacy of TRAF6 
siRNA gene depletion in SCC12 cells
Western blot of SCC12 cell lysates 72 hours post-transfection showing 
the efficient knockdown of TRAF6. These lysates were made in parallel 
with Block 1 of the organotypic assay illustrated in Figure 5.14.
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Figure 5.17 SCC12 organotypic invasion assay: ZA20d1 gene 
depletion
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Quantification 
of carcinoma invasion in organotypic gels in the absence of stromal 
fibroblasts, in the presence of stromal fibroblasts and with Cdc42 or 
ZA20d1 inhibited by siRNA in SCC12 cells. The average of 10 visual 
fields from 2 experiments is shown. The error bars represent the s.e. 
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Figure 5.18 ZA20d1 is required in SCC12 cells for carcinoma 
invasion in vitro
(a) Scatter plot displaying quantification of carcinoma invasion of the  
organotypic assay illustrated in Figure 5.17. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error 
bars represent the s.e. (b) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.007.
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5.4.3 TRAF6 and ZA20d1 double gene depletion in SCC12 cells
Having validated TRAF6 and ZA20d1 as regulators of carcinoma invasion in SCC12 
cells, I performed invasion assays in which carcinoma cells were depleted of both 
proteins. Double knockdown of TRAF6 and ZA20d1 was achieved by adding equal 
concentrations of the respective siRNA duplexes to the transfection mix (Chapter 2, 
Section 2.2.8.4).
Figures 5.19-5.21 illustrate the results of these double knockdown experiments. As 
expected, double gene depletion of TRAF6 and ZA20d1 in SCC12 cells resulted in 
statistically significant inhibition of carcinoma invasion (Figure 5.21a). 
However, double gene depletion when compared to single gene depletion of either 
TRAF6 or ZA20d1 did not lead to greater inhibition of SCC12 cell invasion and was 
not statistically significant (Figure 5.21b).
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Figure 5.19 SCC12 organotypic invasion assay: TRAF6 and ZA20d1 
double gene depletion
Quantification of carcinoma invasion in organotypic gels in the absence of 
stromal fibroblasts, in the presence of stromal fibroblasts and with Cdc42, 
TRAF6 and ZA20d1 inhibited by siRNA in SCC12 cells. Double gene 
depletions were performed by co-transfection of the specified 
oligonucleotides in equal concentration. The average of 10 visual fields 
from 2 experiments is shown. The error bars represent the s.e. 
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Figure 5.20 SCC12 organotypic invasion assay: TRAF6 and 
ZA20d1 double gene depletion - scatter plots
Scatter plots displaying quantification of carcinoma invasion of the  
organotypic assay illustrated in Figure 5.19. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and 
error bars represent the s.e. 
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Reject0.000017Control siRNA vs TRAF6 siRNA #B
Reject0.000143Control siRNA vs TRAF6 siRNA #3
Reject0.000125Control siRNA vs TRAF6 siRNA #2
Decision p<0.0166p ValueRandomized Block ANOVA
Reject0.000130Control siRNA vs TRAF6 + ZA20d1 siRNA #2 + #2
Reject0.000125Control siRNA vs TRAF6 + ZA20d1 siRNA #3 + #3
Reject0.000019Control siRNA vs TRAF6 + ZA20d1 siRNA #B + #A
Decision p<0.025p ValueRandomized Block ANOVA
Do not reject0.816283TRAF6 siRNA #2 vs TRAF6 + ZA20d1 siRNA #2 + #2
Do not reject0.438116TRAF6 siRNA #3 vs TRAF6 + ZA20d1 siRNA #3 + #3
Do not reject0.076399TRAF6 siRNA #B vs TRAF6 + ZA20d1 siRNA #B + #A
Reject0.000019Control siRNA vs ZA20d1 siRNA #A
Reject0.000159Control siRNA vs ZA20d1 siRNA #3
Reject0.000167Control siRNA vs ZA20d1 siRNA #2
Do not reject0.224467ZA20d1 siRNA #2 vs TRAF6 + ZA20d1 siRNA #2 + #2
Do not reject0.239008ZA20d1 siRNA #3 vs TRAF6 + ZA20d1 siRNA #3 + #3
Do not reject0.784810ZA20d1 siRNA #A vs TRAF6 + ZA20d1 siRNA #B + #A
Figure 5.21 SCC12 organotypic invasion assay: TRAF6 and ZA20d1 
double gene depletion - randomized block ANOVA statistical analysis
Randomized block ANOVA statistical analysis of organotypic assay
illustrated in Figures 5.19. Null hypothesis (NØ) rejected if (a) p < 0.0166 
and (b) p < 0.025.
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5.4.4 TRAF6 and ZA20d1 are required in A431 cells for carcinoma 
          invasion in vitro
Having shown TRAF6 and ZA20d1 to be regulators of carcinoma invasion in SCC12 
cells, I wanted to see if they also exerted a similar functional influence in A431 cells. 
Since A431 cells were intrinsically less invasive in our organotypic system, the standard 
assay was modified to optimise carcinoma invasion (Chapter 2, Section 2.2.8.5).
Figure 5.22a consists of representative photomicrographs of H&E sections from these 
assays. Gene depletion of either TRAF6 or ZA20d1 inhibited carcinoma invasion 
compared to the control samples, evident by the reduced number of cancer cells 
infiltrating the ECM. Figure 5.22b shows the quantification of carcinoma invasion. A 
scatter plot of the individual experimental blocks is presented in Figure 5.23a. The 
reduction in carcinoma invasion observed following either TRAF6 or ZA20d1 gene 
depletion was statistically significant for each of the siRNA duplexes (Figure 5.23b).
Figure 5.24 demonstrates the efficacy of TRAF6 siRNA gene depletion in A431 cells 
96 hours following transfection. Cell lysates were made in parallel with Block 1 of the 
organotypic assay illustrated in Figure 5.22.
5.4.5 Apoptotic counts in gene depleted A431 cells
Figures 5.25 and 5.26 show the percentage of apoptotic A431 cells per visual field 72 
hours following TRAF6 and ZA20d1 gene depletion respectively. Knocking down 
either TRAF6 or ZA20d1 was not associated with an increase in cell apoptosis 
compared to the control samples.
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Figure 5.22 A431 organotypic invasion assay: TRAF6 and ZA20d1 
gene depletion
(a) H&E stained sections of A431 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Quantification of 
carcinoma invasion in organotypic gels in the absence of stromal
fibroblasts, in the presence of stromal fibroblasts and with Cdc42, TRAF6 
or ZA20d1 inhibited by siRNA in A431 cells. The average of 10 visual 
fields from 2 experiments is shown. The error bars represent the s.e. 
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Figure 5.23 TRAF6 and ZA20d1 are required in A431 cells for 
carcinoma invasion in vitro
(a) Scatter plot displaying quantification of carcinoma invasion of the  
organotypic assay illustrated in Figure 5.22. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and 
error bars represent the s.e. (b) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.007.
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Figure 5.24 Western blot demonstrating the efficacy of TRAF6 
siRNA gene depletion in A431 cells
Western blot of A431 cell lysates 96 hours post-transfection showing 
the efficient knockdown of TRAF6. These lysates were made in parallel 
with Block 1 of the organotypic assay illustrated in Figure 5.22.
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Figure 5.25 Apoptotic counts in TRAF6 gene depleted A431 cells
(a) Scatter plot displaying the percentage of apoptotic A431 cells per 
visual field 72 hours following transfection with control, Rho A and 
TRAF6 siRNA duplexes. (b) Kruskal-Wallis non-parametric ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.05.
a
A
p
o
p
to
ti
c
 C
e
ll
s
(%
)
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
Ctrl 
siRNA
Rho A 
siRNA TRAF6 siRNA
#2 #3 #B #C
MOCK
b
Decision p<0.05p ValueKruskal-Wallis non-parametric ANOVA
Do not reject0.491971MOCK vs siRNA duplexes
NØ - All medians are equal
205
Figure 5.26 Apoptotic counts in ZA20d1 gene depleted A431 cells
(a) Scatter plot displaying the percentage of apoptotic A431 cells per 
visual field 72 hours following transfection with control, Rho A and 
ZA20d1 siRNA duplexes. (b) Kruskal-Wallis non-parametric ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.05.
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5.5 Summary
 Following further validation of my 5 gene hits using Qiagen® siRNA, qPCR 
and IMF, 3 genes (RKHD2, TRAF6 and ZA20d1) remained as potential 
candidates for detailed study.
 A review of the scientific literature indicated that ZA20d1 was the 
complementary DUB to TRAF6 and that both were key regulators of canonical 
NF-ĸB signalling in epithelial cells 163, 307. Given the importance of NF-ĸB 
pathways in the pathogenesis of SCC, TRAF6 and ZA20d1 were selected as 
candidate genes for further study.
 Currently there is no experimental data regarding the function of RKHD2 other 
than a single study which speculatively links its E3 ligase activity to the 
pathogenesis of essential hypertension 309. The role RKHD2 in carcinoma 
invasion was not studied beyond the point of validation.
 Having selected TRAF6 and ZA20d1 as candidate genes, both were functionally 
validated as regulators of carcinoma invasion in vitro in SCC12 and A431 cells.
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Chapter 6
NF-ĸB signalling in SCC invasion
6.1 Introduction
Having selected TRAF6 and ZA20d1 as my candidate genes for detailed study and 
validated them as regulators of carcinoma invasion in our organotypic system   
(Chapter 5), the next phase of my research was focused on elucidating the signalling 
mechanisms underlying their pro-invasive effects. 
Literature suggested that TRAF6 and ZA20d1 were positive and negative regulators of 
canonical NF-ĸB signalling in epithelial cells 163, 307. Co-immunoprecipitation studies 
also indicated that ZA20d1 was the complementary DUB to TRAF6 and that both 
proteins were critical to downstream events following TNFR and IL-1R activation 308. 
Given the importance of NF-ĸB signalling in the pathogenesis of SCC, I wondered 
whether TRAF6 and ZA20d1 were influencing cancer cell invasion in an NF-ĸB 
dependent manner.
To address the above hypothesis I initially examined the significance of NF-ĸB 
pathways in carcinoma invasion in our organotypic system using TNFα, IL-1α, several 
IKK inhibitors and infliximab (a monoclonal antibody to TNFα in clinical use). The 
results of these investigations are presented in this chapter.
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6.2 Tumour necrosis factor alpha (TNFα)
The importance of TNFα in the development and progression of a number of cancers is 
well established 191, 310. I therefore investigated its influence on carcinoma invasion in 
our organotypic system.
6.2.1 TNFα promotes A431 carcinoma invasion in vitro in a dose
         responsive manner
Figure 6.1a consists of representative photomicrographs of H&E sections from A431 
invasion assays in which both the stromal and epithelial components of the organotypic 
cultures were stimulated daily with TNFα at concentrations of 1, 3.1, 10 and 31ng/ml.
Figure 6.1b shows the quantification of carcinoma invasion. A scatter plot of the 
individual experimental blocks is presented in Figure 6.2a. The Invasion Index 
increased with escalating concentrations of TNFα and was statistically significant at a 
dose of 31ng/ml (Figure 6.2b).
Figure 6.3 illustrates the log linear relationship of mean carcinoma invasion in response 
to TNFα stimulation. 
6.2.2 TNFα activates NF-ĸB signalling in A431 cells and HNCAF
Cancer cell and stromal cell production of TNFα has been observed in a variety of 
experimental tumours 191. Collectively, this phenomenon is responsible for the 
constitutive activation of NF-ĸB 264.
Figure 6.4 demonstrates the activation of IKK in A431 cells following stimulation with 
TNFα (31ng/ml). This results in the phosphorylation and reciprocal degradation of IĸBα
(Figure 6.5). Consequently, NF-ĸB p65 is activated (Figure 6.6).
Figure 6.7 demonstrates the activation of IKK in HNCAF following stimulation with 
TNFα (31ng/ml). This results in the phosphorylation and reciprocal degradation of IĸBα
(Figure 6.8). Consequently, NF-ĸB p65 is activated (Figure 6.9).
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Figure 6.1 Organotypic invasion assay: HNCAF and A431 TNFα
stimulation
(a) H&E stained sections of A431 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Quantification 
of carcinoma invasion. Both the stromal and epithelial components of 
the organotypic cultures were stimulated daily with TNFα at the 
specified concentrations. The average of 10 visual fields from 2
experiments is shown. The error bars represent the s.e. 
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Figure 6.2 Organotypic invasion assay: HNCAF and A431 TNFα
stimulation. (a) Scatter plot and (b) randomized block ANOVA 
statistical analysis
(a) Scatter plot displaying quantification of carcinoma invasion in 
cultures from the organotypic assay illustrated in Figure 6.1. Individual 
experimental blocks are illustrated. The average of 5 visual fields is 
shown and error bars represent the s.e. (b) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.0125.
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Figure 6.3 TNFα promotes A431 cell invasion in vitro in a dose 
responsive manner
(a) Line plot displaying the log linear relationship of mean carcinoma 
invasion in response to TNFα stimulation. The average of 10 fields is 
shown and error bars represent the s.e. *Denotes an expanded Y-axis.
(b) ANOVA test for linear trend. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 6.4 TNFα activates IKK in A431 cells 
Western blots of A431 cell lysates showing the activation of IKK in 
response to stimulation with TNFα (31ng/ml). This leads to the 
degradation of IĸBα (Figure 6.5) with the subsequent activation of NF-ĸB
(Figure 6.6). 
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Figure 6.5 TNFα induced NF-ĸB activation is associated with the 
phosphorylation and reciprocal degradation of IĸBα in A431 cells
Western blots of A431 cell lysates showing the phosphorylation and 
reciprocal degradation of IĸBα in response to stimulation with TNFα
(31ng/ml). 
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Figure 6.6 TNFα activates NF-ĸB in A431 cells
Western blots of A431 cell lysates showing the phosphorylation of 
NF-ĸB p65  in response to stimulation with TNFα (31ng/ml). 
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Figure 6.7 TNFα activates IKK in HNCAF
Western blots of HNCAF cell lysates showing the activation of IKK in 
response to stimulation with TNFα (31ng/ml). This leads to the 
degradation of IĸBα (Figure 6.8) with the subsequent activation of NF-ĸB
(Figure 6.9). 
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Figure 6.8 TNFα induced NF-ĸB activation is associated with the 
phosphorylation and reciprocal degradation of IĸBα in HNCAF
Western blots of HNCAF cell lysates showing the phosphorylation and 
reciprocal degradation of IĸBα in response to stimulation with TNFα
(31ng/ml). 
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Figure 6.9 TNFα activates NF-ĸB in HNCAF
Western blots of HNCAF cell lysates showing the phosphorylation of 
NF-ĸB p65  in response to stimulation with TNFα (31ng/ml). 
31ng/ml
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6.2.3 TNFα promotes SCC12 carcinoma invasion in vitro in a dose
         responsive manner
Figure 6.10a consists of representative photomicrographs of H&E sections from SCC12 
invasion assays in which both the stromal and epithelial components of the organotypic 
cultures were stimulated daily with TNFα at concentrations of 1, 3.1, 10 and 31ng/ml.
Figure 6.10b shows the quantification of carcinoma invasion. A scatter plot of the 
individual experimental blocks is presented in Figure 6.11a. The Invasion Index 
increased with escalating concentrations of TNFα and was statistically significant at 
doses of 10 and 31ng/ml (Figure 6.11b).
Figure 6.12 illustrates the log linear relationship of mean carcinoma invasion in 
response to TNFα stimulation. 
6.2.4 TNFα stimulation of  SCC12 cells  promotes  carcinoma invasion in
         remodelled collagen-Matrigel® matrix in a dose responsive manner
         in the absence of stromal fibroblasts
         
TNFα, through its ability to activate several signalling pathways in a variety of cells, 
has been shown to be integral to the cytokine network that exists within the tumour 
micro-environment 257. Having established A431 and SCC12 carcinoma invasion to be 
TNFα driven, I investigated the influence of TNFα on the epithelial and stromal 
components of our organotypic system independently of each other.
Figure 6.13 shows the quantification of SCC12 invasion in organotypic cultures in 
which only the epithelial component was stimulated daily with TNFα at concentrations 
of 1, 3.1, 10 and 31ng/ml. Fibroblasts were removed from the collagen-Matrigel® gels 
after five days of matrix remodelling by treating with puromycin (5µg/ml) daily for 48 
hours prior to the addition of SCC12 cells.  A scatter plot of the individual experimental 
blocks is presented in Figure 6.14a. The Invasion Index increased with escalating 
concentrations of TNFα but did not achieve statistical significance (Figure 6.14b).
Figure 6.15 illustrates the log linear relationship of mean carcinoma invasion in 
response to SCC12 TNFα stimulation. 
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Figure 6.16 confirms that TNFα stimulated SCC12 cells do not invade ‘naïve’ collagen-
Matrigel® matrix in fibroblast-deficient organotypic cultures.
6.2.5 TNFα stimulation of HNCAF promotes carcinoma invasion in a 
         dose responsive manner in the absence  of  direct  stimulation 
         of SCC12 cells
         
Figure 6.17 shows the quantification of SCC12 invasion in organotypic cultures in 
which only the stromal component was stimulated daily with TNFα at concentrations of 
1, 3.1, 10 and 31ng/ml. Fibroblasts were removed from the collagen-Matrigel® gels 
after five days of matrix remodelling by treating with puromycin (5µg/ml) daily for 48 
hours prior to the addition of SCC12 cells.  A scatter plot of the individual experimental 
blocks is presented in Figure 6.18a. The Invasion Index increased with escalating 
concentrations of TNFα but did not achieve statistical significance (Figure 6.18b).
Figure 6.19 illustrates the log linear relationship of mean carcinoma invasion in 
response to HNCAF TNFα stimulation.
Figure 6.10 Organotypic invasion assay: HNCAF and SCC12 TNFα
stimulation
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Quantification of 
carcinoma invasion. Both the stromal and epithelial components of the 
organotypic cultures were stimulated daily with TNFα at the specified 
concentrations. The average of 10 visual fields from 2 experiments is 
shown. The error bars represent the s.e. 
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Figure 6.11 Organotypic invasion assay: HNCAF and SCC12 TNFα
stimulation. (a) Scatter plot and (b) randomized block ANOVA 
statistical analysis
(a) Scatter plot displaying quantification of carcinoma invasion in 
cultures from the  organotypic assay illustrated in Figure 6.10. Individual 
experimental blocks are illustrated. The average of 5 visual fields is 
shown and error bars represent the s.e. *Denotes an expanded Y-axis.
(b) Randomized block ANOVA statistical analysis. Null hypothesis (NØ) 
rejected if p < 0.0125.
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Figure 6.12 TNFα promotes SCC12 cell invasion in vitro in a dose 
responsive manner
(a) Line plot displaying the log linear relationship of mean carcinoma 
invasion in response to TNFα stimulation. The average of 10 visual 
fields is shown and error bars represent the s.e. *Denotes an expanded 
Y-axis. (b) ANOVA test for linear trend. Null hypothesis (NØ) rejected if 
p < 0.05.
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Figure 6.13 Organotypic invasion assay: SCC12 TNFα stimulation
Quantification of carcinoma invasion in organotypic cultures in which gels 
were treated with puromycin (5µg/ml) daily for 48 hours after 5 days of 
matrix remodelling. Fibroblasts were removed prior to the addition of 
SCC12 cells which were then stimulated daily with TNFα at the specified 
concentrations. The average of 10 visual fields from 2 experiments is 
shown. The error bars represent the s.e. 
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Figure 6.14 Organotypic invasion assay: SCC12 TNFα stimulation. 
(a) Scatter plot and (b) randomized block ANOVA statistical 
analysis
(a) Scatter plot displaying quantification of carcinoma invasion in 
cultures from the  organotypic assay illustrated in Figure 6.13. Individual 
experimental blocks are illustrated. The average of 5 visual fields is 
shown and error bars represent the s.e. *Denotes an expanded Y-axis. 
(b) Randomized block ANOVA statistical analysis. Null hypothesis (NØ) 
rejected if p < 0.0125.
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Figure 6.15 TNFα stimulation of SCC12 cells promotes carcinoma 
invasion in remodelled collagen-Matrigel® matrix in a dose 
responsive manner in the absence of stromal fibroblasts
(a) Line plot displaying the log linear relationship of mean carcinoma 
invasion in response to TNFα stimulation. The average of 10 fields is 
shown and error bars represent the s.e. *Denotes an expanded Y-axis.
(b) Linear trend ANOVA analysis. Null hypothesis (NØ) rejected if            
p < 0.05.
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Figure 6.16 TNFα stimulated SCC12 cells do not invade ‘naïve’
collagen-Matrigel® matrix
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Quantification 
of carcinoma invasion. SCC12 cells were stimulated daily with TNFα
(10ng/ml) on gels with and with out stromal fibroblasts. The average of 
10 visual fields from 2 experiments is shown. The error bars represent 
the s.e. 
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Figure 6.17 Organotypic invasion assay: HNCAF TNFα stimulation
Quantification of carcinoma invasion in organotypic cultures in which gels 
were stimulated daily with TNFα at the specified concentrations and then
treated with puromycin (5µg/ml) daily for 48 hours after 5 days of matrix 
remodelling. Fibroblasts were removed prior to the addition of SCC12 
cells and the cultures allowed to proceed to completion. The average of 
10 visual fields from 2 experiments is shown. The error bars represent 
the s.e. 
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Figure 6.18 Organotypic invasion assay: HNCAF TNFα stimulation. 
(a) Scatter plot and (b) randomized block ANOVA statistical analysis
(a) Scatter plot displaying quantification of carcinoma invasion in cultures 
from the organotypic assay illustrated in Figure 6.17. Individual 
experimental blocks are illustrated. The average of 5 visual fields is shown 
and error bars represent the s.e. *Denotes an expanded Y-axis. (b) 
Randomized block ANOVA statistical analysis. Null hypothesis (NØ) 
rejected if p < 0.0125.
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Figure 6.19 TNFα stimulation of HNCAF promotes carcinoma 
invasion in a dose responsive manner in the absence of direct 
stimulation of SCC12 cells
(a) Line plot displaying the log linear relationship of mean carcinoma 
invasion in response to TNFα stimulation. The average of 10 visual 
fields is shown and error bars represent the s.e. *Denotes an 
expanded Y-axis. (b) ANOVA test for linear trend. Null hypothesis (NØ) 
rejected if p < 0.05.
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6.2.6 TNFα    promotes   fibroblast-dependent   collagen-Matrigel®   matrix   
         contraction in a dose responsive manner which correlates positively
         with carcinoma invasion
As highlighted in Chapter 4, a good correlation between the degree of macroscopic gel 
contraction and the extent of microscopic matrix remodelling exists 77, 303. The latter is 
in turn intimately associated with the ability of stromal fibroblasts to promote SCC 
invasion 77, 303. Therefore, I also assessed the effect of TNFα stimulation on fibroblast-
dependent collagen-Matrigel® matrix contraction.
The collagen-Matrigel® gels constructed for the assays detailed in Section 6.2.5 were 
photographed after 5 days of fibroblast-mediated matrix remodelling (Figure 6.20a) and 
the Contraction Index for each gel calculated (Figure 6.20b). As expected, TNFα
stimulated fibroblast-deficient gels did not contract. A line plot of the individual 
experimental blocks is presented in Figure 6.21a. Gel contraction was statistically 
significant at all concentrations of TNFα (Figure 6.21b).
Figure 6.22 illustrates the log linear relationship of mean collagen-Matrigel® matrix 
contraction in response to HNCAF TNFα stimulation.
To exclude the possibility that the TNFα-induced HNCAF effects on carcinoma 
invasion and matrix contraction were secondary to an enhanced proliferative response, 
fibroblast number per unit area was assessed on Day 1 and Day 5 of the assays in gels 
with and without daily TNFα stimulation (Figure 6.23). TNFα at concentrations of 1-
31ng/ml did not affect HNCAF proliferation (Figure 6.24).
Figure 6.25 is a scatter plot displaying the relationship between the mean Invasion 
Index and the mean Contraction Index for the TNFα stimulated HNCAF-containing 
organotypic cultures presented in Section 6.2.5. TNFα stimulation of HNCAF at 
concentrations of 1-31ng/ml resulted in an increase in both collagen-Matrigel® matrix 
contraction and carcinoma invasion.
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Figure 6.20 Assessment of TNFα stimulated fibroblast-dependent 
collagen-Matrigel® matrix contraction
(a) Images of organotypic gels after 5 days of matrix remodelling and 
daily TNFα stimulation at the specified concentrations prior to the 
removal of HNCAF. The dotted line represents the area of the gel.    
(b) Quantification of the degree of matrix remodelling. The Contraction 
Index was calculated using the formula 1 - (Gel Area / Well Area). The 
average of 2 experiments is shown and error bars represent the s.e. 
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Figure 6.21 TNFα promotes fibroblast-dependent collagen-
Matrigel® matrix  contraction
(a) Line plot displaying the Contraction Index of the TNFα
stimulated fibroblast containing gels of the organotypic assay 
illustrated in Figure 6.20. Individual experimental blocks are shown. 
*Denotes an expanded Y-axis. (b) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.0125.
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Figure 6.22 TNFα stimulation of HNCAF promotes collagen-
Matrigel® matrix contraction in a dose responsive manner
(a) Line plot displaying the log linear relationship of the Contraction 
Index in response to TNFα stimulation of the fibroblast containing gels 
of the organotypic assay illustrated in Figure 6.20. *Denotes an
expanded Y-axis. (b) ANOVA test for linear trend. Null hypothesis (NØ) 
rejected if p < 0.05.
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Figure 6.23 Assessment of fibroblast number in organotypic cultures 
after 5 days of collagen-Matrigel® matrix remodelling with and 
without daily TNFα stimulation
Examples of low power phase images of HNCAF in collagen-Matrigel®
matrix taken on Day 1 and Day 5 of the organotypic gels illustrated in 
Figure 6.20. The number of fibroblasts per unit area was quantified from 6 
representative regions of each culture and corrected for the degree of gel 
contraction. (n=2)
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Figure 6.24 TNFα at concentrations of 1-31ng/ml does not affect 
HNCAF proliferation
Fibroblast count per unit area (corrected for degree of gel contraction) 
after 5 days of matrix remodelling and daily TNFα stimulation at the 
specified concentrations (a) bar chart and (b) line plot. The average of 12 
fields from 2 experiments is shown. The error bars represent the s.e. 
*Denotes an expanded Y-axis. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 6.25 TNFα stimulation of HNCAF promotes collagen-Matrigel®
matrix contraction in a dose responsive manner which correlates 
positively with carcinoma invasion 
Scatter plot displaying the relationship between mean carcinoma invasion 
and mean gel contraction in response to TNFα stimulation. Error bars 
represent the s.e. *Denotes an expanded Y-axis.
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6.3 Interleukin-1α (IL-1α) 
Like TNFα, current literature suggests that IL-1α production by malignant cells 
regulates tumour progression and correlates with cancer cell invasiveness 281. As well as 
acting in an autocrine manner, IL-1α has also been shown to have a paracrine influence 
on neighbouring stromal fibroblasts 192. Given the responsiveness of our organotypic 
system to TNFα stimulation, I investigated whether IL-1α exerted a similar influence on 
carcinoma invasion.
6.3.1 IL-1α promotes SCC12 carcinoma invasion in vitro in a dose
         responsive manner
Figure 6.26 shows the quantification of SCC12 invasion assays in which both the 
stromal and epithelial components of the organotypic cultures were stimulated daily 
with IL-1α at concentrations of 100, 213, 467 and 1000pg/ml. Vehicle controls (0.1% 
BSA at concentrations comparable to those of IL-1α) were also included. The Invasion 
Index increased with escalating concentrations of IL-1α and was statistically significant
at doses of 467 and 1000pg/ml (Figures 6.27-6.30).
Figure 6.31 illustrates the log linear relationship of mean carcinoma invasion in 
response to IL-1α stimulation.
6.3.2 IL-1α stimulation  of  SCC12 cells  promotes  carcinoma invasion in
         remodelled collagen-Matrigel® matrix in a dose responsive manner
         in the absence of stromal fibroblasts
         
Having determined SCC12 carcinoma invasion to be IL-1α driven, as for TNFα, I 
examined the effect of IL-1α stimulation on the epithelial and stromal components of 
our organotypic system independently of each other.
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Figure 6.26 Organotypic invasion assay: HNCAF and SCC12 IL-1α
stimulation
Quantification of carcinoma invasion. Both the stromal and epithelial 
components of the organotypic cultures were stimulated daily with IL-1α
at the specified concentrations. Vehicle controls (0.1% BSA at 
concentrations comparable to those of IL-1α) were also included in the 
assay. The average of 10 visual fields from 2 experiments is shown. 
The error bars represent the s.e.
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Figure 6.27 Organotypic invasion assay: HNCAF and SCC12 IL-1α
stimulation (100pg/ml)
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Scatter plot displaying 
quantification of carcinoma invasion. Individual experimental blocks are 
illustrated. The average of 5 visual fields is shown and error bars represent 
the s.e. *Denotes an expanded Y-axis. (c) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
*
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Figure 6.28 Organotypic invasion assay: HNCAF and SCC12 IL-1α
stimulation (213pg/ml)
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Scatter plot 
displaying quantification of carcinoma invasion. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error bars 
represent the s.e. *Denotes an expanded Y-axis. (c) Randomized block 
ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
*
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Figure 6.29 Organotypic invasion assay: HNCAF and SCC12 IL-1α
stimulation (467pg/ml)
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Scatter plot 
displaying quantification of carcinoma invasion. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error bars 
represent the s.e. *Denotes an expanded Y-axis. (c) Randomized block 
ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
*
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Figure 6.30 Organotypic invasion assay: HNCAF and SCC12 IL-1α
stimulation (1000pg/ml)
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Scatter plot displaying 
quantification of carcinoma invasion. Individual experimental blocks are 
illustrated. The average of 5 visual fields is shown and error bars represent the 
s.e. *Denotes an expanded Y-axis. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
*
243
bFigure 6.31 IL-1α promotes SCC12 carcinoma invasion in vitro in a 
dose responsive manner
(a) Line plot displaying the log linear relationship of mean carcinoma 
invasion in response to IL-1α. The average of 10 visual fields is shown and 
error bars represent the s.e. *Denotes an expanded Y-axis. (b) ANOVA test 
for linear trend. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 6.32 shows the quantification of SCC12 invasion in organotypic cultures in 
which only the epithelial component was stimulated daily with IL-1α at concentrations 
of 100, 213, 467 and 1000pg/ml. Vehicle controls (0.1% BSA at concentrations 
comparable to those of IL-1α) were also included. Fibroblasts were removed from the 
collagen-Matrigel® gels after five days of matrix remodelling by treating with 
puromycin (5µg/ml) daily for 48 hours prior to the addition of SCC12 cells. A scatter 
plot of the individual experimental blocks is presented in Figure 6.33. The Invasion 
Index increased with escalating concentrations of IL-1α (Figure 6.34a) and was 
statistically significant at doses of 100, 467 and 1000pg/ml (Figure 6.34b).
Figure 6.35 illustrates the log linear relationship of mean carcinoma invasion in 
response to SCC12 IL-1α stimulation.
6.3.3 IL-1α stimulation  of  HNCAF  does not promote carcinoma invasion  
         in a dose responsive manner in the absence of direct stimulation of
         SCC12 cells
      
Figure 6.36 shows the quantification of SCC12 invasion in organotypic cultures in 
which only the stromal component was stimulated daily with IL-1α at concentrations of 
100, 213, 467 and 1000pg/ml. Vehicle controls (0.1% BSA at concentrations 
comparable to those of IL-1α) were also included. Fibroblasts were removed from the 
collagen-Matrigel® gels after five days of matrix remodelling by treating with 
puromycin (5µg/ml) daily for 48 hours prior to the addition of SCC12 cells. A scatter 
plot of the individual experimental blocks is presented in Figure 6.37. The Invasion 
Index remained relatively constant with escalating concentrations of IL-1α (Figure 
6.38).
In contrast to TNFα, IL-1α did not potentiate the ability of HNCAF to promote SCC12 
carcinoma invasion. A log linear relationship of mean Invasion Index in response to IL-
1α stimulation was not observed (Figure 6.39). 
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Figure 6.32 Organotypic invasion assay: SCC12 IL-1α stimulation
Quantification of carcinoma invasion in organotypic cultures in which gels were 
treated with puromycin (5µg/ml) daily for 48 hours after 5 days of matrix 
remodelling. Fibroblasts were removed prior to the addition of SCC12 cells 
which were then stimulated daily with IL-1α at the specified concentrations. 
Vehicle controls (0.1% BSA at concentrations comparable to those of IL-1α) 
were also included in the assay. The average of 10 visual fields from 2 
experiments is shown. The error bars represent the s.e.
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Figure 6.33 Organotypic invasion assay: SCC12 IL-1α stimulation -
scatter plot
Scatter plot displaying quantification of carcinoma invasion in cultures 
from the organotypic assay illustrated in Figure 6.32. Individual 
experimental blocks are illustrated. The average of 5 visual fields is shown 
and error bars represent the s.e. *Denotes an expanded Y-axis.
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Figure 6.34 IL-1α stimulation of SCC12 cells results in statistically 
significant carcinoma invasion which is independent of its 
potential effect on carcinoma associated fibroblasts 
(a) Line plot of quantification of carcinoma invasion of the IL-1α
stimulated cultures from the organotypic assay illustrated in Figure 6.32 
Individual experimental blocks are illustrated. The average of 5 visual 
fields is shown. *Denotes an expanded Y-axis. (b) Randomized block 
ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.35 IL-1α stimulation of SCC12 cells promotes carcinoma 
invasion in remodelled collagen-Matrigel® matrix in a dose 
responsive manner in the absence of stromal fibroblasts
(a) Line plot displaying the log linear relationship of mean carcinoma 
invasion in response to IL-1α. The average of 10 visual fields is shown and 
error bars represent the s.e. *Denotes an expanded Y-axis. (b) ANOVA test 
for linear trend. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 6.36 Organotypic invasion assay: HNCAF IL-1α stimulation
Quantification of carcinoma invasion in organotypic cultures in which gels were 
stimulated daily with IL-1α at the specified concentrations and then treated 
with puromycin (5µg/ml) daily for 48 hours after 5 days of matrix remodelling. 
Fibroblasts were removed prior to the addition of SCC12 cells and the cultures 
allowed to proceed to completion. Vehicle controls (0.1% BSA at 
concentrations comparable to those of IL-1α) were also included in the assay. 
The average of 10 visual fields from 2 experiments is shown. The error bars 
represent the s.e.
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Figure 6.37 Organotypic invasion assay: HNCAF IL-1α stimulation -
scatter plot
Scatter plot displaying quantification of carcinoma invasion in cultures 
from the organotypic assay illustrated in Figure 6.36. Individual 
experimental blocks are illustrated. The average of 5 visual fields is 
shown and error bars represent the s.e. *Denotes an expanded Y-axis.
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Figure 6.38 Organotypic invasion assay: HNCAF IL-1α stimulation. 
(a) Line plot and (b) randomized block ANOVA statistical analysis 
(a) Line plot of quantification of carcinoma invasion of the IL-1α
stimulated cultures from the organotypic assay illustrated in Figure 6.36 
Individual experimental blocks are illustrated. The average of 5 visual 
fields is shown. *Denotes an expanded Y-axis. (b) Randomized block 
ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.025
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Figure 6.39 IL-1α stimulation of HNCAF does not promote 
carcinoma invasion in a dose responsive manner in the absence of
direct stimulation of SCC12 cells
(a) Line plot displaying the log linear relationship of mean carcinoma 
invasion in response to IL-1α. The average of 10 visual fields is shown 
and error bars represent the s.e. *Denotes an expanded Y-axis.
(b) ANOVA test for linear trend. Null hypothesis (NØ) rejected if 
p < 0.05.
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6.3.4 IL-1α does not potentiate fibroblast-dependent collagen-Matrigel®
         matrix contraction
As for TNFα, I also assessed the effect of IL-1α stimulation on fibroblast-dependent 
collagen-Matrigel® matrix contraction.
The collagen-Matrigel® gels constructed for the assays detailed in Section 6.3.3 were 
photographed after 5 days of fibroblast-mediated matrix remodelling (Figure 6.40a) and 
the Contraction Index for each gel calculated (Figure 6.40b). Scatter plots of the 
individual experimental blocks for each concentration of IL-1α are presented in Figure 
6.41. IL-1α stimulation of HNCAF did not potentiate fibroblast-dependent collagen-
Matrigel® matrix contraction at any of the tested concentrations (Figure 6.42).
To exclude the possibility that IL-1α was inhibiting HNCAF proliferation, fibroblast 
number per unit area was assessed on Day 1 and Day 5 of the assays in gels with and 
without daily IL-1α stimulation (Figure 6.43). IL-1α at concentrations of 100-
1000pg/ml did not affect HNCAF proliferation (Figures 6.44-6.47).
6.3.5 IL-1α activates NF-ĸB signalling in A431 cells but not in HNCAF
IL1-α and TNFα are potent activators of canonical NF-ĸB signalling. Given the 
disparity between the effects of TNFα and IL-1α stimulation on the ability of HNCAF 
to promote carcinoma invasion, I wondered whether this was a reflection of the 
underlying NF-ĸB response.  
Figure 6.48 demonstrates the activation of IKK in A431 cells following stimulation with 
IL-1α (1000pg/ml). This results in the phosphorylation and reciprocal degradation of 
IĸBα (Figure 6.49). Consequently, NF-ĸB p65 is activated (Figure 6.50).
Figure 6.51 demonstrates that IKK is not activated in HNCAF following stimulation 
with IL-1α (1000pg/ml). Consequently, IĸBα is not degraded (Figure 6.52) and NF-ĸB 
p65 is not phosphorylated (Figure 6.53).
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Figure 6.40 Assessment of the influence of IL-1α on fibroblast-dependent 
collagen-Matrigel® matrix contraction 
(a) Images of organotypic gels after 5 days of matrix remodelling and daily 
treatment with either IL-1α or vehicle (0.1% BSA) at the specified concentrations 
prior to the removal of HNCAF. The dotted line represents the area of the gel. 
(b) Quantification of the degree of matrix remodelling. The Contraction Index was 
calculated using the formula 1 - (Gel Area / Well Area). The average of 2 
experiments is shown and error bars represent the s.e. 
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Figure 6.41 Assessment of the influence of IL-1α on fibroblast-dependent 
collagen-Matrigel® matrix  contraction - scatter plots
Scatter plots displaying the Contraction Index of the fibroblast containing gels 
treated with either IL-1α or vehicle (0.1% BSA) of the organotypic assay 
illustrated in Figure 6.40. Individual experimental blocks are shown. *Denotes an 
expanded Y-axis.
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Do not reject0.1003000.1% BSA 100  vs IL-1α 100
Do not reject0.160396Control vs 0.1% BSA 100
Decision p<0.025p ValueRandomized Block ANOVA
Do not reject0.6099590.1% BSA 213  vs IL-1α 213
Do not reject0.743311Control vs 0.1% BSA 213
Do not reject0.3027430.1% BSA 467  vs IL-1α 467
Do not reject0.337494Control vs 0.1% BSA 467
Do not reject0.5616720.1% BSA 1000  vs IL-1α 1000
Do not reject0.759417Control vs 0.1% BSA 1000
Figure 6.42 IL-1α does not potentiate fibroblast-dependent 
collagen-Matrigel® matrix  contraction
Randomized block ANOVA statistical analysis of the Contraction 
Indices of the fibroblast containing gels treated with either IL-1α or 
vehicle (0.1% BSA) from the organotypic assay illustrated in 
Figure 6.40. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.43 Assessment of fibroblast number in organotypic cultures 
after 5 days of collagen-Matrigel® matrix remodelling with and 
without daily treatment with IL-1α
Examples of low power phase images of HNCAF in collagen-Matrigel®
matrix taken on Day 1 and Day 5 of the organotypic gels illustrated in 
Figure 6.40. The number of fibroblasts per unit area was quantified from 6 
representative regions of each culture and corrected for the degree of gel 
contraction. (n=2)
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Figure 6.44 IL-1α at a concentration of 100pg/ml does not affect 
HNCAF proliferation
Fibroblast count per unit area (corrected for degree of gel contraction) 
after 5 days of matrix remodelling and daily treatment with IL-1α at a 
concentration of 1pg/ml (a) bar chart and (b) line plot. The average of 
12 fields from 2 experiments is shown. The error bars represent the s.e. 
*Denotes an expanded Y-axis. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 6.45 IL-1α at a concentration of 213pg/ml does not affect 
HNCAF proliferation
Fibroblast count per unit area (corrected for degree of gel contraction) 
after 5 days of matrix remodelling and daily treatment with IL-1α at a 
concentration of 213pg/ml (a) bar chart and (b) line plot. The average 
of 12 fields from 2 experiments is shown. The error bars represent the 
s.e. *Denotes an expanded Y-axis. (c) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 6.46 IL-1α at a concentration of 467pg/ml does not affect 
HNCAF proliferation
Fibroblast count per unit area (corrected for degree of gel contraction) 
after 5 days of matrix remodelling and daily treatment with IL-1α at a 
concentration of 467pg/ml (a) bar chart and (b) line plot. The average 
of 12 fields from 2 experiments is shown. The error bars represent the 
s.e. *Denotes an expanded Y-axis. (c) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 6.47 IL-1α at a concentration of 1000pg/ml does not affect 
HNCAF proliferation
Fibroblast count per unit area (corrected for degree of gel contraction) 
after 5 days of matrix remodelling and daily treatment with IL-1α at a 
concentration of 1000pg/ml (a) bar chart and (b) line plot. The 
average of 12 fields from 2 experiments is shown. The error bars
represent the s.e. *Denotes an expanded Y-axis. (c) Randomized 
block ANOVA statistical analysis. Null hypothesis (NØ) rejected if 
p < 0.05.
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Figure 6.48 IL-1α activates IKK in A431 cells 
Western blots of A431 cell lysates showing the activation of IKK in 
response to stimulation with IL-1α (1000pg/ml). This leads to the 
degradation of IĸBα (Figure 6.49) with the subsequent activation of 
NF-ĸB (Figure 6.50). Control samples in which cells were treated 
with the vehicle (0.1% BSA at a concentration comparable to that of 
IL-1α) are also included. 
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Figure 6.49 IL-1α induced NF-ĸB activation is associated with the 
phosphorylation and reciprocal degradation of IĸBα in A431 cells
Western blots of A431 cell lysates showing the phosphorylation and 
reciprocal degradation of IĸBα in response to stimulation with IL-1α
(1000pg/ml). Control samples in which cells were treated with the 
vehicle (0.1% BSA at a concentration comparable to that of IL-1α) are 
also included. 
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Figure 6.50 IL-1α activates NF-ĸB in A431 cells
Western blots of A431 cell lysates showing the phosphorylation of 
NF-ĸB p65  in response to stimulation with IL-1α (1000pg/ml). Control 
samples in which cells were treated with the vehicle (0.1% BSA at a 
concentration comparable to that of IL-1α) are also included. 
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Figure 6.51 IL-1α does not activate IKK in HNCAF 
Western blots of A431 and HNCAF cell lysates demonstrating that IL-1α
(1000pg/ml) does not activate IKK in HNCAF and consequently does not 
induce NF-ĸB signalling (Figures 6.52 and 6.53). This is in contrast to its 
action on A431 cells. Control samples in which cells were treated with the 
vehicle (0.1% BSA at a concentration comparable to that of IL-1α) are also 
included. 
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Figure 6.52 IL-1α does not result in the phosphorylation and reciprocal 
degradation of IĸBα in HNCAF
Western blots of A431 and HNCAF cell lysates demonstrating that IL-1α
(1000pg/ml) does not induce the phosphorylation and reciprocal degradation 
of IĸBα in HNCAF. This is in contrast to its action on A431 cells. Control 
samples in which cells were treated with the vehicle (0.1% BSA at a 
concentration comparable to that of IL-1α) are also included. 
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Figure 6.53 IL-1α does not activate NF-ĸB in HNCAF
Western blots of A431 and HNCAF cell lysates demonstrating that IL-1α
(1000pg/ml) does not induce NF-ĸB p65 phosphorylation in HNCAF. This is 
in contrast to its action on A431 cells. Control samples in which cells were 
treated with the vehicle (0.1% BSA at a concentration comparable to that of 
IL-1α) are also included. 
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6.4 The IKK complex
Having demonstrated cancer cell invasion within our organotypic system to be TNFα
and IL-1α driven, I sought to substantiate or refute the data from my Western blots 
which suggested that carcinoma progression in this setting was NF-ĸB dependent. My 
initial approach involved examining the action of a single IKK inhibitor, IKKI-II, on 
A431 and SCC12 cell invasion.
6.4.1 IKKI-II reduces A431 carcinoma invasion in vitro
Figure 6.54 shows the quantification of A431 invasion assays in which both the stromal 
and epithelial components of the organotypic cultures were inhibited daily with IKKI-II 
at concentrations of 1 and 10µM. Vehicle controls (DMSO at concentrations 
comparable to those of IKKI-II) were also included. Figures 6.55 and 6.56 consist of (a) 
photomicrographs of H&E sections demonstrating the degree of carcinoma infiltration 
into the underlying matrix, (b) a scatter plot of the individual experimental blocks and 
(c) randomized block ANOVA statistical analysis. Statistically significant reductions in 
the Invasion Index were seen at both concentrations of IKKI-II.
6.4.2 IKKI-II reduces SCC12 carcinoma invasion in vitro
Figure 6.57 shows the quantification of SCC12 invasion assays in which both the 
stromal and epithelial components of the organotypic cultures were inhibited daily with 
IKKI-II at concentrations of 1 and 10µM. Vehicle controls (DMSO at concentrations 
comparable to those of IKKI-II) were also included. Figures 6.58 and 6.59 consist of (a) 
photomicrographs of H&E sections demonstrating the degree of carcinoma infiltration 
into the underlying matrix, (b) a scatter plot of the individual experimental blocks and 
(c) randomized block ANOVA statistical analysis. Statistically significant reductions in 
the Invasion Index were seen at both concentrations of IKKI-II.
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Figure 6.54 Organotypic invasion assay: inhibition of HNCAF 
and A431 with IKKI-II
Quantification of carcinoma invasion. Both the stromal and epithelial 
components of the organotypic cultures were treated daily with 
IKKI-II at the specified concentrations. Vehicle controls (DMSO at 
concentrations comparable to those of IKKI-II) were also included in 
the assay. The average of 10 visual fields from 2 experiments is
shown. The error bars represent the s.e.
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Figure 6.55 Organotypic invasion assay: inhibition of HNCAF and 
A431 with IKKI-II (1µM)
(a) H&E stained sections of A431 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Scatter plot 
displaying quantification of carcinoma invasion. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error 
bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.56 Organotypic invasion assay: inhibition of HNCAF and 
A431 with IKKI-II (10µM)
(a) H&E stained sections of A431 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Scatter plot 
displaying quantification of carcinoma invasion. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error 
bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.57 Organotypic invasion assay: inhibition of HNCAF and 
SCC12 with IKKI-II
Quantification of carcinoma invasion. Both the stromal and epithelial 
components of the organotypic cultures were treated daily with IKKI-II 
at the specified concentrations. Vehicle controls (DMSO at 
concentrations comparable to those of IKKI-II) were also included in 
the assay. The average of 10 visual fields from 2 experiments is
shown. The error bars represent the s.e.
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Figure 6.58 Organotypic invasion assay: inhibition of HNCAF and 
SCC12 with IKKI-II (1µM)
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. Arrows 
point to the invading front of carcinoma cells. (b) Scatter plot displaying 
quantification of carcinoma invasion. Individual experimental blocks are 
illustrated. The average of 5 visual fields is shown and error bars represent 
the s.e. *Denotes an expanded Y-axis. (c) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.59 Organotypic invasion assay: inhibition of HNCAF and 
SCC12 with IKKI-II (10µM)
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Scatter plot 
displaying quantification of carcinoma invasion. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error 
bars represent the s.e. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.025.
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6.4.3 Inhibition of  SCC12 cells with IKKI-II reduces  carcinoma invasion 
         in remodelled collagen-Matrigel® matrix in the absence of stromal
         fibroblasts
I next investigated the effect of IKKI-II on the epithelial and stromal components of our 
organotypic system independently of each other. These experiments mirrored those 
previously performed using TNFα (Sections 6.2.4-6.2.6) and IL-1α (Sections 6.3.2-
6.3.4).
Figure 6.60 shows the quantification of SCC12 invasion in organotypic cultures in 
which only the epithelial component was inhibited daily with IKKI-II at concentrations 
of 1 and 10µM. Vehicle controls (DMSO at concentrations comparable to those of 
IKKI-II) were also included. Fibroblasts were removed from the collagen-Matrigel® 
gels after five days of matrix remodelling by treating with puromycin (5µg/ml) daily for 
48 hours prior to the addition of SCC12 cells. A scatter plot of the individual 
experimental blocks is presented in Figure 6.61a. A statistically significant reduction in 
the Invasion Index was seen at a 10µM concentration of IKKI-II (Figure 6.61b).
6.4.4 Inhibition of HNCAF with IKKI-II reduces carcinoma invasion in the
         absence of direct inhibition of SCC12 cells 
Figure 6.62 shows the quantification of SCC12 invasion in organotypic cultures in 
which only the stromal component was inhibited daily with IKKI-II at concentrations of 
1 and 10µM. Vehicle controls (DMSO at concentrations comparable to those of IKKI-
II) were also included. Fibroblasts were removed from the collagen-Matrigel® gels after 
five days of matrix remodelling by treating with puromycin (5µg/ml) daily for 48 hours 
prior to the addition of SCC12 cells. A scatter plot of the individual experimental blocks 
is presented in Figure 6.63a. A statistically significant reduction in the Invasion Index 
was seen at a 10µM concentration of IKKI-II (Figure 6.63b).
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
HNCAF - Ctrl - Ctrl Ctrl Ctrl
SCC12 Ctrl Ctrl Ctrl Ctrl Ctrl
IKKI-II - - - - 1 10
- 1- - -DMSO
In
va
si
o
n
 I
n
d
ex
 (
A
U
)
Figure 6.60 Organotypic invasion assay: Inhibition of SCC12 with
IKKI-II
Quantification of carcinoma invasion in organotypic cultures in which gels 
were treated with puromycin (5µg/ml) daily for 48 hours after 5 days of 
matrix remodelling. Fibroblasts were removed prior to the addition of 
SCC12 cells which were then treated daily with IKKI-II at the specified 
concentrations. Vehicle controls (DMSO at concentrations comparable to 
those of IKKI-II) were also included in the assay. The average of 10 visual 
fields from 2 experiments is shown. The error bars represent the s.e.
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Figure 6.61 Organotypic invasion assay: inhibition of SCC12 with
IKKI-II. (a) Scatter plot and (b) randomized block ANOVA 
statistical analysis
(a) Scatter plot displaying quantification of carcinoma invasion in 
cultures from the organotypic assay illustrated in Figure 6.60. 
Individual experimental blocks are illustrated. The average of 5 fields is 
shown and error bars represent the s.e. (b) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.62 Organotypic invasion assay: inhibition of HNCAF with
IKKI-II
Quantification of carcinoma invasion in organotypic cultures in which gels 
were treated daily with IKKI-II at the specified concentrations followed by 
puromycin (5µg/ml) daily for 48 hours after 5 days of matrix remodelling. 
Fibroblasts were removed prior to the addition of SCC12 cells and the 
cultures allowed to proceed to completion. Vehicle controls (DMSO at 
concentrations comparable to those of IKKI-II) were also included in the 
assay. The average of 10 visual fields from 2 experiments is shown. The 
error bars represent the s.e.
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Figure 6.63 Organotypic invasion assay: inhibition of HNCAF with
IKKI-II. (a) Scatter plot and (b) randomized block ANOVA 
statistical analysis
(a) Scatter plot displaying quantification of carcinoma invasion in 
cultures from the organotypic assay illustrated in Figure 6.62. 
Individual experimental blocks are illustrated. The average of 5 fields is 
shown and error bars represent the s.e. (b) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
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6.4.5 IKKI-II reduces fibroblast-dependent collagen-Matrigel® matrix
         contraction
As for TNFα and IL-1α, I also recorded the effect of IKKI-II inhibition on fibroblast-
dependent collagen-Matrigel® matrix contraction.
The collagen-Matrigel® gels constructed for the assays detailed in Section 6.4.4 were 
photographed after 5 days of fibroblast-mediated matrix remodelling (Figure 6.64a) and 
the Contraction Index for each gel calculated (Figure 6.64b). Scatter plots of the 
individual experimental blocks for each concentration of IKKI-II are presented in 
Figure 6.65a. Statistically significant reductions in the Contraction Index were seen at 
both concentrations of IKKI-II (Figure 6.65b).
To exclude the possibility that IKKI-II was inhibiting HNCAF proliferation, fibroblast 
number per unit area was assessed on Day 1 and Day 5 of the assays in gels with and 
without daily IKKI-II inhibition (Figure 6.66). IKKI-II at concentrations of 1 and10µM
did not affect HNCAF proliferation (Figures 6.67 and 6.68).
Figure 6.69 consists of scatter plots displaying the relationship between the mean 
Invasion Index and the mean Contraction Index for the organotypic cultures presented 
in Section 6.4.4. IKKI-II at concentrations of 1 and 10µM resulted in a reduction in both 
collagen-Matrigel® matrix contraction and carcinoma invasion.
Figure 6.64 Assessment of the influence of IKKI-II on fibroblast-
dependent collagen-Matrigel® matrix contraction 
(a) Images of organotypic gels after 5 days of matrix remodelling and 
daily treatment with IKKI-II at the specified concentrations prior to the 
removal of HNCAF. The dotted line represents the area of the gel. (b) 
Quantification of the degree of matrix remodelling. The Contraction Index 
was calculated using the formula 1 - (Gel Area / Well Area). The average 
of 2 experiments is shown and error bars represent the s.e. 
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Figure 6.65 IKKI-II reduces fibroblast-dependent collagen-Matrigel®
matrix  contraction
(a) Scatter plots displaying the Contraction Index of the fibroblast 
containing gels treated with IKKI-II illustrated in Figure 6.64. Individual 
experimental blocks are shown. *Denotes an expanded Y-axis. 
(b) Randomized block ANOVA statistical analysis. Null hypothesis (NØ) 
rejected if p < 0.025.
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Figure 6.66 Assessment of fibroblast number in organotypic cultures 
after 5 days of collagen-Matrigel® matrix remodelling with and without 
daily treatment with IKKI-II
Examples of low power phase images of HNCAF in collagen-Matrigel®
matrix taken on Day 1 and Day 5 of the organotypic gels illustrated in Figure 
6.64. The number of fibroblasts per unit area was quantified from 6 
representative regions of each culture and corrected for the degree of gel 
contraction. (n=2)
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Figure 6.67 IKKI-II at a concentration of 1µM does not affect HNCAF 
proliferation
Fibroblast count per unit area (corrected for degree of gel contraction) after 
5 days of matrix remodelling and daily treatment with IKKI-II at a 
concentration of 1µM (a) bar chart and (b) line plot. The average of 12 fields 
is shown from 2 experiments. The error bars represent the s.e. *Denotes an 
expanded Y-axis. (c) Randomized block ANOVA statistical analysis. Null 
hypothesis (NØ) rejected if p < 0.05.
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Figure 6.68 IKKI-II at a concentration of 10µM does not affect HNCAF 
proliferation
Fibroblast count per unit area (corrected for degree of gel contraction) 
after 5 days of matrix remodelling and daily treatment with IKKI-II at a 
concentration of 10µM (a) bar chart and (b) line plots. The average of 12 
fields from 2 experiments is shown. The error bars represent the s.e. 
*Denotes an expanded Y-axis. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 6.69 Inhibition of HNCAF with IKKI-II reduces collagen-Matrigel®
matrix remodelling and is associated with a reduction in carcinoma 
invasion
Scatter plots displaying the relationship between mean carcinoma invasion 
and mean gel contraction in response to treatment with IKKI-II at (a) 1µM and 
(b) 10µM. Error bars represent the s.e. *Denotes an expanded Y-axis.
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6.4.6 Validation of IKK inhibitor influence
The results of my IKKI-II experiments indicated that carcinoma invasion in our 
organotypic system could be blocked by inhibiting NF-ĸB signalling at the level of the 
IKK complex. To validate these findings, I tested three other IKK inhibitors.
Figure 6.70 shows the quantification of SCC12 invasion assays in which both the 
stromal and epithelial components of the organotypic cultures were inhibited daily with 
either IKKI-II, IKKI-2, IKKI-III or IKKI-X at concentrations of 1 and 10µM. Vehicle 
controls (DMSO at concentrations comparable to those of the IKK inhibitors) were also 
included. Figures 6.71-6.74 illustrate the results with respect to each inhibitor and 
consist of (a) scatter plots of the individual experimental blocks and (b) randomized 
block ANOVA statistical analyses. Daily treatment with IKKI-II, IKKI-2 and IKKI-III 
at a concentration of 10µM resulted in statistically significant reductions in carcinoma 
invasion.
6.4.7 IKKI-II and IKKI-III inhibit TNFα induced activation of NF-ĸB
         signalling in A431 cells and HNCAF
Figure 6.75 demonstrates that pre-treating A431 cells with either IKKI-II (10µM) or 
IKKI-III (10µM) inhibits TNFα (10ng/ml) induced IKK activation. Consequently, IĸBα
is not degraded (Figure 6.76) and NF-ĸB p65 is not phosphorylated (Figure 6.77).
Figure 6.78 demonstrates that pre-treating HNCAF with either IKKI-II (10µM) or 
IKKI-III (10µM) inhibits TNFα (10ng/ml) induced IKK activation. Consequently, IĸBα
is not degraded (Figure 6.79) and NF-ĸB p65 is not phosphorylated (Figure 6.80).
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Figure 6.70 Organotypic invasion assay: validation of IKK inhibitor 
influence 
Quantification of carcinoma invasion. Both the stromal and epithelial 
components of the organotypic cultures were treated daily with IKKI-II, 
IKKI-2, IKKI-III and IKKI-X at the specified concentrations. Vehicle 
controls (DMSO at concentrations comparable to those of the IKK 
inhibitors) were also included in the assay. The average of 10 visual 
fields from 2 experiments is shown. The error bars represent the s.e.
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Figure 6.71 Validation of IKK inhibitor influence: IKKI-II
(a) Scatter plots displaying the quantification of carcinoma invasion of 
IKKI-II treated cultures from the organotypic assay illustrated in Figure 
6.70. Individual experimental blocks are illustrated. The average of 5 
visual fields is shown and error bars represent the s.e. *Denotes an 
expanded Y-axis. (b) Randomized block ANOVA statistical analysis. 
Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.72 Validation of IKK inhibitor influence: IKKI-2
(a) Scatter plots displaying the quantification of carcinoma invasion of 
IKKI-2 treated cultures from the organotypic assay illustrated in Figure 
6.70. Individual experimental blocks are illustrated. The average of 5 
visual fields is shown and error bars represent the s.e. *Denotes an 
expanded Y-axis. (b) Randomized block ANOVA statistical analysis. 
Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.73 Validation of IKK inhibitor influence: IKKI-III
(a) Scatter plots displaying the quantification of carcinoma invasion of 
IKKI-III treated cultures from the organotypic assay illustrated in Figure 
6.70. Individual experimental blocks are illustrated. The average of 5 
visual fields is shown and error bars represent the s.e. *Denotes an 
expanded Y-axis. (b) Randomized block ANOVA statistical analysis. 
Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.74 Validation of IKK inhibitor influence: IKKI-X
(a) Scatter plots displaying the quantification of carcinoma invasion of 
IKKI-X treated cultures from the organotypic assay illustrated in Figure 
6.70. Individual experimental blocks are illustrated. The average of 5 
visual fields is shown and error bars represent the s.e. *Denotes an 
expanded Y-axis. (b) Randomized block ANOVA statistical analysis. 
Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.75 IKKI-II and IKKI-III inhibit TNFα induced activation of IKK in 
A431 cells
Western blots of lysates of A431 cells which had been treated with either IKKI-II 
or IKKI-III at a concentration of 10µM for 2 hours prior to stimulation with TNFα
(10ng/ml). Both IKK inhibitors prevented TNFα induced activation of IKK and 
consequently inhibited NF-ĸB signalling. Control samples in which cells had 
either not been treated or were treated with the vehicle (DMSO at a 
concentration comparable to that of the IKK inhibitors) are also included. 
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Figure 6.76 IKKI-II and IKKI-III inhibit TNFα induced phosphorylation and 
reciprocal degradation of IĸBα in A431 cells
Western blots of lysates of A431 cells which had been treated with either IKKI-II 
or IKKI-III at a concentration of 10µM for 2 hours prior to stimulation with TNFα
(10ng/ml). Both IKK inhibitors prevented TNFα induced  phosphorylation and 
reciprocal degradation of IĸBα. Control samples in which cells had either not 
been treated or were treated with the vehicle (DMSO at a concentration 
comparable to that of the IKK inhibitors) are also included. 
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Figure 6.77 IKKI-II and IKKI-III inhibit TNFα induced activation of NF-ĸB
in A431 cells
Western blots of lysates of A431 cells which had been treated with either 
IKKI-II or IKKI-III at a concentration of 10µM for 2 hours prior to stimulation 
with TNFα (10ng/ml). Both IKK inhibitors prevented TNFα induced activation 
of NF-ĸB p65. Control samples in which cells had either not been treated or 
were treated with the vehicle (DMSO at a concentration comparable to that of 
the IKK inhibitors) are also included. 
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Figure 6.78 IKKI-II and IKKI-III inhibit TNFα induced activation of IKK in 
HNCAF
Western blots of lysates of HNCAF which had been treated with either IKKI-II 
or IKKI-III at a concentration of 10µM for 2 hours prior to stimulation with 
TNFα (10ng/ml). Both IKK inhibitors prevented TNFα induced activation of IKK 
and consequently inhibited NF-ĸB signalling. Control samples in which cells 
had either not been treated or were treated with the vehicle (DMSO at a 
concentration comparable to that of the IKK inhibitors) are also included. 
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Figure 6.79 IKKI-II and IKKI-III inhibit TNFα induced degradation of IĸBα in 
HNCAF
Western blots of lysates of HNCAF which had been treated with either IKKI-II or 
IKKI-III at a concentration of 10µM for 2 hours prior to stimulation with TNFα
(10ng/ml). Both IKK inhibitors prevented TNFα induced degradation of IĸBα. 
Control samples in which cells had either not been treated or were treated with 
the vehicle (DMSO at a concentration comparable to that of the IKK inhibitors) 
are also included. 
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Figure 6.80 IKKI-II and IKKI-III inhibit TNFα induced activation of NF-ĸB
in HNCAF
Western blots of lysates of HNCAF which had been treated with either IKKI-II 
or IKKI-III at a concentration of 10µM for 2 hours prior to stimulation with 
TNFα (10ng/ml). Both IKK inhibitors prevented TNFα induced activation of 
NF-ĸB p65. Control samples in which cells had either not been treated or 
were treated with the vehicle (DMSO at a concentration comparable to that of 
the IKK inhibitors) are also included. 
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6.5 Anti-TNFα therapy
Collectively, my experimental data strongly supported the notion that carcinoma 
invasion in our organotypic model was both TNFα driven and NF-ĸB dependent. To 
further corroborate these findings I investigated whether infliximab (a monoclonal anti-
TNFα antibody in clinical use) could block cancer cell invasion in this setting. 
6.5.1 Infliximab reduces SCC12 carcinoma invasion in vitro
Figure 6.81 shows the quantification of SCC12 invasion assays in which both the 
stromal and epithelial components of the organotypic cultures were treated daily with 
infliximab at concentrations of 10 and 31µg/ml. Controls treated with TNFα (31ng/ml)  
and TNFα (31ng/ml) + infliximab (31µg/ml) were also included. Figures 6.82 and 6.83 
consist of (a) photomicrographs of H&E sections demonstrating the degree of 
carcinoma infiltration into the underlying matrix, (b) a line plot of the individual 
experimental blocks and (c) randomized block ANOVA statistical analysis. Statistically 
significant reductions in the Invasion Index were seen at both concentrations of 
infliximab.
6.5.2 Infliximab reduces fibroblast-dependent collagen-Matrigel® matrix
         contraction
The collagen-Matrigel® gels constructed for the assays detailed in Section 6.5.1 were 
photographed after 3 days of fibroblast-mediated matrix remodelling (Figure 6.84a) and 
the Contraction Index for each gel calculated. A line plot of the individual experimental 
blocks for each concentration of infliximab is presented in Figure 6.84b. A statistically 
significant reduction in the Contraction Index was seen at a 31µg/ml concentration of 
infliximab (Figure 6.84c).
To exclude the possibility that infliximab was inhibiting HNCAF proliferation, 
fibroblast number per unit area was assessed on Day 1 and Day 3 of the assays in gels 
with and without daily infliximab (Figure 6.85). Infliximab at concentrations of 10 and 
31µg/ml did not affect HNCAF proliferation (Figures 6.86).
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Figure 6.81 Organotypic invasion assay: treatment of HNCAF and 
SCC12 with infliximab
Quantification of carcinoma invasion. Both the stromal and epithelial 
components of the organotypic cultures were treated daily with infliximab at 
the specified concentrations. TNFα and TNFα with infliximab controls were 
also included in the assay. The average of 10 visual fields from 2 
experiments is shown. The error bars represent the s.e.
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Figure 6.82 Treatment of HNCAF and SCC12 with infliximab: TNFα
and TNFα with infliximab controls
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Line plot 
displaying quantification of carcinoma invasion. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown. *Denotes 
an expanded Y-axis. (c) Randomized block ANOVA statistical analysis. 
Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.83 Treatment of HNCAF and SCC12 with infliximab at 
10µg/ml and 31µg/ml reduces carcinoma invasion in vitro
(a) H&E stained sections of SCC12 cells cultured in organotypic gels. 
Arrows point to the invading front of carcinoma cells. (b) Line plot 
displaying quantification of carcinoma invasion. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown.
*Denotes an expanded Y-axis. (c) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.84 Assessment of the influence of infliximab on fibroblast-
dependent collagen-Matrigel® matrix remodelling 
(a) Images of organotypic gels after 3 days of matrix remodelling and daily 
treatment with infliximab at the specified concentrations. The dotted line 
represents the area of the gel. (b) Line plot displaying quantification of the 
degree of matrix remodelling. The Contraction Index was calculated using 
the formula 1 - (Gel Area / Well Area). Individual experimental blocks are 
illustrated. *Denotes an expanded Y-axis. (c) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.025.
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Figure 6.85 Assessment of fibroblast number in organotypic cultures 
after 3 days of collagen-Matrigel® matrix remodelling with and without 
daily treatment with infliximab
Examples of low power phase images of HNCAF in collagen-Matrigel®
matrix taken on Day 1 and Day 3 of the organotypic gels illustrated in Figure 
6.84. The number of fibroblasts per unit area was quantified from 6 
representative regions of each culture and corrected for the degree of gel 
contraction. (n=2)
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Figure 6.86 Infliximab at concentrations of 10µg/ml and 31µg/ml does 
not affect HNCAF proliferation
Fibroblast count per unit area (corrected for degree of gel contraction) after 
3 days of matrix remodelling and daily treatment with infliximab at the 
specified concentrations (a) bar chart and (b) line plot. The average of 12 
fields from 2 experiments is shown. The error bars represent the s.e. 
*Denotes an expanded Y-axis. (c) Randomized block ANOVA statistical 
analysis. Null hypothesis (NØ) rejected if p < 0.05.
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6.5.3 Infliximab inhibits TNFα induced activation of NF-ĸB signalling in   
         A431 cells and HNCAF
Figure 6.87 demonstrates that pre-treating A431 cells with infliximab (10µg/ml) inhibits 
TNFα (31ng/ml) induced IKK activation. Consequently, IĸBα is not degraded (Figure 
6.88) and NF-ĸB p65 is not phosphorylated (Figure 6.89).
Figure 6.90 demonstrates that pre-treating HNCAF with infliximab (10µg/ml) inhibits 
TNFα (31ng/ml) induced IKK activation. Consequently, IĸBα is not degraded (Figure 
6.91) and NF-ĸB p65 is not phosphorylated (Figure 6.92).
mins
Figure 6.87 Infliximab inhibits TNFα induced activation of IKK in 
A431 cells
Western blots of lysates of A431 cells which had been treated with 
infliximab at a concentration of 10µg/ml for 1 hour prior to stimulation 
with TNFα (31ng/ml). Infliximab prevented TNFα induced activation of 
IKK and consequently inhibited NF-ĸB signalling. Control samples in 
which cells had not been treated with infliximab or were treated with 
both infliximab and TNFα simultaneously are also included. 
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Figure 6.88 Infliximab inhibits TNFα induced phosphorylation and 
reciprocal degradation of IĸBα in A431 cells
Western blots of lysates of A431 cells which had been treated with infliximab
at a concentration of 10µg/ml for 1 hour prior to stimulation with TNFα
(31ng/ml). Infliximab prevented TNFα induced phosphorylation and 
reciprocal degradation of IĸBα. Control samples in which cells had not been 
treated with infliximab or were treated with both infliximab and TNFα
simultaneously are also included. 
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Figure 6.89 Infliximab inhibits TNFα induced activation of NF-ĸB
in A431 cells
Western blots of lysates of A431 cells which had been treated with 
infliximab at a concentration of 10µg/ml for 1 hour prior to stimulation 
with TNFα (31ng/ml). Control samples in which cells had not been 
treated with infliximab or were treated with both infliximab and TNFα
simultaneously are also included. 
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Figure 6.90 Infliximab inhibits TNFα induced activation of IKK in 
HNCAF
Western blots of lysates of HNCAF which had been treated with 
infliximab at a concentration of 10µg/ml for 1 hour prior to stimulation 
with TNFα (31ng/ml). Infliximab prevented TNFα induced activation of 
IKK and consequently inhibited NF-ĸB signalling. Control samples in 
which cells had not been treated with infliximab or were treated with 
both infliximab and TNFα simultaneously are also included. 
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Figure 6.91 Infliximab inhibits TNFα induced degradation of IĸBα in 
HNCAF
Western blots of lysates of HNCAF which had been treated with infliximab at 
a concentration of 10µg/ml for 1 hour prior to stimulation with TNFα
(31ng/ml). Infliximab prevented TNFα induced degradation of IĸBα. Control 
samples in which cells had not been treated with infliximab or were treated 
with both infliximab and TNFα simultaneously are also included. 
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Figure 6.92 Infliximab inhibits TNFα induced activation of NF-ĸB
in HNCAF
Western blots of lysates of HNCAF which had been treated with 
infliximab at a concentration of 10µg/ml for 1 hour prior to stimulation 
with TNFα (31ng/ml). Control samples in which cells had not been 
treated with infliximab or were treated with both infliximab and TNFα
simultaneously are also included. 
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6.6 Summary
 TNFα promotes A431 carcinoma invasion in vitro in a dose responsive manner.
 TNFα promotes SCC12 carcinoma invasion in vitro in a dose responsive manner 
via a combined effect on both the epithelial and stromal components of the 
organotypic culture.
 TNFα promotes fibroblast-dependent collagen-Matrigel® matrix contraction in a 
dose responsive manner which correlates positively with carcinoma invasion.
 IL-1α promotes SCC12 carcinoma invasion in vitro in a dose responsive manner 
but, in contrast to TNFα, does not potentiate the invasive promoting and ECM 
remodelling functions of HNCAF.
 SCC invasion in our organotypic sytem is NF-ĸB dependent. Inhibition of NF-
ĸB signalling at the level of the IKK complex reduces A431 and SCC12 
carcinoma invasion in vitro in a dose responsive manner. 
 The disparity between the effects of TNFα and IL-1α stimulation on the ability 
of HNCAF to promote carcinoma invasion was a reflection of the underlying 
NF-ĸB response.
 Infliximab, (a monoclonal anti-TNFα antibody in clinical use), blocks NF-ĸB 
signalling in both A431 cells and HNCAF, inhibits fibroblast-dependent 
collagen-Matrigel® matrix contraction and reduces SCC12 carcinoma invasion 
in vitro in a dose responsive manner.
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Chapter 7
TRAF6, ZA20d1 and NF-ĸB signalling in SCC invasion
7.1 Introduction
The results in Chapter 5 confirmed that both TRAF6 and ZA20d1 were functionally 
important for SCC12 and A431 cell invasion in our organotypic carcinoma model. 
Moreover, the investigations undertaken in Chapter 6 demonstrated that the extent of 
carcinoma infiltration into the collagen-Matrigel® ECM was NF-ĸB dependent and 
could be driven by stimulation with both TNFα and IL-1α. The data also suggested that 
TNFα promoted SCC12 carcinoma invasion by exerting a duel influence on both the 
stromal and epithelial compartments of the system. This was not the case with respect to 
IL-1α, to which the stromal fibroblasts were essentially unresponsive. Furthermore, gel 
contraction data indicated that TNFα stimulation potentiated fibroblast-dependent force-
mediated matrix remodelling of the ECM.
In view of the above and given current literature concerning the regulatory functions of 
my candidate genes in NF-ĸB signalling, I investigated the influence of TNFα 
stimulation on carcinoma invasion using SCC12 cells depleted of either TRAF6 or 
ZA20d1.
7.2 The influence of TNFα on carcinoma invasion of siRNA  
      gene depleted SCC12 cells
Two-stage organotypic assays were performed in which collagen-Matrigel® gels were 
stimulated daily with TNFα (31ng/ml) to promote fibroblast-dependent matrix 
remodelling. After five days, the HNCAF were removed by treating with puromycin 
(5µg/ml) for 48 hours prior to the addition of siRNA gene depleted SCC12 cells. 
Cultures were set up in duplicate with one half being stimulated daily with TNFα 
(31ng/ml) thereafter. 
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Figures 7.1-7.3 show the quantification and statistical analysis of SCC12 invasion in the 
‘Control’ gels of these assays. Interestingly, prolonged daily TNFα stimulation of 
HNCAF and SCC12 did not result in statistically significant carcinoma invasion when 
compared to an unstimulated control (Figure 7.2). 
7.2.1 TNFα rescues carcinoma invasion in TRAF6 gene depleted SCC12
         cells
Figure 7.4 shows the quantification of TRAF6 gene depleted SCC12 cell invasion in 
organotypic cultures with and without daily stimulation with TNFα (31ng/ml). Figure 
7.5 consists of (a) scatter plots of the individual experimental blocks and (b) 
randomized block ANOVA statistical analyses. As expected, TRAF6 gene depletion 
resulted in a statistically significant reduction in carcinoma invasion compared to the 
control under basal conditions. In contrast, the invasion of TNFα stimulated TRAF6 
gene depleted SCC12 cells was not impaired. 
Figure 7.6 illustrates the magnitude of the carcinoma invasion response of SCC12 cells 
following stimulation with TNFα (31ng/ml) normalised to each individual TRAF6 
siRNA duplex.
7.2.2 TNFα rescues carcinoma invasion in ZA20d1 gene depleted SCC12
         cells
Figure 7.7 shows the quantification of ZA20d1 gene depleted SCC12 cell invasion in 
organotypic cultures with and without daily stimulation with TNFα (31ng/ml). Figure 
7.8 consists of (a) scatter plots of the individual experimental blocks and (b) 
randomized block ANOVA statistical analyses. As expected, ZA20d1 gene depletion 
resulted in a statistically significant reduction in carcinoma invasion compared to the 
control under basal conditions. In contrast, the invasion of TNFα stimulated ZA20d1 
gene depleted SCC12 cells was not impaired. 
Figure 7.9 illustrates the magnitude of the carcinoma invasion response of SCC12 cells 
following stimulation with TNFα (31ng/ml) normalised to each individual ZA20d1 
siRNA duplex.
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Figure 7.1 Organotypic invasion assay: TNFα stimulation of siRNA gene 
depleted SCC12 cells - ‘Control’ gels
Quantification of carcinoma invasion in organotypic cultures which acted as the 
controls for the assessment of the influence of TNFα stimulation on siRNA 
gene depleted SCC12 cells as illustrated in Figures 7.4 and 7.7. The average of 
10 visual fields from 2 experiments is shown. The error bars represent the s.e. 
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Figure 7.2 Prolonged daily TNFα stimulation of HNCAF and SCC12 does 
not result in statistically significant carcinoma invasion when compared 
to an unstimulated control
(a) Scatter plots displaying quantification of carcinoma invasion in cultures 
from the organotypic assay illustrated in Figure 7.1. Both the stromal and 
epithelial components of the TNFα-stimulated culture were treated daily for 11 
days. Individual experimental blocks are illustrated. The average of 5 visual 
fields is shown and error bars represent the s.e. *Denotes an expanded          
Y-axis. (b) Randomized block ANOVA statistical analysis. Null hypothesis 
(NØ) rejected if p < 0.05.
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Figure 7.3 Organotypic invasion assay: TNFα stimulation of siRNA gene 
depleted SCC12 cells - ‘Control’ gels. (a) Scatter plot and (b) randomized 
block ANOVA statistical analysis
(a) Scatter plot displaying quantification of carcinoma invasion in cultures from 
the organotypic assay illustrated in Figure 7.1. Individual experimental blocks 
are illustrated. The average of 5 visual fields is shown and error bars represent 
the s.e. *Denotes an expanded Y-axis. (b) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 7.4 Organotypic invasion assay: TNFα stimulation of TRAF6 gene 
depleted SCC12 cells 
Quantification of carcinoma invasion in organotypic gels in which stromal  
fibroblasts were stimulated daily with TNFα (31ng/ml) and then treated with 
puromycin (5µg/ml) daily for 48 hours after 5 days of matrix remodelling. 
Fibroblasts were removed prior to the addition of TRAF6 siRNA gene depleted 
SCC12 cells. Cultures were performed in duplicate with one half being 
stimulated daily by TNFα (31ng/ml) thereafter. The average of 10 visual fields 
from 2 experiments is shown. The error bars represent the s.e. 
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Figure 7.5 Organotypic invasion assay: TNFα stimulation of TRAF6 gene 
depleted SCC12 cells. (a) Scatter plot and (b) randomized block ANOVA 
statistical analysis
(a) Scatter plots displaying quantification of carcinoma invasion in cultures 
from the organotypic assay illustrated in Figure 7.4. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error bars 
represent the s.e. *Denotes an expanded Y-axis. (b) Randomized block 
ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 7.6 TNFα stimulation at a concentration of 31ng/ml rescues 
carcinoma invasion in TRAF6 gene depleted SCC12 cells 
(a) Bar chart depicting the magnitude of the carcinoma invasion response of 
SCC12 cells following stimulation with TNFα (31ng/ml) normalised to the siRNA 
duplex for cultures from the organotypic assay illustrated in Figure 7.4. The 
average of 10 visual fields is shown. The error bars represent the s.e. (b) Scatter 
plot. Individual experimental blocks are illustrated. The average of 5 visual fields 
is shown and error bars represent the s.e. (c) Randomized block ANOVA 
statistical analysis. Null hypothesis (NØ) rejected if p < 0.05.
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Figure 7.7 Organotypic invasion assay: TNFα stimulation of ZA20d1 
gene depleted SCC12 cells
Quantification of carcinoma invasion in organotypic gels in which stromal  
fibroblasts were stimulated daily with TNFα (31ng/ml) and then treated with 
puromycin (5µg/ml) daily for 48 hours after 5 days of matrix remodelling. 
Fibroblasts were removed prior to the addition of ZA20d1 siRNA gene 
depleted SCC12 cells. Cultures were performed in duplicate with one half 
being stimulated daily by TNFα (31ng/ml) thereafter. The average of 10 visual 
fields from 2 experiments is shown. The error bars represent the s.e. 
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Figure 7.8 Organotypic invasion assay: TNFα stimulation of ZA20d1 
gene depleted SCC12 cells. (a) Scatter plot and (b) randomized block 
ANOVA statistical analysis 
(a) Scatter plots displaying quantification of carcinoma invasion in cultures 
from the organotypic assay illustrated in Figure 7.7. Individual experimental 
blocks are illustrated. The average of 5 visual fields is shown and error bars 
represent the s.e. *Denotes an expanded Y-axis. (b) Randomized block 
ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.0083.
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Figure 7.9 TNFα stimulation at a concentration of 31ng/ml rescues 
carcinoma invasion in ZA20d1 gene depleted SCC12 cells 
(a) Bar chart depicting the magnitude of the carcinoma invasion response of 
SCC12 cells following stimulation with TNFα (31ng/ml) normalised to the 
siRNA duplex for cultures from the organotypic assay illustrated in Figure 7.7. 
The average of 10 visual fields is shown. The error bars represent the s.e.  
(b) Scatter plot. Individual experimental blocks are illustrated. The average of 
5 visual fields is shown and error bars represent the s.e. (c) Randomized 
block ANOVA statistical analysis. Null hypothesis (NØ) rejected if p < 0.0083.
a
c
Block 1
Block 2
N
o
rm
al
is
ed
 In
va
si
o
n
 I
n
d
ex
 (
A
U
)
Decision p<0.0083p ValueRandomized Block ANOVA
Reject0.000007Control siRNA vs ZA20d1 siRNA #B
Reject0.000009Control siRNA vs ZA20d1 siRNA #3
Reject0.000035Control siRNA vs ZA20d1 siRNA #2
SCC12
Ctrl   
siRNA
#2 #3 #A
ZA20d1 siRNA
SCC12
Ctrl   
siRNA
#2 #3 #A
ZA20d1 siRNA
b
N
o
rm
al
is
ed
 In
va
si
o
n
 I
n
d
ex
 (
A
U
)
325
326
7.3 The influence of TRAF6 and ZA20d1 gene depletion on
      NF-ĸB signalling
7.3.1 TRAF6 gene depletion in SCC12 cells influences the degradation of
         IĸBα
  
Figure 7.10 demonstrates a reduction in the phosphorylation and reciprocal degradation 
of IĸBα in TRAF6 gene depleted SCC12 cells compared to the control 96 hours 
following transfection. Figure 7.11 confirms the efficacy of TRAF6 gene depletion in 
these samples. Cell lysates were made in parallel with Block 2 of the organotypic assay 
illustrated in Figure 7.4.
7.3.2 ZA20d1 gene depletion in SCC12 cells does not influence the 
         degradation of IĸBα
  
Figure 7.12 shows the phosphorylation and reciprocal degradation of IĸBα in ZA20d1 
gene depleted SCC12 cells 96 hours following transfection. In contrast to TRAF6 gene 
depletion, silencing of ZA20d1 did not affect IĸBα degradation. Cell lysates were made 
in parallel with Block 2 of the organotypic assay illustrated in Figure 7.7.
7.3.3 TRAF6 gene depletion in A431 cells influences the degradation of
         IĸBα
Figure 7.13 shows the phosphorylation and reciprocal degradation of IĸBα in TRAF6 
and ZA20d1 gene depleted A431 cells 96 hours following transfection. Unlike ZA20d1, 
silencing of TRAF6 was associated with a reduction in the degradation of IĸBα 
compared to the control. Figure 7.14 confirms the efficacy of TRAF6 gene depletion in 
these samples. Cell lysates were made in parallel with Block 2 of the organotypic assay 
illustrated in Figure 5.22.
Figure 7.10 TRAF6 siRNA gene depletion in SCC12 cells is associated 
with a reduction in the phosphorylation and reciprocal degradation of 
IĸBα
Western blots of SCC12 cell lysates 96 hours post-transfection showing a 
reduction in the phosphorylation and reciprocal degradation of IĸBα in TRAF6 
gene depleted cells. Lanes 6-8 contain lysates in which TRAF6 gene depleted 
SCC12 cells had been stimulated daily with TNFα at a concentration of 
31ng/ml. In this TNFα enriched environment, IĸBα phosphorylation and 
degradation was restored to a similar magnitude to that observed in the control 
siRNA samples. These lysates were made in parallel with Block 2 of the 
organotypic assay illustrated in Figure 7.4.
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Figure 7.11 Western blot demonstrating the efficacy of TRAF6 siRNA 
gene depletion in SCC12 cells
Western blot of SCC12 cell lysates 96 hours post-transfection showing the 
efficient knockdown of TRAF6. These lysates were made in parallel with 
Block 2 of the organotypic assay illustrated in Figure 7.4.
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Figure 7.12 ZA20d1 siRNA gene depletion in SCC12 cells is not 
associated with a reduction in the phosphorylation and reciprocal 
degradation of IĸBα
Western blots of SCC12 cell lysates 96 hours post-transfection showing 
that the phosphorylation and reciprocal degradation of IĸBα was 
unaffected by ZA20d1 gene depletion. Lanes 6-8 contain lysates in which 
ZA20d1 gene depleted SCC12 cells had been stimulated daily with TNFα
at a concentration of 31ng/ml. These lysates were made in parallel with 
Block 2 of the organotypic assay illustrated in Figure 7.7.
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Figure 7.13 TRAF6 siRNA gene depletion in A431 cells is associated 
with a reduction in the phosphorylation and reciprocal degradation 
of IĸBα
Western blots of A431 cell lysates 96 hours post-transfection showing a 
reduction in the phosphorylation and reciprocal degradation of IĸBα in 
TRAF6 gene depleted cells. This observation was inconclusive with 
respect to the lysates of the ZA20d1 gene depleted cells. These lysates
were made in parallel with Block 2 of the organotypic assay illustrated in 
Figure 5.22.
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Figure 7.14 Western blot demonstrating the efficacy of TRAF6 
siRNA gene depletion in A431 cells
Western blot of A431 cell lysates 96 hours post-transfection showing 
the efficient knockdown of TRAF6. These lysates were made in parallel 
with Block 2 of the organotypic assay illustrated in Figure 5.22.
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7.4 Summary
 TNFα (31ng/ml) stimulation of either TRAF6 or ZA20d1 gene depleted SCC12 
cells rescued carcinoma invasion in vitro.
 TRAF6 gene depletion in SCC12 and A431 cells was associated with a 
reduction in the phosphorylation and reciprocal degradation of IĸBα. 
 In contrast to TRAF6 gene depletion, silencing of ZA20d1 in SCC12 and A431 
cells did not influence IĸBα degradation. 
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Chapter 8
Tissue banking and analysis of tumour samples
8.1 Introduction
Human tissue banks are integral to cancer research 299. The analysis of tumour samples 
has led to new insights into cancer development and progression, as well as improved 
diagnostic techniques and more effective chemotherapeutic agents. 
This chapter details the establishment and management of a human tissue bank of 
SCCHN tumour specimens with patient matched control tissue. These samples and 
commercial tissue microarrays were analysed to investigate the expression of TRAF6 in 
several types of SCC as well as its potential as a diagnostic tumour marker.
8.2 Establishing a SCCHN tissue bank
8.2.1 Ethical and R&D approval
NHS Research Ethics Committee (NREC) approval was obtained following Site 
Specific Assessment (SSA) for the recruitment of patients and the collection of tissue 
samples at three Acute Teaching NHS Trusts in London (REC reference: 
06/Q0403/125). 
The Chief or Principal Investigators at each site were as follows: Dr Kevin Harrington 
(Senior Lecturer and Honorary Consultant in Clinical Oncology) - The Royal Marsden 
NHS Foundation Trust, Mr Peter Clarke (Consultant ENT / Head & Neck Surgeon) -
The Hammersmith Hospitals NHS Trust and Mr Peter Williamson (Consultant ENT / 
Head & Neck Surgeon) - St George’s Healthcare NHS Trust. 
NHS R&D approval was authorised by the Committee for Clinical Research (CCR) at 
the Royal Marsden NHS Trust (CCR reference: 2924) and the Research Office (RO) at 
St George’s Healthcare NHS Trust (RO reference: 07.0003).
334
The Royal Marsden NHS Foundation Trust granted sponsorship across all sites for the 
establishment of the tissue bank. A Material Transfer Agreement (MTA) was also set up 
to cover the transfer of samples from their source to the Cancer Research UK London 
Research Institute for storage and subsequent analysis. Dr Erik Sahai (Tumour Cell 
Biology Laboratory) is the Principal Investigator at this site.
8.2.2 Tissue freezing
In preparation for the collection of human tissue samples, I assessed the quality of tissue 
preservation upon freezing using various fixation reagents. These experiments were 
performed in conjunction with Dr Erik Sahai.
Figure 8.1 shows photomicrographs of H&E sections of mouse skin fixed in (a) dry ice, 
(b) isopentane and (c) liquid nitrogen. Snap freezing of samples in liquid nitrogen was 
most effective at preserving epidermal and dermal tissue architecture.
8.2.3 Banking and storage of tissue
Individuals with histopathologically confirmed SCCHN considered to be medically fit 
for surgery under general anaesthesia were identified by the Head & Neck Surgeon 
responsible for their care during regular hospital attendance. Patients under the age of 
18 years and those who had received either local radiotherapy or systemic 
chemotherapy within four weeks prior to their scheduled surgery were excluded from 
the study. 
Posters advertising the need for tissue donation were placed in clinic and ward patient 
waiting areas (Appendix I). An information sheet detailing the purpose of the tumour 
bank was provided to patients (Appendix II) and written consent for tissue donation 
obtained by their Head & Neck Surgeon prior to surgery (Appendix III). A letter 
confirming the patients’ participation in the study was also sent to their general medical 
practitioner (Appendix IV).
Samples were collected under general anaesthesia whilst the patient underwent head and 
neck surgery for excision  of  their primary tumour. Tissue was harvested from: (a) the 
Figure 8.1 Tissue freezing
H&E stained sections of mouse skin comparing tissue fixation  
reagents (a) dry ice, (b) isopentane and (c) liquid nitrogen. 
Image magnification 20x.
a
b
c
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resected SCC specimen and (b) clinically healthy mucosa adjacent to the surgical 
margin. Samples were fixed by snap freezing in liquid nitrogen at -80ºC and transferred 
to the Cancer Research UK London Research Institute for long-term storage in a secure 
facility. Each specimen has been given a unique research number, the key to which is 
known only to the Principal Investigator at each NHS Trust site. To date, 40 pairs of 
matched samples have been accrued. All database systems are password protected and 
subject to audit trail in line with current NHS Trust policy. 
Patients were followed up post-operatively by their Head & Neck Surgeon as dictated 
by their routine clinical care with no further participation beyond the point of tissue 
donation. Individuals retain the right to withdraw consent to the use of their tissues at 
any time. 
8.3 TRAF6 immunohistochemistry (IHC)
8.3.1 Optimisation of TRAF6 IHC
Figure 8.2a consists of representative photomicrographs of immunostained sections of 
A431 cells showing endogenous TRAF6 at primary antibody concentrations of 1:60 and 
1:20 72 hours following transfection. 
TRAF6 immunostaining was cytosolic in nature and was assessed as detailed in Chapter 
2, Section 2.10.5. Figure 8.2b illustrates the quantification of TRAF6 positive regions. 
TRAF6 expression was best demonstrated with a primary antibody concentration of 
1:20. 
To validate the above finding, endogenous and exogenous TRAF6 expression in A431 
cells 72 hours following transfection with the pUNO-hTRAF6-HA construct was 
examined (Figure 8.3a). The TRAF6 level in TRAF6-HA positive cells was 
approximately twice that of untransfected cells (Figure 8.3b). 
Finally, I assessed TRAF6 expression in A431 cells 72 hours following siRNA gene 
depletion (Figure 8.4a). A 60% or greater reduction in normalised mean intensity of 
immunostaining was noted compared to the mock sample (Figure 8.4b).
H&E
TRAF6 1:60
Anti-rabbit
TRAF6 1:20
Figure 8.2 Optimisation of TRAF6 IHC in A431 cells
(a) Immunostained sections of A431 cells showing the expression of 
endogenous TRAF6 at primary antibody concentrations of 1:60 and 1:20 72 
hours following transfection. Sections stained with H&E and the anti-rabbit 
secondary antibody are also shown. Image magnification 20x. (b) Quantitative 
analysis of TRAF6 immunostaining. The average of 10 representative 
immunostained areas is shown and error bars represent the s.e.
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Figure 8.3 Optimisation of TRAF6 IHC: TRAF6-HA positive A431 cells
(a) Immunostained sections of A431 cells showing the expression of 
endogenous and exogenous TRAF6 72 hours following transfection with the 
pUNO-hTRAF6-HA construct. Cells stained with rabbit anti-TRAF6 (1:20). 
Image magnification 20x. (b) Quantitative analysis of TRAF6 immunostaining. 
The average of 10 representative immunostained areas is shown and error 
bars represent the s.e.
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Figure 8.4 Optimisation of TRAF6 IHC: TRAF6 siRNA gene depleted 
A431 cells
(a) Immunostained sections of A431 cells showing TRAF6 expression 72 
hours following transfection with TRAF6 siRNA duplexes. Cells stained 
with rabbit anti-TRAF6 (1:20). (b) Quantitative analysis of TRAF6 
immunostaining. The average of 10 representative immunostained areas 
is shown and error bars represent the s.e.
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8.4 Analysis of commercial tissue microarrays
To investigate the relevance of TRAF6 as a potential tumour marker, a variety of 
paraffin embedded tissue microarrays were purchased for analysis. For each tumour, 
TRAF6 expression was assessed by measuring the normalised mean pixel intensity of 
10 representative immunostained areas as described in Chapter 2, Section 2.10.5. 
Neither the relative proportion of TRAF6 positive cells nor their distribution within 
each sample was recorded. Consequently, the data that follows does not signify the 
absolute or total TRAF6 expression level.
8.4.1 TRAF6 expression in SCCHN
Table 8.1 summarises the clinical cases included in the SCCHN tissue microarray 
purchased from US Biomax Inc. (BC34011). The patient’s age, gender, tumour site and 
histological grade are listed. Cases 21 and 22 were unmatched samples of normal tissue. 
Representative photomicrographs of H&E and TRAF6 immunostained sections of 
tumour tissue and normal tissue included in this array are shown in Figure 8.5. The 
normalised mean intensity of TRAF6 positive regions for each case is presented in 
Figure 8.6a. Paraffin embedded A431 cell pellets with and without TRAF6-HA 
expressing cells were also stained alongside the tissue array (Figure 8.6b). 
Five of the 15 tumours (33%) had TRAF6 positive regions with a normalised mean 
intensity equal to or greater than that expressed in A431 cells.
NormalGingivaM4122
NormalGingivaM3321
IIINasopharynxF5620
IIINasopharynxM5019
IIINasopharynxM6218
IIINasopharynxM5017
IILarynxM5116
IILarynxF6915
IITongueM5014
IIMaxillaM5413
IIILarynxM4612
ITongueF4811
IIIBuccal mucosaF5210
ILarynxM569
IITongueM578
IBuccal mucoasM497
IIILarynxM526
IIITongueM605
IIBuccal mucosaM524
IILarynxM653
IITongueM532
IBuccal mucosaF511
GradeSiteGenderAgeCase
Table 8.1 SCCHN tissue microarray: summary of cases
Cases included in the SCCHN tissue microarray purchased from US Biomax
Inc. (BC34011). The patient’s age, gender, tumour site and histological 
grade are shown. Cases 21 and 22 were unmatched samples of normal 
tissue.
Histological Grade
I      Well differentiated                    II      Moderately differentiated
III     Poorly differentiated                IV     Undifferentiated
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Figure 8.5 SCCHN tissue microarray: TRAF6 IHC
Examples of cases included in the SCCHN tissue microarray purchased 
from US Biomax Inc. (BC34011). (a) Case 2. 53 year old male with Grade II 
SCC of the tongue. (b) Case 16. 51 year old male with Grade II SCC of the 
larynx. (c) Case 22. 41 year old male. Normal mucosa from the gingiva. 
Sections stained with H&E, rabbit anti-TRAF6 (1:20), and anti-rabbit 
secondary antibody. Image magnification 20x. 
a
b
c
H&E TRAF6 Anti-rabbit
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Figure 8.6 SCCHN tissue microarray: analysis of TRAF6 positive 
regions
Quantitative analysis of TRAF6 immunostaining. (a) SCCHN tissue 
microarray and A431 cells (endogenous TRAF6 expression). (b) A431 
cells 72 hours following transfection with the pUNO-hTRAF6-HA 
construct. This sample was stained alongside the tissue microarray
and acted as a positive control. The average of 10 representative 
immunostained areas is shown and error bars represent the s.e.
SCCHN
A431: Endogenous TRAF6
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8.4.2 TRAF6 expression in OSCC
Tables 8.2 and 8.3 summarise the clinical cases included in the OSCC tissue microarray 
purchased from US Biomax Inc. (OR601). The patient’s age, gender, tumour site and 
histological grade are listed. Cases 51-59 were unmatched samples of normal tissue. 
Representative photomicrographs of H&E and TRAF6 immunostained sections of 
tumour tissue and normal tissue included in this array are shown in Figure 8.7. The 
normalised mean intensity of TRAF6 positive regions for each case is presented in 
Figure 8.8a. Paraffin embedded A431 cell pellets with and without TRAF6-HA 
expressing cells were also stained alongside the tissue array (Figure 8.8b).
40 of the 50 tumours (80%) had TRAF6 positive regions with a normalised mean 
intensity equal to or greater than that expressed in A431 cells.
Table 8.2 OSCC tissue microarray: summary of cases 1-30
Cases included in the OSCC tissue microarray purchased from US Biomax
Inc. (OR601). The patient’s age, gender, tumour site and histological grade 
are shown. 
Histological Grade
I      Well differentiated                    II      Moderately differentiated
III     Poorly differentiated                IV     Undifferentiated
IIBuccal mucosaM4930
ITongueM6029
IGingivaM6028
IBuccal mucosaM5527
ITongueM5526
I-IILipM6125
I-IITongueF5024
I-IITongueM7623
Not gradedTongueF5522
I-IIBuccal mucosaM4921
I-IITongueM5620
ITongueF6319
I-IITongueF4718
I-IINot specifiedM6317
IBuccal mucosaM5216
INot specifiedM5815
Not gradedTongueF3614
I-IITongueF5713
Not gradedBuccal mucosaM5312
I-IILipM6411
I-IITongueF4610
I-IITongueF399
I-IIGingivaM608
ITongueM787
IITongueF356
I-IIBuccal mucosaF565
I-IIGingivaM664
I-IIBuccal mucosaF653
I-IIBuccal mucosaF512
I-IITongueM571
GradeSiteGenderAgeCase
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Table 8.3 OSCC tissue microarray: summary of cases 31-59
Cases included in the OSCC tissue microarray purchased from US Biomax
Inc. (OR601). The patient’s age, gender, tumour site and histological grade 
are shown. Cases 51-59 were unmatched samples of normal tissue.
Histological Grade
I      Well differentiated                    II      Moderately differentiated
III     Poorly differentiated                IV     Undifferentiated
NormalPalateM6259
NormalGingivaM4058
NormalTongueM4957
NormalTongueF4256
NormalTongueF4955
NormalTongueF4554
NormalTongueM6653
NormalTongueM3852
NormalTongueM4851
IIITongueM7350
IINot specifiedM7749
II-IIITongueM6048
IINot specifiedF5647
II-IIITongueM6046
Not gradedNot specifiedF4045
IITongueM3744
IITongueM6043
IITongueF4842
II-IIIGingivaM5541
I-IIBuccal mucosaM4540
IILipM8039
IITongueF4838
IITongueF4637
I-IITongueM3536
IITongueF4535
IITongueF4634
IITongueF5033
IITongueF5232
ITongueM6431
GradeSiteGenderAgeCase
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Figure 8.7 OSCC tissue microarray: TRAF6 IHC
Examples of cases included in the OSCC tissue microarray purchased from 
US Biomax Inc. (OR601). (a) Case 6. 35 year old female with Grade II SCC 
of the tongue. (b) Case 40. 45 year old male with Grade I-II SCC of the 
buccal mucosa. (c) Case 54. 45 year old female. Normal mucosa from the 
tongue. Sections stained with H&E, rabbit anti-TRAF6 (1:20), and anti-rabbit 
secondary antibody. Image magnification 20x. 
a
b
c
H&E TRAF6 Anti-rabbit
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Figure 8.8 OSCC tissue microarray: analysis of TRAF6 positive 
regions 
Quantitative analysis of TRAF6 immunostaining. (a) OSCC tissue 
microarray and A431 cells (endogenous TRAF6 expression). (b) A431 
cells 72 hours following transfection with the pUNO-hTRAF6-HA 
construct. This sample was stained alongside the tissue microarray and 
acted as a positive control. The average of 10 representative 
immunostained areas is shown and error bars represent the s.e.
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8.4.3 TRAF6 expression in CSCC
Tables 8.4 and 8.5 summarise the clinical cases included in the CSCC tissue microarray 
purchased from US Biomax Inc. (SK483). The patient’s age, gender, tumour site and 
histological grade are listed. Cases 40-46 were unmatched samples of normal tissue. 
Representative photomicrographs of H&E and TRAF6 immunostained sections of 
tumour tissue and normal tissue included in this array are shown in Figure 8.9. The 
normalised mean intensity of TRAF6 positive regions for each case is presented in 
Figure 8.10a. Paraffin embedded A431 cell pellets with and without TRAF6-HA 
expressing cells were also stained alongside the tissue array (Figure 8.10b). 
22 of the 39 tumours (56%) had TRAF6 positive regions with a normalised mean 
intensity equal to or greater than that expressed in A431 cells.
Table 8.4 CSCC tissue microarray: summary of cases 1-23
Cases included in the CSCC tissue microarray purchased from US 
Biomax Inc. (SK483). The patient’s age, gender, tumour site and 
histological grade are shown. 
Histological Grade
I      Well differentiated                    II      Moderately differentiated
III     Poorly differentiated                IV     Undifferentiated
ISacrumF7623
ILeft legF6422
INot specifiedM7021
IRight heelF4220
IVulvaF7019
IVulvaF6418
IVertexM6917
IRight groinF4816
INot specifiedF5315
IRight upper armF5214
IHeadM5213
INot specifiedF6212
ITongueF5311
ILeft orbitF7910
ISacrumF779
ILeft upper armM378
IOcciputM637
IRight legF626
IRight legF515
IScalpM634
IRight thighM643
ILeft templeM782
IRight templeM681
GradeSiteGenderAgeCase
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Table 8.5 CSCC tissue microarray: summary of cases 24-46
Cases included in the CSCC tissue microarray purchased from US 
Biomax Inc. (SK483). The patient’s age, gender, tumour site and 
histological grade are shown. Cases 40-46 were unmatched 
samples of normal tissue. 
Histological Grade
I      Well differentiated                    II      Moderately differentiated
III     Poorly differentiated                IV     Undifferentiated
NormalWristM4746
NormalNot specifiedF2145
NormalNot specifiedF2144
NormalNot specifiedM4043
NormalNot specifiedM4042
NormalNeckM3541
NormalNot specifiedM2240
IIFaceF6539
IIRight buttockM3238
IINot specifiedF8237
IIBackM5636
INot specifiedF3535
IIScalpM2534
IIHeadF8333
IIAbdomenM6532
IBackM5131
IIRight cheekF8730
I-IIScalpF4829
I-IIRight thighF5028
ILeft cheekF7427
INot specifiedM6026
IOcciputM6725
I-IILeft faceF8224
GradeSiteGenderAgeCase
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Figure 8.9 CSCC tissue microarray: TRAF6 IHC
Examples of cases included in the CSCC tissue microarray purchased from US 
Biomax Inc. (SK483). (a) Case 20. 42 year old female with Grade I SCC of the 
right heel. (b) Case 30. 87 year old female with Grade II SCC of the right cheek. 
(c) Case 41. 35 year old female. Normal skin from the neck. Sections stained with 
H&E, rabbit anti-TRAF6 (1:20), and anti-rabbit secondary antibody. Image 
magnification 20x. 
a
b
c
H&E TRAF6 Anti-rabbit
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Figure 8.10 CSCC tissue microarray: analysis of TRAF6 positive 
regions 
Quantitative analysis of TRAF6 immunostaining. (a) CSCC tissue 
microarray and A431 cells (endogenous TRAF6 expression).                
(b) A431 cells 72 hours following transfection with the pUNO-
hTRAF6-HA construct. This sample was stained alongside the tissue 
microarray and acted as a positive control. The average of 10 
representative immunostained areas is shown and error bars 
represent the s.e.
Cutaneous SCC
A431: Endogenous TRAF6
Normala
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8.4.4 TRAF6 expression in vulval SCC
Table 8.6 summarises the clinical cases included in the vulval SCC tissue microarray 
purchased from US Biomax Inc. (UV241). The patient’s age, gender, tumour site and 
histological grade are listed. Cases 11 and 12 were unmatched samples of normal tissue. 
Representative photomicrographs of H&E and TRAF6 immunostained sections of 
tumour tissue and normal tissue included in this array are shown in Figure 8.11. The 
normalised mean intensity of TRAF6 positive regions for each case is presented in 
Figure 8.12a. Paraffin embedded A431 cell pellets with and without TRAF6-HA 
expressing cells were also stained alongside the tissue array (Figure 8.12b). 
7 of the 10 tumours (70%) had TRAF6 positive regions with a normalised mean 
intensity equal to or greater than that expressed in A431 cells.
Table 8.6 Vulval SCC tissue microarray: summary of cases
Cases included in the vulval SCC tissue microarray purchased from 
US Biomax Inc. (UV241). The patient’s age, gender, tumour site and 
histological grade are shown. Cases 11 and 12 were unmatched 
samples of normal tissue.
Histological Grade
I      Well differentiated                    II      Moderately differentiated
III     Poorly differentiated                IV     Undifferentiated
NormalVulva-adjacent skinF4812
NormalVulva-adjacent skinF4211
IVulvaF4810
IVulvaF509
IVulvaF588
IIVulvaF467
IVulvaF516
IVulvaF565
IIVulvaF424
IVulvaF853
IIVulvaF592
IVulvaF291
GradeSiteGenderAgeCase
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Figure 8.11 Vulval SCC tissue microarray: TRAF6 IHC
Examples of cases included in the vulval SCC tissue microarray purchased from 
US Biomax Inc. (UV241). (a) Case 1. 29 year old female with Grade I SCC of 
the vulva. (b) Case 10. 48 year old female with Grade I SCC of the vulva. (c) 
Case 11. 42 year old female. Normal vulva-adjacent skin. Sections stained with 
H&E, rabbit anti-TRAF6 (1:20), and anti-rabbit secondary antibody. Image 
magnification 20x. 
a
b
c
H&E TRAF6 Anti-rabbit
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Figure 8.12 Vulval SCC tissue microarray: analysis of TRAF6 
positive regions 
Quantitative analysis of TRAF6 immunostaining. (a) Vulval SCC tissue 
microarray and A431 cells (endogenous TRAF6 expression). (b) A431 
cells 72 hours following transfection with the pUNO-hTRAF6-HA 
construct. This sample was stained alongside the tissue microarray
and acted as a positive control. The average of 10 representative 
immunostained areas is shown and error bars represent the s.e.
Vulvar SCC
A431: Endogenous TRAF6
Normala
b
357
358
8.5 Analysis of SCCHN tissue bank samples
8.5.1 Immunohistochemistry (IHC)
TRAF6 expression in these samples was assessed as previously detailed in Sections 8.3 
and 8.4. 
Representative photomicrographs of H&E and TRAF6 immunostained sections of 
tumour tissue from three SCCHN tissue bank cases are shown in Figure 8.13. The 
normalised mean intensity of TRAF6 positive regions is presented in Figure 8.14. 
Paraffin embedded A431 cell pellets with and without TRAF6-HA expressing cells 
were also stained alongside the tissue array. 
Figures 8.15-8.18 demonstrate NF-ĸB p65, IĸBα, pan-cytokeratin and vimentin 
immunostaining of the SCCHN tissue bank samples illustrated in Figure 8.13. The 
optimisation of these antibodies for IHC was performed by Emma Nye of the Cancer 
Research UK Experimental Histopathology Laboratory (data not shown).
TRAF6 expression in Case (c) - a 53 year old male with SCC of the right tonsil (T2N2) 
was similar to that of TRAF6-HA positive A431 cells. Furthermore, stromal fibroblasts 
were also TRAF6 positive. These observations were accompanied by the loss of pan-
cytokeratin markers and strong vimentin immunostaining (Figure 8.19).  
8.5.2 Confocal imaging  
Immunofluoresence staining of matched normal and tumour tissue from the three 
SCCHN tissue bank cases illustrated in Figures 8.13-8.18 is shown in Figures 8.20-8.22. 
Tissue architecture was well preserved and detailed imaging of cytoskeletal structures 
was possible (Figure 8.23).
Figure 8.13 SCCHN tissue bank: TRAF6 IHC
Examples of cases from the SCCHN tissue bank. (a) 53 year old male with 
SCC of the left tonsil (T4N3). (b) 70 year old male with SCC of the right floor 
of the mouth (T2N2). (c) 53 year old male with SCC of the right tonsil (T2N2). 
Sections stained with H&E, rabbit anti-TRAF6 (1:20), and anti-rabbit 
secondary antibodies. Image magnification 20x. 
a
b
c
H&E TRAF6 Anti-rabbit
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Figure 8.14 SCCHN tissue bank: analysis of TRAF6 positive regions 
Quantitative analysis of TRAF6 immunostaining of the SCCHN samples 
illustrated in Figure 8.13 compared to that of A431 cells 72 hours following 
transfection with the pUNO-hTRAF6-HA construct. The A431 cell pellet was 
stained alongside the tissue bank samples and acted as a positive control. 
The average of 10 representative immunostained areas is shown and error 
bars represent the s.e.
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Figure 8.15 SCCHN tissue bank: NF-ĸB p65 IHC
NF-ĸB p65 immunostaining of the SCCHN tissue bank samples previously 
illustrated in Figure 8.13. (a) 53 year old male with SCC of the left tonsil 
(T4N3). (b) 70 year old male with SCC of the right floor of the mouth (T2N2). 
(c) 53 year old male with SCC of the right tonsil (T2N2). Sections stained 
with rabbit anti-NF-ĸB (1:20) and anti-rabbit secondary antibodies. Image 
magnification 20x. 
a
b
c
NF-ĸB p65 Anti-rabbit
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Figure 8.16 SCCHN tissue bank: IĸBα IHC
IĸBα immunostaining of the SCCHN tissue bank samples previously 
illustrated in Figure 8.13. (a) 53 year old male with SCC of the left tonsil 
(T4N3). (b) 70 year old male with SCC of the right floor of the mouth (T2N2). 
(c) 53 year old male with SCC of the right tonsil (T2N2). Sections stained 
with mouse anti-IĸBα (1:20) and anti-mouse secondary antibodies. Image 
magnification 20x. 
a
b
c
IĸBα Anti-mouse
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Figure 8.17 SCCHN tissue bank: pan-cytokeratin IHC
Pan-cytokeratin immunostaining of the SCCHN tissue bank samples 
previously illustrated in Figure 8.13. (a) 53 year old male with SCC of the left 
tonsil (T4N3). (b) 70 year old male with SCC of the right floor of the mouth 
(T2N2). (c) 53 year old male with SCC of the right tonsil (T2N2). Sections 
stained with mouse AE1 / AE3 (1:100) and anti-mouse secondary antibodies. 
Image magnification 20x. 
a
b
c
AE1 / AE3 Anti-mouse
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Figure 8.18 SCCHN tissue bank: vimentin IHC
Vimentin immunostaining of the SCCHN tissue bank samples previously 
illustrated in Figure 8.13. (a) 53 year old male with SCC of the left tonsil 
(T4N3). (b) 70 year old male with SCC of the right floor of the mouth (T2N2). 
(c) 53 year old male with SCC of the right tonsil (T2N2). Sections stained 
with rabbit anti-vimentin (1:50) and anti-rabbit secondary antibodies. Image 
magnification 20x. 
a
b
c
Vimentin Anti-rabbit
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Figure 8.19 IHC of SCC of the right tonsil
SCC of the right tonsil (T2N2) from a 53 year old male: Case (c) of the 
SCCHN tissue bank samples previously illustrated in Figure 8.13. Arrows 
indicate carcinoma-associated fibroblasts. Sections stained with rabbit 
anti-TRAF6 (1:20), mouse AE1 / AE3 (1:100), rabbit anti-vimentin (1:50), 
rabbit anti-NF-ĸB p65 (1:20), and mouse anti-IĸBα (1:50) antibodies. 
TRAF6
AE1 / AE3 Vimentin
NF-ĸB IĸBα
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Figure 8.20 Confocal imaging:  SCC of the left tonsil
Immunofluoresence staining of matched normal and tumour tissue from a 
53 year old male with SCC of the left tonsil (T4N3): Case (a) of the 
SCCHN tissue bank samples illustrated in Figures 8.13-8.18. Sections 
stained with TRITC phalloidin (1:500), rabbit anti-TRAF6 (1:100), mouse 
anti-collagen IV (1:100) and DAPI (1:500). Scale bars represent 50µm.
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Figure 8.21 Confocal imaging:  SCC of the right FOM
Immunofluoresence staining of matched normal and tumour tissue from a 70 
year old male with SCC of the right floor of the mouth (T2N2): Case (b) of the 
SCCHN tissue bank samples illustrated in Figures 8.13-8.18. Sections 
stained with TRITC phalloidin (1:500), rabbit anti-TRAF6 (1:100), mouse 
anti-collagen IV (1:100) and DAPI (1:500). Scale bars represent 50µm.
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Figure 8.22 Confocal imaging:  SCC of the right tonsil
Immunofluoresence staining of matched normal and tumour tissue from a 
53 year old male with SCC of the right tonsil (T2N2): Case (c) of the 
SCCHN tissue bank samples illustrated in Figures 8.13-8.18. Sections 
stained with TRITC phalloidin (1:500), rabbit anti-TRAF6 (1:100), mouse 
anti-collagen IV (1:100) and DAPI (1:500). Scale bars represent 50µm.
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TRAF6 Collagen IVF-actin DAPI
Figure 8.23 High power confocal imaging of SCC of the right FOM
Immunofluoresence staining of tumour tissue from a 70 year old male with 
SCC of the right floor of the mouth (T2N2): Case (b) of the SCCHN tissue 
bank samples illustrated in Figures 8.13-8.18. Sections stained with TRITC 
phalloidin (1:500), rabbit anti-TRAF6 (1:100), mouse anti-collagen IV (1:100) 
and DAPI (1:500). Scale bars represent 50µm.
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8.6 Summary
 Ethical and R&D approval for the establishment of a human tissue bank was 
obtained and SCCHN tumour samples with patient matched control tissue is 
now being accrued.
 TRAF6 immunohistochemistry was optimised by assessing endogenous and 
exogenous protein expression in A431 cells 72 hours following siRNA gene 
depletion or transfection with the pUNO-hTRAF6-HA construct. 
 Immunostaining of commercial tissue microarrays demonstrated that the 
normalised mean intensity of TRAF6 positive regions was equal to or greater 
than that expressed in A431 cells in a subset of SCC: SCCHN (33%), OSCC 
(80%), CSCC (56%) and vulval SCC (70%).
 Confocal microscopy in association with immunofluoresence staining allowed 
detailed imaging of tumour tissue, including the visualisation of cytoskeletal 
structures.
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Chapter 9
Discussion
9.1 Introduction
Squamous cell carcinoma (SCC) is an epithelial derived cancer of variable clinical 
presentation. Important tumour-related factors which govern patient prognosis include 
the tumour type, size and grade, the depth of carcinoma invasion, and the presence or 
absence of metastases 3, 4. 
Tumourigenesis is complex and is dependent on contextual signals between cancer cells 
and their associated stroma within the setting of a ‘tumour micro-environment’ 32. 
Cancer cell invasion is accompanied by dramatic changes of cell phenotype and this 
requires remodelling of a cell’s actin cytoskeleton as well as dynamic interactions with 
the surrounding ECM 108. Understanding the regulatory pathways that govern cancer 
cell morphology, motility and invasion are therefore essential to gaining new insights 
into the clinical behaviour of tumours and their pattern of spread.
Three dimensional (3D) invasion assays and intra-vital imaging indicate that the HECT 
domain E3 ubiquitin ligase, Smurf1, regulates tumour cell plasticity by targeting Rho A 
for degradation at the leading edge of motile cells 142. Given the integral role 
ubiquitination has in cell biology, knowledge of the temporal and spatial dynamics of 
ubiquitin-dependent processes is fundamental to understanding the pathological 
consequences of ubiquitin signalling in cancer. 
The work described in this thesis was based upon the premise that ubiquitin-linked 
pathways are central to the process of cancer cell invasion. The results presented in 
Chapters 3-8 and their clinical implications are discussed here. Future investigations are 
also suggested.
372
9.2 Morphological siRNA screening
To test the hypothesis that ubiquitin-linked pathways are key regulators of the actin 
cytoskeleton, a series of morphological screens using siRNA targeting 289 E3 ubiquitin 
ligases and 137 DUBs were performed as detailed in Chapter 3. Cells were plated on 
collagen-Matrigel® matrix since this was considered to more closely resemble an in 
vivo environment compared to conventional two-dimensional (2D) cell culture. In a 3D 
matrix cells have distinct patterns of morphology and migration compared with those on 
a 2D planar surface 311, 312. This is due to the deformable nature of the substrate which 
allows the contractile forces exerted by the cell to remodel the matrix and thus influence 
cell morphology. On rigid surfaces cells frequently appear flat with the underlying 
changes in contractility affecting cell phenotype being masked.
Morphological screening was initially carried out using A431 vulval carcinoma cells. 
Gene silencing was accompanied by a variety of cell phenotypes compared to control 
cells. These included cell rounding, cell elongation, actin-rich spikes, membrane blebs 
and a disrupted actin cell cortex (Figures 3.2-3.4). Cell morphology was assessed 
qualitatively and scored descriptively by at least two independent observers (Tables 3.1-
3.6). Each screen was blind and performed twice. Prior to commencing this project, 
experience within our group had validated this screening process and, although labour 
intensive, the technique proved to be appropriate for the overall size of the screen (426 
genes). Developing a high throughput automated system (as described by Bakal et al.) 
with the specificity and sensitivity to distinguish the cell phenotypes observed following 
gene depletion was beyond the scope of this work 313. However such a system would be 
useful for future siRNA morphometric screens.
Forty-five ‘1st Round’ gene hits were identified (Tables 3.7 and 3.8). Subsequent de-
convolution of the respective SMARTpools to exclude ‘off-target’ phenomena reduced 
this number to 29 ‘2nd Round’ hits (Table 3.9). Several of these genes: USP2, BAP1, 
RNF12 and RNF14 are up-regulated in a variety of cancers including breast, prostate 
and renal cell carcinoma 314. Mdm4 regulates the activity of the tumour suppressor 
protein p53 and is frequently overexpressed in SCCHN 315, 316. p53 is mutated in more 
than 50% of human tumours and has been studied principally for its functions in cell 
cycle arrest and apoptosis. There is growing evidence, however, for a role of p53 in cell 
motility 317, 318, 319 . Moreover, Mdm4 translocates to the cytoplasm of tumour cells 
which suggests that it may function independently of p53. Testing co-operation and 
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redundancy of Mdm4 with its regulatory partner Mdm2 in relation to p53, the actin 
cytoskeleton and cell movement may therefore be of future interest.
Tumours are not only composed of carcinoma cells, but of several other cell types 
capable of interacting with each other within a highly ordered ECM. Both stromal and 
epithelial phenotypes co-evolve during tumourigenesis and it is now clear that these 
stromal cells are not merely innocent bystanders 36. Given this, an additional siRNA 
screen was performed to further test my 29 ‘2nd Round’ gene hits as regulators of the 
actin cytoskeleton and to investigate their potential role in CAF function.  
The morphology and behaviour of a fibroblast in a 3D collagen gel is dependent on the 
matrix organization and the overall physical environment of the cell 320. In the floating 
matrix model (a low tension system) actin stress fibres are not seen in fibroblasts, few 
focal adhesion phenotypes are observed and matrix biosynthesis is limited 305. 
Conversely, in attached or restrained matrices (as used here), a high tension state exists 
and fibroblasts become bipolar following massive cytoskeletal reorganization (Figure 
3.8). This is characterised by the formation of stress fibres (Figure 3.13b) and focal 
adhesions 321. Fibroblasts associate with collagen fibrils, are under isometric tension and 
develop reciprocal mechanical interactions with the collagen matrix. Consequently, 
fibroblast tractional forces are transmitted to the surrounding matrix inducing local and 
global matrix remodelling (contraction and compaction) 322. This process is analogous 
to that seen in normal tissue, wound healing, tissue fibrosis and, importantly in the 
context of this work, cancer stromagenesis 305.
Eight genes (MKRN2, RKHD2, TRAF6, Mdm4, HERC4, SAE1, ZA20d1 and USP6) 
when individually depleted in HNCAF, resulted in markedly abnormal cell phenotypes 
(Figures 3.8-3.12). Of interest was the observation that the cell bodies in the majority of 
these cases had fewer stress fibres and an increased spread area. This appearance is 
more typical of a fibroblast in a floating matrix model where cells are not under 
isometric tension and tissue remodelling occurs primarily as a result of the motile 
activity of cells rather than force-mediated contraction 323. Furthermore, these 
morphological traits resemble those of fibroblasts in ‘quiescent’ tissue in vivo 324. Thus, 
these genes are likely to be important to the matrix remodelling activities of stromal 
fibroblasts in the context of the tumour micro-enviroment.
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9.3 Functional siRNA screening
9.3.1 Organotypic modelling
Traditionally, cancer cell behaviour has been studied in vitro using 2D monolayer 
culture on plastic or glass with or without matrix. Although useful for investigating 
many aspects of cell biology, 2D systems are of limited value when studying dynamic 
processes such as tumour invasion. A defining feature of malignancy is the infiltration 
of cancer cells into the surrounding stroma. In turn, expansion of the stroma occurs to 
support tumour growth and is fundamental to further progression of the carcinoma. 
Tumour invasion occurs in three dimensions and thus the development of 3D model 
systems which recapitulate the tumour micro-environment in vitro continues to be of 
interest. 
The organotypic culture (Figure 4.1) is one such system and was first used to study SCC 
invasion by Fusenig and colleagues 325.  By varying the cellular and matrix components, 
organotypic modelling has subsequently proven to be a resourceful technique to 
investigate many aspects of carcinoma invasion. It is particularly useful with regards to 
interrogating epithelial-stromal interactions 326. Moreover, an objective and quantitative 
method for the analysis of SCC invasion in organotypic culture has been developed. 
The ‘Invasion Index’ combines depth and pattern of invasion in a single value and is a 
robust, accurate and reproducible method for the assessment of cancer cell invasion in 
vitro 302.
To investigate the role of my 29 ‘2nd Round’ gene hits (Table 3.9) on SCC invasion, a 
functional siRNA screen was performed using an established organotypic model 
incorporating carcinoma cells (SCC12) with stromal fibroblasts (HNCAF) in a 
collagen-Matrigel® matrix 77. Cdc42 is a key regulator of carcinoma invasion in this 
system and was included as the positive control to assess the effect of gene depletions 
on SCC12 behaviour 77. Serial assays were undertaken and three genes, RKHD2 (Figure 
4.3), TRAF6 (Figure 4.4) and ZA20d1 (Figure 4.8), emerged as regulators of cancer cell 
invasion. In addition, these three genes (along with MKRN2 and USP6) when 
individually knocked down in HNCAF impaired the ability of the stroma to support 
carcinoma invasion (Figures 4.10-4.12).
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These results highlight the benefit of 3D ‘physiological’ systems in cancer cell biology. 
Twenty-one of the 29 genes identified as cytoskeletal regulators in A431 cells had no 
obvious effect on carcinoma invasion when depleted in SCC12 cells (data not shown). 
Bearing in mind potential intrinsic differences between the two cell lines, this 
observation emphasises that morphological changes (even if assessed in a 3D 
environment) do not necessarily translate to functional significance. The ease with 
which the system was adapted to examine the ability of gene depleted HNCAF to 
promote cancer cell invasion also demonstrates its versatile nature. Molecular and 
dynamic interactions between cells and their surrounding ECM can now be studied in 
detail, either together or in isolation, in an in vitro environment that mimics many 
aspects of biological tissue 305. 
Obvious limitations of the organotypic culture system in its current form are the absence 
of a vasculature network and the lack of a tumour associated inflammatory response. 
The inclusion of endothelial cells, either within or beneath the matrix, would potentially 
allow modelling of angiogenesis alongside existing epithelial-stromal interactions 326. 
Incorporating immune cells in to the system is another area for improvement since 
several studies have demonstrated the invasive promoting role of TAM 71.
A novel organotypic model based on human uterine leiomyoma tissue has recently been 
described 327. In this system several oral, breast and melanoma cell lines were shown to 
invade with highly distinct patterns which were less discernible in collagen-based gels. 
The authors concluded that myoma-based cultures, compared to traditional organotypic 
models, more closely resembled the tumour micro-environment and that this was 
attributable to the natural nature of the stromal scaffold. Given these findings, the 
pattern of carcinoma invasion observed in our system may actually reflect the relative 
capacity of the stroma to support invasion rather than the intrinsic behaviour of the 
carcinoma cells themselves. 
Large scale functional RNAi screens using organotypic cultures may be possible in the 
future. Such screens being more biologically representative are likely to yield results 
which are readily translated into clinically relevant findings 326.
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9.3.2 Fibroblast-dependent collagen-Matrigel® matrix remodelling
Matrix remodelling by fibroblasts is integral to tumourigenesis and critical to cancer 
cell invasion 304. In recent years significant progress has been made in understanding the 
adaptive and reciprocal interactions that occur between fibroblasts, their neighbouring 
cells and the ECM in tissues. Studies of fibroblasts in 3D collagen matrices have 
demonstrated the importance of both biomechanical conditions and molecular cues for 
co-ordinated cell signalling and movement 305. Fibroblasts have the ability to contract 
collagen gels; a phenomenon that can be observed at the macroscopic level 303, 306. 
Furthermore, a good correlation between the degree of macroscopic gel contraction and 
the extent of microscopic matrix remodelling exists 77. 
Figure 4.17 presents scatterplots of mean carcinoma invasion and mean gel contraction 
for the organotypic assay assessing the functional significance of HNCAF interference 
(Section 4.2.2). Consistent with previous findings, the ability of ROCK depleted 
fibroblasts to contract their ECM was noticeably impaired (Figure 4.15) and was 
associated with reduced carcinoma invasion 77. Five genes (MKRN2, RKHD2, TRAF6, 
ZA20d1 and USP6) when individually silenced in HNCAF resulted in a statistically 
significant decrease in SCC invasion. The relationship of the Contraction Index to the 
Invasion Index for each of these gels, however, was inconsistent. There are several 
potential explanations for this. Firstly, the Contraction Index is exactly that - it measures 
the degree of gel contraction but gives no indication of the other architectural changes 
that have occurred in the matrix. Gel contraction is therefore not a perfect marker of the 
extent of matrix remodelling and the latter by itself does not necessarily translate to 
increased cancer cell invasion. Secondly, protease-mediated matrix remodelling has 
been shown to be important for carcinoma invasion in this system and its contribution, 
relative to force-mediated remodelling, is possibly under represented by the Contraction 
Index 77. Finally, as matrix remodelling progresses the gels contract and spontaneously 
detach from the underlying plate. In doing so, the system probably shifts from a high 
tension to a low tension state at which point fibroblast traction and force-mediated 
remodelling is likely to be restricted. Current evidence suggests that matrix remodelling 
in this setting primarily reflects the motile activity of fibroblasts, a situation which 
would still favour the collective invasion of cancer cells 323.  
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9.4 Validation of gene hits and candidate genes 
A summary of the results of the morphological and functional screens described in 
Chapters 3 and 4 is presented in Figure 4.18. From the original 426 gene library, three 
E3 ubiquitin ligases (MKRN2, RKHD2 and TRAF6) and 2 de-ubiquitinating enzymes 
(ZA20d1 and USP6) emerged as potential candidate genes. 
9.4.1 TRAF6 and ZA20d1
Following further validation using Qiagen® siRNA, qPCR and IMF (Chapter 5, Section 
5.2) and after reviewing the scientific literature, TRAF6 and ZA20d1 were selected for 
in depth study. Data at this time suggested that ZA20d1 was the complementary DUB to 
TRAF6 and that both proteins participated in canonical NF-ĸB signalling following 
TNFR and IL-1R activation 163, 307, 308.
Having selected TRAF6 and ZA20d1 as candidate genes, I sought to confirm their 
function as regulators of carcinoma invasion. To this end, SCC12 organotypic assays 
using six targeting siRNA duplexes for each gene were performed. The results of these 
experiments were particularly convincing (Figures 5.14-5.18). Moreover, double gene 
depletion when compared to single gene depletion of either TRAF6 or ZA20d1 did not 
lead to greater inhibition of carcinoma invasion (Figures 5.19-5.21). This finding was 
not unexpected given the supposition of both proteins converging on the same NF-ĸB 
regulatory checkpoint.
Next, the functional significance of TRAF6 and ZA20d1 in A431 cells was assessed. 
Compared to SCC12 cells, A431 cells were intrinsically less invasive in organotypic 
culture and therefore the duration of the assays was lengthened to 2 weeks (Chapter 2, 
Section 2.2.8.5). Individual gene depletion of either TRAF6 or ZA20d1 in A431 cells 
resulted in a statistically significant reduction in cancer cell invasion (Figures 5.22-
5.24). 
A431 carcinoma invasion was characterised by a thick ‘epithelial’ layer and a broad 
based cohesive invasive front. These histological features, along with the inherently less 
invasive nature of A431 cells and their inability to metastasise in vivo, tentatively 
suggest that the cell line may have been derived from a verrucous vulval carcinoma. 
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Unfortunately, information in the literature pertaining to the nature of the original 
tumour is sparse.
9.4.2 RKHD2
To date, there is no experimental data regarding the function of RKHD2 other than a 
single study which speculatively links its E3 ligase activity to the pathogenesis of 
essential hypertension 309. Knocking down RKHD2 in both SCC cells and HNCAF 
resulted in phenotypic changes similar to those observed with Rho A gene depletion 
(Chapter 3). Functionally, silencing RKHD2 in stromal fibroblasts impaired their ability 
to promote carcinoma invasion (Chapter 4, Section 4.2.2). These findings are consistent 
with previous work which has demonstrated that the activation of Rho is necessary for 
fibroblast-led collective invasion of cancer cells 77. Examining a possible interaction of 
RKHD2 with the Rho-ROCK pathway would therefore be a natural starting point to 
investigate this gene further. Given that the Rho-ROCK pathway is an established 
regulator of smooth muscle contraction and hypertension 328, an interaction with 
RKHD2 would provide a potential explanation for the latter’s association with essential 
hypertension.
9.4.3 MKRN2
MKRN2 is a well conserved member of the makorin RING zinc-finger gene family and 
possibly functions as a co-regulator of the Raf-1 proto-oncogene 329. Raf occurs 
downstream of Ras in the MEK-ERK (ERK) pathway, a kinase signalling cascade that 
is constitutively active in several human cancers 330. Activated ERKs are pleiotropic 
effectors of many aspects of cell physiology and have been linked to tumour growth, 
angiogenesis, invasion and metastasis. As Raf is integral to the ERK pathway several 
novel agents targeting it are currently being developed for clinical use 330, 331. Given that 
somatic mutations of B-Raf are common in papillary thyroid cancer, it is particularly 
interesting to note that MKRN2 was recently included in a 19 gene molecular classifier 
capable of discriminating the latter from normal thyroid tissue 332. If MKRN2 is in fact 
a co-regulator of Raf-1, it could be a valuable therapeutic target and as such would merit 
further investigation. 
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9.4.4 USP6
USP6 (TRE2 or TRE17) was originally identified in multiple transfection-based screens 
for novel oncogenes by its ability to transform MEFs 333. It was subsequently shown to 
function as a ubiquitin-specific protease and is derived from the chimeric fusion of two 
genes (USP32 and TBC1D3) as a result of genomic rearrangement during evolution 334. 
Translocation of USP6 occurs in over 60% of aneurysmal bone cysts (ABCs) 335. ABCs 
were previously regarded as reactive inflammatory lesions but are now considered to be 
neoplastic in nature, accounting for 1-2% of all primary bone tumours 336. They usually 
occur in the first two decades of life and may result in extensive local bone destruction 
leading to pathological fracture 337. Histologically, ABCs are complex lesions consisting 
of blood-filled spaces separated by connective tissue septa composed of fibroblasts and 
reactive woven bone with osteoclast-like giant cells. 
The mechanisms by which USP6 overexpression contributes to the pathogenesis of 
ABCs are poorly understood. Ye et al., however, have recently shown that USP6 
induces the production of MMP9 in a USP-dependent manner via Rho A - ROCK 
mediated NF-ĸB activation 335. Prior to this, previous IHC studies of ABCs have 
consistently shown that MMP9 is expressed in the fibrous stroma. The authors therefore 
suggest that MMP9 is an effector of USP6 in vivo and is fundamental to the 
pathogenesis of ABCs 335. They go on to comment that USP-specific inhibitors or NF-
ĸB antagonists may represent novel therapies for ABCs in the future.
Due to the conserved nature of USP6 with respect to USP32, I was unable to generate a 
functional set of DNA primers necessary to validate the knockdown efficiency of the 
USP6 siRNA duplexes using qPCR (Chapter 5, Section 5.2.2). Consequently, USP6 
was ‘dropped’ at that stage. The finding that USP6 was functionally significant in 
HNCAF is interesting, however, particularly in light of the data regarding its oncogenic 
role in ABCs. The signalling pathway of USP6 > Rho A - ROCK > NF-ĸB > MMP9 
proposed by Ye et al. may be equally applicable to the stromal compartment of SCC.
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9.5 NF-ĸB signalling in SCC invasion 
Chapters 3, 4 and 5 describe the identification and selection of TRAF6 and ZA20d1 as 
candidate genes, as well as confirmation of their regulatory roles in carcinoma invasion. 
As mentioned previously, current literature suggested that both proteins were central to 
canonical NF-ĸB signalling in epithelial cells 163, 307. In view of the latter’s importance 
in the pathogenesis of SCC (Chapter 1, Section 1.5), it was conceivable that TRAF6 and 
ZA20d1 were influencing cancer cell invasion in a NF-ĸB dependent manner. 
9.5.1 Carcinoma invasion is NF-ĸB dependent
The significance of NF-ĸB pathways in cancer cell invasion in our organotypic system 
was investigated using TNFα, IL-1α, several IKK inhibitors and infliximab (Chapter 6). 
These experiments demonstrated that carcinoma invasion could be driven by 
stimulation with both TNFα and IL-1α. The results also indicated that TNFα promoted 
SCC12 carcinoma invasion in a dose responsive manner by a duel influence on both the 
epithelial and stromal compartments of the system. Moreover, TNFα stimulation was 
associated with a dose responsive increase in fibroblast-dependent gel contraction which 
correlated positively with the Invasion Index. In contrast to this, IL-1α exerted a dose 
responsive effect on SCC12 invasion without potentiating the invasive promoting and 
matrix remodelling functions of HNCAF. The difference with respect to CAF activity 
was a reflection of the underlying NF-ĸB response, the latter failing to be elicited by IL-
1α.
Molecular profiling studies show that NF-ĸB regulates a large array of genes which are 
functionally relevant to many aspects of tumourigenesis such as cell proliferation, cell 
survival, cell migration, angiogenesis and inflammation 219. This work supports 
previous findings that NF-ĸB signalling is pertinent to the local invasion of SCC and, by 
inference, metastasis. 
During tumourigenesis, the stroma facilitates disease progression through its interaction 
with carcinoma cells and the significance of this relationship with respect to carcinoma 
invasion was further demonstrated here. The importance of TNFα and IL-1α in the 
pathogenesis of several cancers is well established and has been previously discussed in 
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Chapter 1, Sections 1.6 and 1.7. Both cytokines have also been shown to sustain 
canonical NF-ĸB signalling 192, 310. 
The results presented in Chapter 6 corroborate the above and provide additional 
evidence for the role of TNFα and IL-1α in the regulation of SCC invasion. Subsequent 
work performed by our group (data not shown) has confirmed that SCC12 cells 
constitutively express 10 times as much TNFα than either A431 cells or HNCAF.
Comparative expression of TNFR1 across the three cell lines was also examined and 
shown to be 1.4, 1 and 1.8 respectively. Further delineating the intracrine, autocrine and 
paracrine activities of TNFα and IL-1α within the tumour micro-environment may 
therefore lead to novel advances in cancer therapy. 
Recently, a short-term ex vivo organotypic culture method that utilises freshly procured 
tumour tissue has been described 338. In this system, tissue architecture, cell viability, 
epithelial and stromal signalling activity as well as global gene expression profiles were 
preserved for up to 5 days. The authors were also able to demonstrate the value of this 
technique in predicting tumour sensitivity to small molecular inhibitors in a patient-
specific manner. 
Overall, the assortment of cytokines, their relative concentrations and the expression 
patterns of their receptors effectively mediate the interactions a cancer cell has with its 
neighbouring stromal and host immune cells 257. It is the summation of these cellular 
interactions which ultimately determines the biological nature and behaviour of a 
tumour. 
9.5.2 NF-ĸB as a therapeutic target in SCC
The role of NF-ĸB signalling in tissue homeostasis, acute and chronic inflammation as 
well as autoimmune disease is well documented 187. There is also considerable evidence 
that NF-ĸB is constitutively active in SCC and is of broad importance to cancer in 
general 239, 240. Consequently, NF-ĸB and the signalling pathways that regulate its 
activity have become a focal point for intense drug development 339.
To date, over 750 inhibitors of NF-ĸB have been identified but for the majority of these 
compounds the molecular basis of their action is poorly understood 340. Broadly 
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speaking however, inhibition of NF-ĸB signalling can occur at the following points 
within the molecular cascade: (a) the receptor or adaptor level (b) the IKK complex, (c) 
the proteasome and (d) transcription in the nucleus. 
The IKK complex has been an obvious target for the development of small molecular 
inhibitors given its central role in canonical NF-ĸB signalling. Approximately 150 
compounds exist and these may be classified on the basis of their mode of action into: 
(a) IKKβ Cys-179 reagents, (b) allosteric inhibitors and (c) ATP analogs 340. Four IKK 
inhibitors were used in this work to investigate whether carcinoma invasion was NF-ĸB 
dependent (Chapter 6, Section 6.4). IKKI-II (Wedelolactone) is the active ingredient of 
the herbal medicine Eclipta alba and interacts with Cys-179 in the activation loop of 
IKKβ. IKKI-III is an allosteric inhibitor of IKKβ. Both IKKI-2 and IKKI-X are 
synthetic ATP analogs. Presently, IKK inhibitors are not in clinical use but given their 
effectiveness at blocking SCC invasion in vitro they may have the potential to be anti-
motility drugs in the future.
Bortezomib (Velcade® or PS-341) was the first selective 26S proteasomal inhibitor to 
be used clinically and has since been approved for the treatment of refractory multiple 
myeloma 341. It has also been shown to have radiosensitizing effects in SCC cell lines 
and murine models which exhibit constitutively activated NF-ĸB 342. At present, data 
regarding the influence of bortezomib on cancer cell invasion is lacking. It would thus 
be interesting to test it in our organotypic system in view of the NF-ĸB dependent 
nature of carcinoma invasion. Clinical trials involving bortezomib in the management of 
SCC are in progress. 
In addition to small molecular NF-ĸB inhibitors, several commonly used compounds 
have been reported to have off-target anti-NF-ĸB activity. These include: non-steroidal 
anti-inflammatory drugs 343, anti-oxidants 344, thalidomide 345, and natural products such 
as curcumin and capsaicin 346. Some of the above are already in use or are being 
investigated within the field of cancer chemotherapeutics. In time a greater knowledge 
of their target specificity, efficacy, and potential toxicity will allow a more rational use 
of these agents in the clinical setting.
Currently, the main factor limiting the clinical use of NF-ĸB inhibitors is the lack of 
target specificity which drastically reduces their therapeutic efficacy. This relates to the 
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varied biological functions of NF-ĸB signalling and the fact that a number of key 
intermediaries overlap with other molecular pathways. The challenge to identify 
compounds that only block NF-ĸB activation therefore remains. Alternatively, low dose 
combination therapy using several inhibitors that target multiple steps in NF-ĸB
signalling may be an effective strategy which limits unwarranted side effects 340.
9.5.3 Targeting TNFα for cancer therapy
TNFα is not present in the plasma of healthy individuals but may be detected in cancer 
patients in picogram concentrations 252. It is a pivotal chemical mediator within the 
tumour micro-environment and is highly expressed by both cancer and stromal cells in a 
variety of malignancies 191. 
General and cell specific deletion of TNFα reduces the incidence of cancer in 
experimental animal models 252. For example, TNFα KO and TNFR1 KO mice are 
resistant to chemically-induced carcinogenesis of the skin 347. Moreover, in a mouse 
model of hepatocellular carcinoma TNFα from parenchymal cells was shown to cause 
paracrine activation of NF-ĸB in neighbouring hepatocytes and be instrumental to 
tumour development 348. 
Other studies suggest that TNFα may confer metastatic properties to tumour cells 191, 245.
In a colon adenocarcinoma-lung metastasis model, metastatic lesions were demonstrated 
to be TNFα dependent 349. Similar observations were also found in an experimental 
fibrosarcoma system in which the number of lung metastases was increased in mice pre-
treated with TNFα and decreased in mice administered an anti-TNFα antibody 350.
Infliximab (Remicade® or cA2) is a chimeric monoclonal antibody composed of 75% 
human-derived and 25% mouse-derived amino acids. It was the first biological to be 
tested in the management of rheumatoid arthritis and is now used for the treatment of 
several chronic inflammatory conditions such as psoriasis and Crohn’s disease 245. 
Infliximab blocks circulating and membrane bound TNFα which in turn limits the 
production of other inflammatory cytokines including IL-1, IL-6, IL-8 and IFNγ. It has 
also been shown to down-regulate cell adhesion proteins and matrix metalloproteinases 
as well as inhibit angiogenesis and leucocyte trafficking to sites of inflammation 245. 
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These findings suggest that infliximab and other TNFα antagonists could have potential 
as cancer chemotherapeutic agents. 
To date, less than ten Phase I and Phase II cancer trials using anti-TNFα therapy have 
been reported 191. Brown et al. assessed the tolerability and biological effects of 
infliximab in 41 patients with a histologically confirmed diagnosis of advanced or 
metastatic non-haematological malignancy 351. Tumour type was as follows: colorectal 
(12), ovarian (8), renal (4), melanoma (3) and other (14). Thirty-eight individuals were 
refractory to previous chemotherapy but all had an estimated life expectancy of at least 
3 months. Participants received infliximab infusions at 0, 2 weeks and every 4 weeks 
thereafter at either 5 or 10mg/kg. Median serum infliximab concentrations one hour post 
administration were 107µg/ml and 252µg/ml respectively. Treatment was well tolerated 
with no dose-limiting side effects and in all cases neutralisation of serum TNFα was 
observed. Seven patients experienced disease stabilisation (range 10-50 weeks) and the 
authors concluded that further trials of infliximab and similar anti-TNFα agents may be 
warranted. Other trials involving etanercept (Enbrel®), a human recombinant TNFR-Fc 
fusion protein, have also reported disease stabilisation in cases of breast, ovarian and 
haematological cancers 352, 353, 354. 
Having established carcinoma invasion in our organotypic system to be TNFα driven 
and NF-ĸB dependent, I corroborated these findings by investigating the effects of 
infliximab on cancer cell invasion (Chapter 6, Section 6.5). Infliximab was shown to 
block NF-ĸB signalling in both A431 cells (Figures 6.87-6.89) and HNCAF (Figures 
6.90-6.92). Furthermore, it inhibited fibroblast-dependent collagen-Matrigel® matrix 
contraction and reduced SCC12 carcinoma invasion in a dose responsive manner 
(Figures 6.81-6.86). 
To my knowledge, there is currently no published literature that specifically reports the 
inhibitory action of TNFα antagonists on SCC invasion. This data is exciting in that it 
suggests that infliximab could potentially be exploited as an anti-invasive cancer drug. 
This would be of considerable benefit to patients with SCCHN in which metastatic 
spread along the cervical chain of lymph nodes is associated with a markedly worse 
clinical prognosis. Given the opportunity, it would be interesting to validate these 
findings with other SCC cell lines, as well as in vivo using either intra-vital imaging 
techniques or experimental models of metastasis. The influence of other TNFα 
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antagonists such as adalimumab (Humira® or D2E7) on carcinoma invasion and tumour 
development as a whole would also be worthy of further investigation.
Patients receiving biological therapy require close monitoring throughout treatment. 
Reported side-effects of infliximab and related drugs include: blood dyscrasias such as 
thrombocytopaenia and aplastic anaemia, hypersensitivity reactions, heart failure, 
opportunistic infections including the re-activation of tuberculosis, septicaemia and 
increased malignancy risk. Prolonged concurrent use of TNFα inhibitors with other 
immunosuppressant agents such as azathioprine, ciclosporin and methotrexate is not 
recommended 245. This dogma would most likely apply to their use in cancer 
chemotherapy.
The future role of TNFα antagonists in cancer treatment will depend on a number of 
factors. Firstly, a greater understanding of the nature of TNFα-associated epithelial-
stromal interactions in early and late-stage malignancy is required. Secondly, criteria for 
identifying the patients and tumours most likely to respond to anti-TNFα therapy are 
needed. A low or absent plasma TNFα level has been suggested as a possible biomarker 
of response but is as yet unsubstantiated 351. Thirdly, the biological efficacy and safety 
of these drugs in the context of the medically compromised cancer patient must be 
evaluated further. Finally, the economic and financial implications of the use of anti-
TNFα drugs in the provision of cancer related healthcare would also need to be 
assessed.
In conclusion, TNFα continues to confound investigators. Conflicting observations 
regarding the actions of TNFα highlight the complexity of its biological roles, many of 
which are still not understood. Recent research has focused on the tumour promoting 
nature of TNFα. From this, however, is the realisation that TNFα may in fact be the 
Achilles heal of cancer in general, and if suitably exploited provide new exciting 
opportunities for targeted cancer therapies 191. 
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9.6 Regulation of the IKK complex by ubiquitination
Under normal circumstances, NF-ĸB activation is tightly controlled by several post-
translational modifications, including phosphorylation and ubiquitination 355. 
Ubiquitin is a 76 amino acid (8kDa) polypeptide which when covalently bound to target 
proteins may alter their half-life, localisation and function 146. Ubiquitination requires 
the sequential action of three proteins: ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2) and ubiquitin ligase (E3) (Figure 1.9). Moreover, it can be 
reversed by proteases termed de-ubiquitinating enzymes (DUBs). This form of 
regulation is known as ubiquitin editing and is integral to NF-ĸB signalling, particularly 
at the level of the IKK complex. 
9.6.1 TNF receptor-associated factors (TRAFs)
TNF receptor-associated factors (TRAFs) are involved in signal transduction of several 
receptor families. These include: TNFRs, IL-1Rs, TLRs, T-cell receptors (TCRs) and B-
cell receptors (BCRs) 356, 357. The TRAF family consists of seven members and all have 
a C-terminal TRAF domain and a series of zinc finger domains. TRAF2-7 also contain a 
well conserved N-terminal RING domain and function as E3 ubiquitin ligases 358, 359. 
TRAF2 and TRAF5 signal only within the TNFR superfamily, where as TRAF6 is 
pleiotropic and important to the downstream events of many receptor systems 360. 
9.6.1.1 TRAF6
TRAF6 is a RING domain E3 ligase which mediates signalling in the IL-1R and TLR 
pathways 361. It also regulates downstream events following TNFR1 activation at 
several levels, but our understanding of these interactions is relatively limited at present.
Current knowledge surrounding the mechanism of IKK and NF-ĸB activation by 
TRAF6 is derived from biochemical investigations using a cell-free system 362. From 
this work, two TRAF6-regulated IKK activators (TRIKAs) were identified 362. TRIKA1 
is a dimeric ubiquitin-conjugating enzyme (E2) complex that consists of UBC13 and the 
UBC-like protein, UEV1A 362. TRIKA2 is a trimeric complex composed of TAK1 and 
two TAK1-binding proteins (TAB1 and TAB2/3) 363, 364.
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Upon ligand binding to IL-1Rs or TLRs, TRAF6 is indirectly recruited to receptor 
complexes and forms oligomers 161. TRAF6 oligomerization stimulates its ligase 
activity and requires dimerization of its N-terminal RING domain via its RING domain 
and linker helix 161. This leads to K63 polyubiquitination of target proteins and TRAF6 
autoubiquitination via the E2-TRAF6 complex described above. Ubiquitinated TRAF6 
then associates with TRIKA2, resulting in TAK1-dependent IKKβ phosphorylation and 
IKK activation (Figure 9.1) 163. Ubiquitinated TAK1 also phosphorylates MKK kinases 
which in turn activate the JNK and p38 kinase pathway 363.
Genetic and biochemical studies indicate that ubiquitinated TAK1 is essential for 
signalling through IKK and JNK 365. Firstly, TAK1 activates both IKKβ and MKK6 363. 
Secondly, siRNA silencing or molecular inhibition of TAK1 reduces IKK activation 
and blocks JNK activation by TNFα and IL-1 364, 366. Thirdly, IKK and JNK activity is 
impaired in Drosophilia melanogaster TAK1 mutants 367. Similar investigations 
focusing on the relative contributions of TAB1, TAB2 and TAB3 to TRIKA2 have 
demonstrated partial redundancy of these proteins with respect to NF-ĸB pathways 163.
Residual IKK activity following TAK1, TAB2 and TAB3 gene depletion may be 
explained by the presence of alternative pathways of IKK activation 163. One such 
pathway involves p62. This is a ubiquitin-associated (UBA) domain protein that binds 
to TRAF6 and RIP, as well as atypical protein kinase C (PKCζ) 368. On IL-1 
stimulation, TRAF6 forms a complex with p62 and PKCζ which functions in a similar 
way to TRIKA2 and activates IKK. Evidence supporting this ‘minor’ pathway comes 
from experiments using dominant negative mutants of PKCζ which block IKK 
activation and NF-ĸB signalling 369, 370. Furthermore, the activation of IKK by TNFα, 
IL-1 and lipopolysaccharide (LPS) is markedly reduced in PKCζ-deficient lung cells 371. 
TRAF6 has also been shown to be crucial for thymosin α1 (Tα1) triggered PKCζ-
dependent IKK activation in mouse embryonic fibroblasts (MEFs) 372. Finally, it is 
possible that residual IKK activation does not require an upstream signal at all. TRAF6 
mediated K63 polyubiquitination of NEMO or IKKαβ may promote IKK 
oligomerization, phosphorylation and autoactivation 163.
Figure 9.1  Regulation of the IKK complex by TRAF6 ubiquitination
Following IL-1R or TLR stimulation, TRAF6 is indirectly recruited to the 
receptor complexes. TRAF6 oligomerization leads to autoubiquitination via 
TRIKA1. Ubiquitinated TRAF6 then associates with TRIKA2 resulting in 
TAK1-dependent IKKβ phosphorylation and IKK activation. Conversely, 
TRAF6 can be de-ubiquitinated by the action of A20, ZA20d1 and CLYD 
there by inhibiting IKK activity.
Figure adapted from Chen ZJ. Ubiquitin signalling in the NF-ĸB pathway. 
Nat Cell Biol 2005; 7: 758-765.
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9.6.1.2 TRAF2 and TRAF5 
Like TRAF6, TRAF2 is a RING-domain E3 ubiquitin ligase which activates canonical 
NF-ĸB signalling by promoting K63 polyubiquitination of UBC13 373. TRAF2 
ubiquitination is also important for the activation of JNK 374. MEFs deficient in TRAF2 
can still activate NF-ĸB following stimulation with TNFα, but not JNK 375. The 
functional redundancy of TRAF2 with respect to NF-ĸB activation relates to TRAF5
since TRAF2-TRAF5 double knockout cells are defective in both NF-ĸB and JNK 
signalling 373.
TRAF2 and TRAF5 have been implicated in the ubiquitination of RIP1 364. This leads to 
the recruitment of the TRIKA2 complex which phosphorylates and activates IKK 376.
Additionally, TRAF6 may also mediate ubiquitin editing of RIP1, performing a similar 
role to the co-operative activity of TRAF2 and TRAF5 377. These aspects of TRAF 
protein function in signal transduction require further investigation.
9.7 Regulation of the IKK complex by de-ubiquitination
9.7.1 A20
The zinc finger molecule A20, also known as TNFAIP3 or OTUD7C is an NF-ĸB 
induced protein and an established negative regulator of NF-ĸB signalling 378, 379. It’s N-
terminal OTU-type DUB domain catalyses removal of K63-linked polyubiquitin chains 
from RIP1 and TRAF6, there by inhibiting IKK activation (Figure 1.10) 163, 380. The 
mixing of A20 with ubiquitinated TRAF6 results in free polyubiquitin chains but not 
monoubiquitin. This observation suggests that TRAF6 polyubiquitin chains are cleaved 
at their proximal end and implies a direct interaction between both molecules 381. A20 
also functions as a ubiquitin ligase through its C-terminal zinc finger domains which 
promote K48-polyubiquitination of RIP1. This leads to the degradation of RIP1 by the 
proteasome and illustrates how A20 regulates its signalling targets by ubiquitin editing.
A20-deficient mice are hypersensitive to stimulation with TNFα and exhibit prolonged 
activation of NF-ĸB. Consequently, they die at an early age from systemic 
inflammatory response syndrome (SIRS) 183. Multiple polymorphisms of the gene 
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encoding A20, TNFAIP3, have also been linked to the autoimmune condition, systemic 
lupus erythematosus (SLE) 382. These findings are in keeping with the role of A20 as a 
negative regulator of NF-ĸB activation and are consistent with the concept that an 
imbalance in NF-ĸB signalling leads to excessive inflammation. 
9.7.2 ZA20d1
Zinc finger A20 domain containing 1 (ZA20d1), also known as Cezanne or OTUD7B, 
is a 100kDa cytoplasmic protein that belongs to the A20 family of de-ubiquitinating 
cysteine proteases 308, 383. Literature regarding ZA20d1 is very sparse, but does indicate 
that it behaves in a similar way to A20 in epithelial and endothelial cells. It too can 
inhibit NF-ĸB signalling at the level of the IKK complex or upstream of it by switching 
polyubiquitin chains and destabilising TRAF6 and RIP1 307. ZA20d1, like A20, can be 
induced by TNFα and IL-1 in cultured cells and has been shown to be recruited to 
activated TNFRs 307.
9.7.3 CYLD
Ubiquitin carboxyl-terminal hydrolase (CYLD) was the first DUB to be identified as a 
regulator of the IKK complex 384. Mutations in CYLD, which is now recognised to be a 
tumour suppressor, are associated with familial cylindromatosis and multiple hereditary 
trichoepithelioma 385. Both conditions are characterised by numerous adnexal skin 
tumours and enhanced activation of NF-ĸB. CYLD has been shown to inhibit IKK 
activation by disassembly of K63-linked polyubiquitin chains on several proteins 
including NEMO, TRAF2, and TRAF6 384, 386.
9.8 TRAF6, ZA20d1 and NF-ĸB signalling in SCC invasion
To test the hypothesis that both TRAF6 and ZA20d1 were influencing cancer cell 
invasion in our organotypic sytem via their regulatory functions on NF-ĸB signalling, I 
investigated the effect of TNFα stimulation on SCC12 cells depleted of either gene 
(Chapter 7). In both cases, TNFα at a concentration of 31ng/ml rescued invasion
(Figures 7.4-7.9). Furthermore, knocking down TRAF6 in SCC12 and A431 cells was 
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associated with a reduction in the phosphorylation and reciprocal degradation of IĸBα
under basal conditions (Figure 7.10 and 7.13).
9.8.1 TRAF6
To date, papers concerning the role of TRAF6 in NF-ĸB activation indicate that it is a 
positive regulator of the canonical pathway following IL-1R or TLR engagement. These 
studies suggest that TRAF6 primarily acts alongside TRIKA2 upstream of the IKK 
complex 151, 161, 163, 377. 
Literature regarding its specific role in TNFR signalling is sparse and contradictory in 
that TNFα induced activation of IKK and NF-ĸB has been shown to be enhanced in 
TRAF6-deficient MEFs. The authors attribute this negative regulatory role of TRAF6 to 
its ubiquitin ligase activity 387. Given the significance of K63 polyubiquitination to 
protein processing in general, TRAF6 E3 function seems to be central to its role as a 
downstream adaptor molecule. 
A signalling mechanism to explain the findings presented in Chapter 7 is suggested 
below and illustrated in Figure 9.2. 
Under basal conditions, TRAF6-dependent cytokines drive IĸBα degradation leading to 
NF-ĸB activation; a situation which favours carcinoma invasion as described in Chapter 
6. Given the established role that TRAF6 has in IL-1 signal transduction, it is likely that 
this pathway dominates over TNFα induced NF-ĸB signalling in this circumstance.
Hence, depleting TRAF6 is associated with a reduction in carcinoma invasion.  
When TRAF6 gene depleted SCC12 cells were stimulated daily with TNFα (31ng/ml) 
carcinoma invasion was rescued (Figures 7.4-7.6), implying that TRAF6 is functionally 
redundant in this instance. Essentially, IĸBα degradation is TRAF6-independent in an 
enriched TNFα environment with downstream NF-ĸB signalling events being mediated 
through other intermediaries, notably TRAF2, TRAF5 and RIP1. Consequently, cancer 
cell invasion is recovered.
Figure 9.2 Regulation of TNFR1 and IL-1R mediated NF-ĸB activation 
by TRAF6 and ZA20d1
Ubiquitin editing is extensively involved in both TNFα and IL-1 induced NF-
ĸB signalling pathways. TRAF6 and ZA20d1 are integral to this process but 
the nature of their interactions with each other is not fully understood at 
present.
Figure adapted from Chen ZJ. Ubiquitin signalling in the NF-ĸB pathway. 
Nat Cell Biol 2005; 7: 758-765.
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Further work is required to validate the above theory. It would be interesting, for 
example, to repeat the experiments detailed in Chapter 7 using IL-1α. Since IL-1α is 
known to transcriptionally regulate TNFα as well as potentiate its action, cancer cell 
invasion could again be rescued. Assessing cancer cell and stromal cell production of 
IL-1α along with the expression of the IL-1R would also be of value. Invasion assays in 
which carcinoma cells are depleted of TRAF2, TRAF5, and RIP1 either in isolation or 
together with TRAF6 would also be of interest.
Recent studies reveal that ubiquitination is extensively involved in TNFα induced NF-
ĸB activation 355. Although TRAF6 is considered to positively regulate NF-ĸB 
signalling upstream of IKK, it is also known to influence the ubiquitination of NEMO 
and IKKß directly. Figures 7.10 and 7.13 demonstrate that depletion of TRAF6 in both 
SCC12 and A431 cells was associated with a reduction in the phosphorylation and 
reciprocal degradation of IĸBα. Whether this represents a further point within the NF-
ĸB signalling cascade by which TRAF6 exerts a direct regulatory function remains to be 
determined. 
The recognition that TRAF6 is itself a target for polyubiquitination suggests that an 
additional level of regulation exists within TNFα and IL-1 induced signalling pathways. 
The predominant autoubiquitination site in TRAF6 has been mapped to K124 151, 161. 
This is located on the linker helix between the first zinc finger domain and the N-
terminal RING domain 388. Dimerization of the latter promotes aggregation of 
ubiquitinated TRAF6. Both K124R and dimerization mutants of TRAF6 have impaired 
abilities to rescue IKK activation in TRAF6 deficient MEFs 388. Comparison of TRAF6 
distribution before and after cell stimulation has demonstrated coalescence and 
clustering of TRAF6 beneath the cell surface upon activation 161. Collectively, these 
findings have led to the hypothesis that TRAF6 aggregation contributes to the formation 
of a protein scaffold which favours recruitment and ubiquitin editing of downstream 
signalling targets. TRAF6 may therefore indirectly influence the ubiquitin handling of a 
wider range of molecular intermediaries than previously thought. 
The concept of an expanded lattice of protein processing and interactions would be 
particularly pertinent to IKK activation.  It would also account for the pleiotropic nature 
of TRAF6 and provide a unifying connection for TNFR1, IL-1R, TLR, TCR, BCR and 
receptor tyrosine kinase (RTK) signalling 161, 377. Considering the importance of these 
394
pathways in cancer, it has been suggested that TRAF6 may be an uncharacterised 
oncogene and as such constitute a valuable therapeutic target 389.
9.8.2 ZA20d1
ZA20d1 and A20 are negative regulators of TNFα induced NF-ĸB signalling 307, 378.
Both proteins contain E3 ligase and de-ubiquitinase domains and act at the level of the 
IKK complex or upstream of it by ubiquitin editing TRAF6 and RIP1 390. Recently 
Shembade et al. have shown that A20 blocks IL-1 induced activation of NF-ĸB by 
binding to TRAF6, thus preventing the latter from associating with the E2 conjugating 
enzyme Ubc13 378. However, the nature of the ubiquitinating and de-ubiquitinating 
functions of A20 with respect to E2-E3 enzyme interactions remain unknown 391. 
In light of the above, the finding that ZA20d1 gene depletion in both SCC12 and A431 
cells reduced carcinoma invasion in organotypic culture was surprising. In fact, one 
might have expected that knocking down ZA20d1 would have resulted in an increase in 
NF-ĸB activation and thus greater carcinoma invasion. This result, however, is not so 
contradictory if the role of ZA20d1 with regards to the ubiquitin processing of TRAF6 
and other key intermediaries is considered. In this context, the regulatory activities of 
ZA20d1 in NF-ĸB signalling take on a much broader significance. 
One possible explanation for the regulatory activities of ZA20d1 on SCC invasion is 
that gene silencing may interfere with the ubiquitin editing of TRAF6 such that it is 
unable to autoubiquitinate, aggregate and activate IKK. Consequently, NF-ĸB signalling
and carcinoma invasion is inhibited as previously described for TRAF6 depletion. 
Knocking down both genes compared to either TRAF6 or ZA20d1 alone did not lead to 
greater inhibition of cancer cell invasion (Section 9.4.1) and is supportive of this 
hypothesis. However, unlike TRAF6 depletion, silencing of ZA20d1 in SCC12 and 
A431 cells did not conclusively influence IĸBα degradation (Figures 7.12 and 7.13); a 
result which is incongruous to the above findings. 
An alternative explanation to the above theory is that ZA20d1 acts in an NF-ĸB 
independent manner with regards to SCC invasion (Section 9.9.2).
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In summary, recent studies have provided additional insight into the role of ubiquitin in 
NF-ĸB activation and have revealed levels of complexity in ubiquitin-linked pathways 
not previously appreciated. Our knowledge of the biological functions of ZA20d1 is 
relatively sparse at present but this work supports previous literature in suggesting that 
the functional relationship of ZA20d1 with TRAF6 is worthy of further investigation.
9.9 Could TRAF6 and ZA20d1 be regulating SCC invasion
      independently of NF-ĸB signalling?
9.9.1 TRAF6
To date, the majority of literature regarding the functions of TRAF6 focuses on NF-ĸB 
activation. Given the overlapping nature of NF-ĸB pathways with other signalling 
cascades and the significance of ubiquitination to cell biology in general, it is likely that 
TRAF6 has a wider sphere of influence regarding signal transduction than previously 
thought. 
TRAF6-deficient mice exhibit skin, hair and dental abnormalities similar to patients 
with X-linked hypohidrotic ectodermal dysplasia (HED) indicating it has a key role in 
epithelial embryogenesis and biology 392, 393. These mice also develop osteopetrosis due 
to a defect in osteoclast function and ECM remodelling which leads to a progressive 
increase in bone density, the obliteration of marrow cavities and haematopoietic failure.
Bone resorption involves: (a) proliferation of osteoclast progenitor cells and 
differentiation to mononuclear prefusion osteoclasts (pOCs), (b) fusion and 
multinucleation of pOCs, (c) osteoclast pit formation and active bone resorption and (d) 
osteoclast apoptosis 394. IL-1 is an important regulator of bone turnover in vivo and is 
associated with destructive bone disease in conditions such as rheumatoid arthritis and 
multiple myeloma 395. It acts in a paracrine manner through osteoblasts and stromal 
cells by stimulating prostaglandin E2 (PGE2) synthesis 
396. Immunocytochemical 
analysis of osteoclast-like multinucleated cells (OCLs) has shown that IL-1 induces 
cytoskeletal reorganization and the redistribution of TRAF6 to F-actin structures at the 
cell’s periphery, where it co-localizes with c-Src 397. This TRAF6-cSrc complex is 
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considered to be necessary for osteoclast activation and the formation of a ruffled cell 
border characteristic of active bone resorption 397. 
Another study using human embryonic kidney 293 (HEK293) cells has also confirmed 
the interaction of TRAF6 with Src and implicated it in PI3K dependent cytoskeletal 
changes 398.
Akt (protein kinase B) signalling is involved in many biological functions and its 
deregulation has been linked to many cancers 399. Recently, Akt K63 ubiquitination was 
shown to be an important step for oncogenic Akt activation. TRAF6 was identified as 
the direct E3 ligase for Akt and was also responsible for its membrane recruitment and 
phosphorylation upon growth-factor stimulation 389. Furthermore, in a xenograft tumour 
model using prostate cancer 3 (PC3) cells, two stable TRAF6 knockdowns had lower 
tumourigenic potential compared to control cells 389. It is also important to note that 
many signalling cascades converge on IKK to promote NF-ĸB activation; Akt and PI3K 
pathways are amongst these. 
Given more time it would have been interesting to investigate these signalling pathways
in our organotypic system by overexpressing wild-type or mutant versions of TRAF6 in 
conjunction with the use of Src, PI3K and Akt inhibitors.
9.9.2 ZA20d1
As previously mentioned, literature regarding ZA20d1 is very limited. Currently it has 
only been reported to have a regulatory function in NF-ĸB signalling. Performing a 
screen to investigate the effect of depleting ZA20d1 on other pathways implicated in 
cancer cell motility and invasion would be useful in light of the reasons discussed in 
Section 9.8.2.
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9.10 TRAF6 - a diagnostic tumour marker?
SCC constitutes a heterogeneous group of malignancies each of which has distinct 
pathophysiology, biological behaviour and varying degrees of response to therapeutic 
intervention 2. This is particularly true for SCCHN for which patient mortality rates still 
exceed 50% in 5 years 1.  Identifying tumour markers and genetic signatures which 
correlate with metastatic risk is therefore of potential prognostic significance. Hence, 
human tissue banks have become a vital part of cancer research with the analysis of 
tumour samples leading to a greater understanding of cancer development and 
progression as well as advances in diagnosis and treatment. 
Chapter 8 describes the establishment and management of a human tissue bank of 
SCCHN tumour specimens with patient matched control tissue. As discussed in Chapter 
1, Section 1.8 the Human Tissue Authority (HTA) was established in 2005 under the 
Human Tissue Act (HT Act) of 2004 to protect the public from the covert collection of 
biological samples. Consequently, NREC and R&D applications for tissue collection
were initially made in mid 2006 and final approval obtained in late 2008. Currently 40 
pairs of matched tissue samples have been accrued. With the importance of bio-banking 
to medical research being increasingly recognised, legislation pertaining to the removal, 
storage and use of human tissue is under constant review. To this end, the Integrated 
Research Application System (IRAS) and the National Institute for Health Research Co-
ordinated System for gaining NHS Permissions (NIHR CSP) were set up in 2008 to
streamline the approval process for health care studies within the UK.
Chapter 8 Section 8.4 details the analysis of TRAF6 expression in several types of SCC 
using commercial tissue microarrays purchased from US Biomax Inc. TRAF6 
immunostaining was cytosolic in nature and was assessed by measuring the normalised 
mean pixel intensity of 10 representative areas for each tumour (Chapter 2, Section 
2.10.5). Paraffin embedded A431 cell pellets with and without TRAF6-HA expressing 
cells were stained alongside the tissue arrays and served as positive controls. 
Figures 8.6, 8.8, 8.10 and 8.12 show the normalised mean pixel intensity of TRAF6 
positive areas of each tumour included in the SCCHN, OSCC, CSCC and vulval SCC 
tissue microarrays respectively. The most significant result was that of the OSCC array 
in which 40 of the 50 cases had TRAF6 positive regions which stained with equal or 
398
greater intensity than that observed in the A431 cell pellet. Furthermore, the values 
recorded for the tumour samples grouped together at a higher mean pixel intensity 
compared to those of the 9 cases of normal tissue included in the array (Figure 8.8). 
The above results suggest that TRAF6 may have potential as a histological tumour 
marker in a subset of SCC but should be interpreted in light of the following: (a) 
absolute or total TRAF6 expression was not calculated since core sampling was not 
standardised and a like to like analysis of a comparative tumour region between cases 
could not be made. Neither the relative proportion of TRAF6 positive cells nor their 
distribution within each sample was recorded. (b) Normal tissue relative to tumour 
tissue was under represented in each array and was not patient matched. (c) The 
histological grade of each tumour included in the arrays was provided but information 
regarding the clinical stage was lacking. As a result, TRAF6 expression could not be 
related to patient outcome. 
Representative photomicrographs of H&E and TRAF6 immunostained sections of 
tumour tissue from three SCCHN tissue bank cases are shown in Figure 8.13. Case (c) -
a 53 year old male with SCC of the right tonsil (T2N2) was particularly interesting in 
that TRAF6 expression was similar to that of TRAF6-HA positive A431 cells (Figure 
8.14). Moreover, stromal fibroblasts were TRAF6 positive - an observation supportive 
of the earlier finding that TRAF6 was functionally important in HNCAF (Chapter 4). 
Loss of pan-cytokeratin markers and strong vimentin immunostaining was also noted in 
this tumour (Figure 8.19). Given these results, an obvious but perhaps controversial 
question to ask is has this tumour undergone an EMT and if so, is it related to the 
increased expression of TRAF6?
In the last few years, SCCHN tumours and cell lines have been investigated using array-
based comparative genomic hybridization and gene expression microarrays. Such 
analyses have resulted in the identification of copy number and gene expression 
alterations of potential importance in tumourigenesis 400. In one such study, 18 OSCC 
cell lines were characterised and 9 high level amplification regions were identified 401. 
Amongst these was 11p12-p13 - the region encoding TRAF6. 
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Figures 8.20-8.22 show matched normal and tumour tissue imaged by confocal 
microscopy. Tissue architecture was well preserved and detailed imaging of cytoskeletal 
structures was possible (Figure 8.23). If developed further this technique would be a 
useful adjunct to IHC to assess protein expression in clinical tumour samples. It could 
also be used to assess the nature of the interface between the invasive edge of a tumour 
and its surrounding stroma 402.
9.11 Targeting the ubiquitin-proteasome system
The recognition of the importance of ubiquitin-linked pathways in oncogenesis has 
generated exciting opportunities for the development of new anti-cancer strategies 403. 
Current efforts are focusing on the discovery of specific inhibitors that target E3 ligases, 
DUBs, the sites of interaction of E3 ligases with their cognate E2s and inhibitors of E1.
Table 9.1 lists examples of current inhibitors of the ubiquitin-proteasome system 404, 405.
Since ubiquitin-linked pathways have emerged as promising drug targets, the 
development of an effective agent capable of inhibiting carcinoma invasion remains a 
possible end result of this work. The 5 genes identified here: MKRN2, RKHD2, 
TRAF6, ZA20d1 and USP6 all have the potential to be the focus of future drug 
development programs.
Understanding the role of ubiquitin editing is fundamental to appreciating the 
pathological consequences of ubiquitin-linked pathways in cancer. As our knowledge of 
ubiquitin signalling improves, it is likely that new regulatory mechanisms will be 
uncovered and this in turn will hopefully lead to novel therapeutic approaches in the 
future.
Block the recognition of p53 by Mdm2Nutlins
E2-E3 
interaction
Blocks the initiation of ubiquitinationPYR-41E1
Block proteasomal degradation of            
ubiquitinated proteins
Cyclopentenone PGsDUBs
Block proteasomal degradation of            
ubiquitinated proteins
Ubistatins
Proteasome
recognition
Block proteasomal degradation of        
ubiquitinated proteins
Bortezomib
Proteasome
degradation
Inhibits the E3 activity of Mdm2SempervirineE3 ligase
Mode of ActionInhibitorTarget
Table 9.1 Examples of inhibitors of the ubiquitin-proteasome system
Table adapted from Yang Y, Kitagaki J, Wang H, Hou D, Peranton AO. 
Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 
2009; 100: 24-28.
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9.12 Conclusion
The work described in this thesis investigated the importance of ubiquitin-linked 
pathways in the process of cancer cell invasion. From a series of cytoskeletal and in 
vitro invasion screens 3 of 289 E3 ubiquitin ligases (MKRN2, RKHD2, and TRAF6) 
and 2 of 137 DUBs (ZA20d1 and USP6) emerged as hits (Chapters 3 and 4). Following 
further validation, TRAF6 and its complementary DUB ZA20d1 were selected as 
candidate genes for in depth study (Chapter 5). 
Current literature suggested that both TRAF6 and ZA20d1 were critical to canonical 
NF-ĸB signalling events following TNFR and IL-1R engagement. Consequently, the 
importance of NF-ĸB activation in our organotypic invasion system was investigated in 
detail using TNFα, IL-1α, several IKK inhibitors and infliximab (Chapter 6). 
Carcinoma invasion was shown to be NF-ĸB dependent and could be driven by 
stimulation with TNFα in a dose responsive manner by a dual influence on both the 
epithelial and stromal compartments of the system. In contrast, IL-1α exerted a dose 
responsive effect on SCC12 invasion without potentiating the invasive promoting and 
matrix remodelling functions of HNCAF. The difference with respect to CAF activity 
was a reflection of the underlying NF-ĸB response, the latter failing to be elicited by IL-
1α. Of particular interest, infliximab inhibited cancer cell invasion at a therapeutic dose 
raising the possibility that TNFα antagonists could be potentially exploited as anti-
invasive agents in cancer chemotherapy.
To test the hypothesis that both TRAF6 and ZA20d1 were influencing carcinoma 
invasion via their regulatory functions on NF-ĸB signalling, the effect of TNFα
stimulation on SCC12 cells depleted of either gene was investigated (Chapter 7). 
TRAF6 was shown to influence NF-ĸB activation in carcinoma cells by modulating the 
levels of IĸBα. The mechanism by which ZA20d1 regulated cancer cell invasion was 
less clear but recent studies have revealed levels of complexity within ubiquitin-linked 
pathways and NF-ĸB activation not previously appreciated. The functional relationship 
of ZA20d1 with TRAF6 requires further investigation. 
Ethical and R&D approval for the establishment of a human tissue bank of SCCHN 
tumour samples, with patient matched control tissue was obtained in accordance with 
the 2004 HT Act (Chapter 8). Analysis of these specimens and commercial tissue 
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microarrays indicated that TRAF6 was overexpressed in a subset of SCC. With further 
work, TRAF6 may have potential as both a histological tumour marker and therapeutic 
target.
Although this work was performed using cancer cell lines and an in vitro model of 
carcinoma invasion it does generate several interesting findings which, if validated in 
vivo, could eventually be translated into the clinical setting. TNFα antagonists, IKK 
inhibitors and drugs targeting the ubiquitin-proteasome system offer exciting new 
strategies in cancer chemotherapy. 
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